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Mechanisms of ß-Amyloid Clearance by Anti-Aß Antibody Therapy.
Donna Marie Wilcock
ABSTRACT
Alzheimer’s disease (AD) is defined as a progressive neurodegenerative disorder
that gradually destroys a person’s memory and ability to learn. There are three
pathological hallmarks of the disease which are necessary for diagnosis of AD, these are;
extracellular amyloid plaques composed of ß-amyloid (Aß) protein, intracellular
neurofibrillary tangles and neuronal loss. Amyloid plaques exist as both compact deposits
which stain with Congo red and more numerous diffuse deposits. Active immunization
against Αβ1-42 or passive immunization with monoclonal anti-Aß antibodies reduces
amyloid deposition and improves cognition in APP transgenic mice.
Over several studies of active immunization in APP+PS1 transgenic mice we
showed a strong correlation between reduction of compact amyloid deposits and the
degree of microglial activation suggesting a potential role of microglia in the removal of
Aß. Injection of anti-Aß antibodies into the frontal cortex and hippocampus of aged APP
transgenic mice revealed an early phase of Aß removal which was removal of only
diffuse amyloid deposits with no associated activation of microglia. A later phase was the
removal of compact amyloid deposits. This was associated with significant activation of
microglia. Prevention of this microglial activation by anti-Aß F(ab’)2 fragments or its
- vii -

inhibition by dexamethasone also precluded the removal of compact amyloid deposits but
did not affect the removal of the diffuse deposits.
Systemic injection of anti-Aß antibodies weekly over a period of 1, 2, 3 and 5
months transiently activated microglia associated with the removal of compact amyloid
deposits and elevated plasma Aß, suggesting a peripheral mechanism contributes to
removal of brain Aß. This systemic administration also dramatically improved cognitive
performance in the Y-maze and in the radial-arm water maze. These studies also showed
a significant increase in vascular amyloid dependent on the number of antibody injections
the mice received. Associated with this increase in vascular amyloid was a dramatic
increase in the numbers of microhemorrhages in the brain. Despite this pathology the
mice showed cognitive improvement with the treatment. These effects could have major
ramifications in humans and should be further investigated prior to any human clinical
trials.
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INTRODUCTION
Alzheimer’s Disease:
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder
characterized by a devastating mental decline. There are three pathological characteristics
of AD. These are amyloid plaques, neurofibrillary tangles and neuron loss characterized
by dystrophic neurites. The amyloid plaque is a microscopic focus of extracellular
amyloid deposition. The plaque contains extracellular deposits of amyloid-β protein (Αβ)
that occurs primarily in filamentous form. Much of the Αβ found in the plaque is the 42
amino acid species (Αβ1-42) which is slightly more hydrophobic than the shorter, 40
amino acid, species (Αβ1-40). Αβ1-40 is normally the more abundant form of Αβ produced
by cells and it does colocalize with Αβ1-42 in the plaque. Αβ can also be deposited as
diffuse deposits, often thought to be an intermediate step in the formation of a compact
amyloid plaque. Amyloid plaques are often termed neuritic plaques, due to the presence
of dystrophic neurites within and immediately surrounding the plaque. The size of the
deposit can vary greatly, ranging from 10 to more than 120µm (Selkoe, 2001).
Neurofibrillary tangles are intraneuronal inclusions of nonmembrane bound bundles of
abnormal fibers consisting of pairs of helical filaments. The filaments consist of
hyperphosphorylated microtubule-associated protein tau. It is unknown what causes this
hyperphosphorylation although studies have implicated the cyclin-dependent kinase 5
(cdk5) (Patrick et al, 1999). Neuron loss is thought to result from toxicity of amyloid
plaques, the inflammatory response which results in cytokine release and acute phase
-1-

protein release, oxidative injury which causes disruption of neuronal metabolic and ionic
homeostasis, and impaired neuronal transport due to the presence of hyperphosphorylated
tau filaments in the neuron.
Despite the many pathological characteristics of AD, the most favored hypothesis
of the disease process is the amyloid hypothesis. This hypothesis suggests that deposition
of Αβ as both diffuse and compact plaques can directly, and indirectly via an
inflammatory cascade, result in progressive synaptic and neuritic injury. This injury is
then thought to result in altered kinase/phophatase activity which leads to
hyperphosphorylation of tau and the formation of neurofibrillary tangles. This cascade of
events is ultimately thought to result in widespread neuron dysfunction and loss which
will cause the dementia characteristic of AD (Hardy et al, 2002). The problem with this
hypothesis has been that researchers have been unable to show a strong correlation
between neuron loss / dysfunction and levels of amyloid deposits, however, recent data
suggests that it is actually small, soluble Αβ oligomers that cause the neurotoxicity in
Alzheimer’s disease (Lue et al, 1999, Klein et al, 2001). Αβ is a product of cleavage of
larger precursor protein, the amyloid precursor protein (APP). APP is a single
transmembrane polypeptide consisting of between 695 and 770 amino acid residues and
is cleaved by enzymes named secretases. The three secretases have specific cleavage
sites, using the 770 numbering α-secretase cleavage occurs at amino acid 687, βsecretase cleavage occurs at amino acid 671, while γ-secretase cleavage can occur at
amino acid 711 or 713. If a β-secretase cleavage occurs along with a γ-secretase cleavage
then Αβ will be produced, the length of the Αβ is dependent on whether the γ-secretase
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cleaves at residue 711 (Αβ1-40) or 713 (Αβ1-42). Most mutations which have been found
to cause early-onset familial AD are in the APP protein at the three secretase sites,
primarily biasing cleavage to the β secretase site or C-terminal mutations increasing the
length of Aβ to the more fibrillogenic 42 length. Other mutations were found in the
presenilin proteins 1 and 2, later it was discovered that these proteins alter APP
metabolism and have a direct effect on γ-secretase by increasing the length of the Aβ
produced (Hardy 1997). It has recently been suggested by several studies that the
presenilin protein is actually the γ-secretase.
Researchers continue to investigate genetic links to susceptibility for Alzheimer’s
disease since only 5% of all AD cases are linked to APP, PS1 or PS2 mutations and all
are early-onset forms of the disease. Apolipoprotein E (ApoE) genotype has been found
to be a significant risk factor for the development of AD. ApoE is a plasma protein
involved in the transport of cholesterol and other lipids. ApoE has been shown to be
present in amyloid deposits and neurofibrillary tangles and has been implicated in
neuronal growth and regeneration during development and following injury. All humans
carry two alleles for ApoE, of which there are three types; 2, 3 and 4. A person can be
ApoE 4/4, ApoE 4/3, ApoE 3/3, ApoE 2/3 or, rarely, ApoE 2/2 (Soininen and Riekkinen
Sr, 1996). It has been shown that onset of AD is earliest in those patients carrying both
ApoE4 alleles while one ApoE4 allele is later but still earlier than other alleles with the
rare ApoE2 allele possibly inferring protection from the disease. ApoE3 is the most
common allele. Although only 16% of the population has ApoE4 as an allele
approximately 40% of sporadic AD cases have been found to carry an ApoE4 allele
(Strittmatter and Roses, 1995). The role of ApoE in the brain is not fully understood, nor
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is the role ApoE4 plays in increasing risk of AD. In vitro it has been shown that ApoE2
and ApoE3 can bind to tau and microtubule associated protein 2c but ApoE4 cannot. This
could suggest that binding of ApoE may stabilize the tau protein and possibly prevent the
aggregation into neurofibrillary tangles (Strittmatter et al, 1994). However, this may be
one of many functions of ApoE as it has been shown to be localized in neurons as well as
the extracellular space of the brain and has been shown to have many metabolic
functions. It is also important to note that an ApoE4/4 genotype does not guarantee that
Alzheimer’s disease will occur, only that the person has an increased risk for developing
the disease. It is highly likely that many more genes like ApoE will be found in the
coming years given that there are still many AD cases without an obvious genetic cause.
Cerebral Amyloid Angiopathy and AD:
Cerebral amyloid angiopathy (CAA) is a common term used to define the
deposition of amyloid in the walls of blood vessels, primarily small and medium sized
arteries and arterioles, of the brain. In humans, CAA primarily occurs in leptominingeal
and cortical vessels and is rarely observed in other brain regions such as the hippocampus
or the striatum (Rensink et al, 2003). The protein accumulating in the vessels causing
CAA has excessive ß-pleated sheet folding and also has a tendency to form fibrils which
are highly insoluble. In order to be defined as CAA the deposits must be stained by
Congo red, a dye which stains fibrils comprised of ß-pleated sheet folding. There are
approximately seven proteins known to cause CAA, these are Aß, cystatin C,
transthyretin, Gelsolin, prion protein, Abri (familial British dementia) and ADan (familial
Danish dementia) (Castellani et al, 2004). In AD the protein causing CAA is the Aß
protein.
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The most severe consequence of CAA is cerebral hemorrhage, known as CAAassociated hemorrhage (CAAH). There are several types of hemorrhages occurring with
CAA ranging from microhemorrhages (small leaks in the vessel wall) to aneurysm (a
blood-filled dilation of the blood vessel) (McCarron and Nicoll, 2004). These
hemorrhages can result in further cognitive decline or, if severe, even death.
CAA can occur alone or in conjunction with parenchymal amyloid deposits and
neurofibrillary tangles in AD. When CAA occurs alone it can cause extensive dementia.
There are several forms of hereditary CAA such as the Dutch type (HCHWA-D) (Natte et
al, 2001) and the Iowa pedigree (D694N) (Grabowski et al, 2001), both mutations
causing these hereditary CAAs lie in the APP molecule and result in Aß formation.
Unlike those mutations of APP occurring in some familial AD cases which produce
excess Aß1-42, mutations causing CAA result in excessive production of Aß1-40 which
appears to be excessively fibrillogenic in human cerebrovascular smooth muscle (HCSM)
(Grabowski et al, 2001).
The role of CAA in AD is not yet fully known. The reported incidence of CAA in
Alzheimer’s cases has ranged from 78% to 98% (Kallaria and Ballard, 1999) which
suggests and important role for CAA in the pathogenesis of AD although not necessary
for diagnosis of AD. Of those cases, approximately 35-40% are associated with some
form of hemorrhage (Jellinger et al, 2002). Support for the contribution of CAA to the
cognitive decline observed in AD arises from observations that CAA produces ischemia
and hemorrhage that in other disease processes is known to result in cognitive
dysfunction (Cadavid et al, 2000) and also that the frequency and severity of CAA is
increased in AD (Yamada, 2002). Howver, there is yet no evidence to suggest that the
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rate of cognitive decline in AD patients without CAA is any dfferent compared to those
AD patients with CAA. Also, in non-demented individuals CAA appears to have no
effect on cognitive ability (Castellani et al, 2004).
Transgenic mouse models of AD:
Transgenic mouse models for AD became an aim for researchers following the
discovery of many genetic mutations in the APP and PS1 genes thought to cause earlyonset familial AD. An ideal AD animal model would develop all pathological hallmarks
of AD, as well as the cognitive and memory deficits characteristic of AD. This mouse
model would then be the closest thing to an AD patient to allow testing of potential
therapies. A mouse carrying the M146L mutation in the PS1 gene (methionine to leucine
at 146) showed increased production of Αβ1-42/Αβ1-40 compared to widtype littermates as
measured by ELISA, however, these mice did not deposit amyloid, either as diffuse or
compact plaques (Duff et al, 1996). Mice expressing mutations in the APP gene showed
more promise and as a result several APP transgenic mice were produced. The PDAPP
mouse carries the V717F mutation under the control of the platelet derived growth factor
promoter and expresses APP695, APP751 and APP770. This mouse begins amyloid
deposition between 4 and 6 months of age, accelerates rapidly at 7 to 9 months of age
with significant numbers of both diffuse and compact amyloid deposits in the frontal
cortex and hippocampus by 1 year of age. The Tg2576 mouse carries the Swedish
mutation of KM670/671NL under the control of the hamster prion protein promoter and
express APP695 (Hsiao et al, 1996). These mice have detectable diffuse and compact
amyloid deposits by 6 months of age and continue to deposit in an age-dependent manner
showing an acceleration between 8 and 12 months of age (Kawarabayashi et al, 2001).
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Despite the ability to produce transgenic mice that develop amyloid deposits in an
age-dependent manner, very few of these APP transgenics demonstrated reproducible
cognitive and memory deficits. Crossing the M146L PS1 mouse with the Tg2576 APP
mouse not only showed accelerated amyloid deposition (Holcomb et al, 1998, Gordon et
al, 2002) but also developed cognitive and memory deficits detectable by several
behavior paradigms which were reproducible at defined ages (Gordon et al, 2001). The
benefits of this mouse model are that therapies can be tested to show not only their effect
on amyloid deposition but also whether they may have any clinical benefit by showing
whether the treatment improves cognitive function. Although this doubly transgenic
mouse is a good model in which to test therapies, it does still lack two of the three
pathological hallmarks of AD, those of neurofibrillary tangles and neuronal loss, despite
the abundance of amyloid deposits.
Recently, there have been several tau transgenic mice developed, which provide a
further step toward the ideal mouse model for AD. The P301L mutation on chromosome
17 expressed in mice results in development of hyperphosphorylated tau and
neurofibrillary tangles detectable by Gallyas silver staining. The disadvantage to this
mouse is that it also develops motor deficits due to expression of mutated tau in the brain
stem and spinal cord, the animals are completely paralyzed by 12 months of age (Lewis
et al, 2000). The mice also show differential expression between males and females, with
females having 3 to 4 times more expression of the mutated tau than males. Despite the
disadvantages of this mouse model it has been shown that crossing the P301L mouse with
the Tg2576 mouse enhances forebrain neurofibrillary tangle formation, suggesting that
the presence of Αβ influences the extent of neurofibrillary pathology (Lewis et al, 2001).
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Transgenic mice expressing V337M mutant human tau show hyperphosphorylated tau
and neurofibrillary tangles in the hippocampus resulting in behavioral abnormality
(Tanemura et al, 2002).
The ideal mouse model would have all pathological hallmarks of AD; amyloid
plaques, neurofibrillary tangles and neuron loss. The closest mouse model to date is a
triple transgenic developed by Frank LaFerla and colleagues (Oddo et al, 2003). This
group showed a mouse with the M146L PS1 mutation knock-in as well as mutant tau and
APP which both have the Th1 promoter and both co-integrate at the same site, this
produces a closer model of AD than had previously been shown. All three transgenes are
expressed to homozygocity and are expressed at the same levels. The mice develop
amyloid plaques and neurofibrillary tangles. Interestingly the mie develop the amyloid
plaques prior to any tau pathology being observed. The mice also demonstrate agedependent LTP impairment although this occurs prior to any AD-like pathology being
present. At 6 months of age the mice have impaired long-term potentiation (LTP)
suggesting that the mice may develop cognitive deficits. However, to this date no neuron
loss has been reported in this transgenic model.
A better mouse model for AD may be possible thanks to a new mouse model of
tau pathology. In a recent report from Peter Davies and colleagues a mouse, known as the
htau mouse, undergoes age related accumulation of hyperphosphorylated tau like those
observed in AD and the presence of neurofibrillary tangles (Andorfer et al, 2003). These
htau mice are a cross of two existing mouse lines. One is a tau transgenic known as the 8c
mouse which expresses all human tau isoforms but alone does not demonstrate any
evidence of tau pathology (Duff et al, 2000). The other is a tau knockout mouse which
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again, alone does not develop any tau pathology (Tucker et al, 2001). When crossed, a
mouse with all human isoforms but no mouse tau is produced which demonstrates
extensive and age-related tau pathology. This htau mouse has also importantly been
shown to develop age related neuron loss in cortical and hippocampal areas. By the age
of 18 months there is a 50% reduction of neurons in the piriform cortex. There is also an
apparent shrinkage of the cortex and enlargement of the ventricles (Andorfer et al, 2004).
Since this mouse appears to show extensive tau pathology and neuron loss, it is hoped
that crossing this mouse with an APP transgenic mouse may yield a more perfect mouse
model in whch to test potential treatments for AD.
Behavioral Analyses of transgenic mice:
The major clinical symptom of AD is cognitive decline so therefore any effective
clinical therapy must act to improve cognitive function of patients so it is critical that
potential therapies are shown not only to affect the pathological characteristics of AD
such as amyloid plaques or neurofibrillary tangles but must also affect memory. To test
memory impairment in mice there have been several behavioral paradigms developed.
The Morris water maze was first described in 1982 by Richard Morris and
colleagues (Morris et al, 1982) where he showed impairment in the task following
hippocampal lesions. This task is consistently used to assess memory retention. It consists
of a water pool with a hidden escape platform where the mouse must learn the location of
the platform using either contextual or local cues. The mouse’s aversion to water and
swimming force it to look for an escape and therefore search out the platform. This task
has been shown to be heavily hippocampal dependent, where lesions to the hippocampus
or its cholinergic input significantly impair performance. Time taken to locate the
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platform is measured which is known as escape latency. Also measured is the time spent
in the quadrant where the platform was once removed, these trials are known as probe
trials. A modification of the Morris water maze is the radial arm water maze (RAWM)
which is a circular pool with six swim alleys (arms) radiated out from an open central
area with a submerged escape platform located at the end of one of the arms which the
animal must find. There are several spatial cues present on the walls and ceiling of the
testing room. The platform remains in the same arm during testing for each mouse,
however, the arm in which the mouse starts each time is different requiring the mouse to
use the visual cues in order to remember where the platform is (Diamond et al, 1999).
The number of wrong arms entered is measured as errors and also time to find the
platform is measured. Again, this is a heavily hippocampal dependent task and
performance has been shown to be impaired in some transgenic mouse models of AD
(Arendash et al, 2001; Morgan et al, 2000).
Another memory task is contextual fear conditioning which uses an aversive
stimulus coupled to sound. The animal learns to freeze when the sound is heard as it is
associated with the aversive stimulus which is commonly a small electric shock. The
amount of freezing is measured and lack of freezing is associated with impaired memory
of the preceeding events (Gerlai, 2001). This task is highly dependent upon the integrity
of the amygdale however is also sensitive to disruptions in hippocampal function.
The Y-maze is not dependent upon learning a new behavior but depends upon the
tendancy of a mouse to explore new environments. The Y maze is a three arm maze with
equal angles between all arms. Mice are initially placed within one arm and the sequence
and number of arm entries is recorded for each mouse over set period of time (usually
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between five and ten minutes). The percentage of triads in which all three arms are
represented is recorded as an alternation to estimate short-term memory of the last arms
entered. The total number of possible alternations is the number of arm entries minus
two. Additionally, the number of arm entries serves as an indicator of activity.
Inflammation and AD:
Along with the three primary characteristics of AD there is also an extensive
inflammatory response in the brain. Microglia and astrocytes are the two primary
inflammatory cells in the brain and these respond to damage and foreign material in much
the same way as do the immune cells of the periphery. Microglial cells are from the
monocytic lineage and are the resident macrophage in the brain. They have the ability to
produce complement proteins in vitro, potentially contributing to the complement
cascade. They can produce and secrete IL-1, a cytokine with many immune functions.
Microglial cells can also enter into a phagocytic state, at which point they are almost
indistinguishable from a macrophage (Streit, 2002, Liu et al, 2003). Astrocytes are cells
native to the CNS and have many normal functions such as inducing the blood brain
barrier and contributing to the local homeostasis of the synapse by expressing reuptake
proteins on their membrane. Astrocytes also have the ability to produce inflammatory
mediators when activated and are thought to communicate with microglial cells through
these mediators.
In AD activated microglia cluster at sites of amyloid deposition, surrounding the
deposit. Activation can be initially detected by an increased expression of the leukocyte
common antigen CD45 (Aloisi, 2001), a functional transmembrane protein-tyrosine
phophatase (Justement, 1997). In later stages of activation there is further increase in
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expression of CD45 along with expression of the major histocompatibility complex class
II (MHC-II).
Much of the literature in the past decade has focused on the deleterious
consequences of microglial activation (Akiyama et al, 2000). Microglia are capable of
producing many cytokines, reactive oxygen intermediates, excitatory amino acids and
nitric oxide (NO) (Streit et al, 1999), all of which could significantly contribute to
neuronal death seen in AD. In vitro, Αβ can stimulate release of IL-1, IL-6, TNF-α and
superoxide free radicals from microglia (McGeer and McGeer, 2001). IL-1 has an
autocrine induction in microglia and also enhances microglia proliferation, it causes
direct neurotoxicity and apoptosis. IL-6 causes astrogliosis but can be both a survival
factor and a neurotoxic factor depending on its levels. TNF-α can cause nitric oxide
production and MHC-II expression in microglia (Wilson et al, 2002). All of this data led
to the hypothesis that inflammation in the AD brain, particularly the activation of
microglia, contributes negatively to the disease process, and inhibition of this
inflammation was the target of AD therapies. It has been shown that the glucocorticoid
anti-inflammatories are capable of inhibiting microglia activation as detected by nitric
oxide production (Chang and Liu, 2000) and by measurement of the extent of
proliferation (Tanaka et al, 1997). Epidemiological studies have shown a beneficial effect
of NSAIDs in the prevention of AD. It was thought that this beneficial effect was due to
inhibition of inflammation, however, a report in 2001 showed that the effects of nonsteroidal anti-inflammatory drugs (NSAIDs) in AD may actually be independent of
cyclooxygenase (COX) activity and may in fact be due to an effect at the γ-secretase
enzyme. This study showed that in cultured cells following treatment with ibuprofen
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there is a decrease in Αβ42 production but an increase in Αβ(1-38), which is not
amyloidogenic, although the concentrations of ibuprofen used in this study are much
greater than those required for COX inhibition (Weggen et al, 2001). A novel nonsteroidal anti-inflammatory drugs (NSAID) with a nitric oxide donor group and an
antioxidant group showed an unexpected increase in microglial activation when
administered to APP+PS1 mice, associated with a significant reduction in diffuse and
compact amyloid deposits (Jantzen et al, 2002). Recent data suggests that inflammation
in AD is much more complex than originally thought and that microglia may have a
beneficial role to play in AD.
Microglia have been shown to phagocytose Αβ both in vitro and in vivo through
several different mechanisms involving opsonization through the complement cascade
(Rogers et al, 2002) or the scavenger receptor (Paresce et al, 1996). Curiously, however,
3D reconstruction of the microglia by electron microscopy in untreated transgenic mice
was unable to detect intracellular amyloid despite amyloid fibrils being completely
engulfed by microglia (Stalder et al, 2001). Interestingly, it has been shown that coculture of microglia with astrocytes suppresses microglia phagocytosis of senile plaques
(DeWitt et al, 1998). Removal of Αβ by microglia has led to the hypothesis that there
exists a dynamic equilibrium between Αβ deposition and Αβ removal, and that inhibition
of microglia activation may, in fact, result in greater deposition of Αβ and a more rapid
progression of the disease. An interesting finding to support the beneficial role of
microglia is that when APP transgenic mice express soluble complement receptor related
protein y (sCrry), a complement inhibitor, a 2 to 3-fold increase in Αβ deposition is seen
as well as a prominent accumulation of degenerating neurons not normally seen in the
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APP transgenic mouse alone. Microglial activation is reduced significantly in this mouse
model, suggesting that inhibiting complement, therefore inhibiting opsonization and
phagocytosis, will have a detrimental effect on the disease process (Wyss-Coray et al,
2002). Another transgenic model that has supported the beneficial role of microglia is a
mouse that overproduces transforming growth factor (TGF)-β1 crossed with an APP
transgenic mouse. In this model, the overexpression of TGF-β1 results in a vigorous
microglial activation along with a 50% reduction in Αβ deposition (Wyss-Coray et al,
2001). TGF-β1 has also been shown to result in clearance of Αβ by microglial cells in
culture. Further support for microglial removal of Αβ was shown when
lipopolysaccharide (LPS) was intracranially injected into the hippocampus of APP+PS1
mice. One week following the injection, there was a significant removal of Αβ associated
with significant microglial activation; however, compact plaques were not removed
(DiCarlo et al, 2001; Herber et al, 2004).
Immunotherapy for AD:
Using the amyloid hypothesis as the basis for the development of AD therapies,
Dale Schenk and colleagues at Elan pharmaceuticals reported the use of Αβ1-42, the
amyloidogenic protein in AD, as an immunogen. They immunized PDAPP transgenic
mice with Αβ1-42 in an aggregated / fibrillar preparation which is emulsified in Freund’s
adjuvant to increase the immune response to the antigen. Each mouse received 100µg
Αβ. This was repeated 2 weeks later and then monthly thereafter. It was shown that
immunization reduced and/or prevented Αβ accumulation in this mouse model and
associated with this reduction was an activation of microglia suggesting that part of the
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mechanism of clearance involved these inflammatory cells. Subsequent work by our
group demonstrated that not only did Αβ immunization modestly reduce amyloid burden
but more importantly it prevented cognitive impairment in the doubly transgenic APP +
PS1 mice (Morgan et al, 2000). This finding was also shown by Janus and colleagues at
the same time in a different mouse model, the TgCRND8 mouse which is transgenic for
APP only (Janus et al, 2000). Following this our group conducted several more
immunization studies which led to the finding that following immunization there is a
strong correlation between microglial activation and reduction in the congophilic,
compact amyloid deposits (Wilcock et al, 2001).
There has also been data to show that anti-Αβ antibodies can dissolve fibrils in
vitro (Solomon et al, 1997). More recent data to support this dissolution of plaques
showed that anti-Αβ F(ab’)2 fragments directly applied to the brains of Tg2576 or PDAPP
mice results in reduction of Αβ and thioflavine-S comparable with the reduction seen
when a whole anti-Αβ IgG is applied (Bacskai et al, 2002).
The vaccine, now known as AN1792, advanced to human clinical trials, however,
during phase II trials there were several patients found to be suffering from cerebral
inflammation and meningoencephalitis (Bowers and Federoff, 2002, Munch et al, 2002).
It is important to note that the occurance of the meningoencephalitis did not correlate at
all with antibody titers in those patients (Orgogozo et al, 2003). Interestingly, it was
shown that the antibodies generated by humans in response to the AN1792 immunization
recognized both diffuse and compact amyloid deposits in transgenic mouse and human
brain tissue, however, it did not cross react with full length APP or vascular Αβ (Hock et
al, 2002).
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Since the original report of meningoencephalitis in some participants of the
AN1792 trial there have been several reports on pathology from some of the participants
following their death. The first was from James Nicoll and colleagues (2003) who
reported on a 72 year old female who had been clinically diagnosed with moderate AD
and had developed meningoencephalitis following the fifth injection. Some features of
AD were detected such as cortical atrophy, ventricle enlargement and the presence of
neurofibrillary tangles and amyloid plaques. However, it was observed that this patient
that amyloid plaques were sparse in comparison with control AD cases throughout most
of the neocortex. Reactive microglia were also observed and appeared to colocalize with
immunostaining for Aß. Importantly, it was shown that vascular amyloid deposits
persisted and appeared not to be reduced by immunization. In a report published a year
later showing the pathology from another patient the findings were very similar (Ferrrer
et al, 2004). This report shows the brain pathology from a 76 year old male who
developed meningoencephalitis following the second immunization. Tau pathology was
comparable to that found in AD control brain, however, very low numbers of amyloid
plaques were observed and remaining plaques were associated with high numbers of
activated microglia. Also observed were severe small blood vessel disease and multiple
cortical hemorrhages.
Hock et al (2003) reported that antibody titers measured by ELISA were not a
good indicator of cognitive performance following immunization, however a new method
for measuring antibody reactivity was developed called the tissue amyloid plaque
immunoreactivity (TAPIR) assay. The TAPIR assay measures the binding capacity of the
circulating antibodies to amyloid plaques in transgenic mouse tissue and human AD brain
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tissue. Those patients showing strong TAPIR results also showed stabilization of
cognitive performance while those patients without TAPIR reactivity results showed a
normal cognitive decline for AD. Together with the pathology reports from two patients
in the trial these data suggest that immunotherapy may be a promising approach to the
treatment of AD if the meningoencephalitis can be avoided.
Subsequent to the initial studies of immunization using Αβ1-42 in 1999 and 2000,
researchers began to look at passive immunization as a potentially safer approach to an
immunotherapy since it had been shown that active immunization may be less effective
in people with a significant amyloid burden. A study suggests that the vaccine may be
much more effective at preventing amyloid deposition as opposed to removal of existing
deposits (Das et al, 2001). It has also been found by work in our laboratory that the
ability to produce sufficient antibody titers against Αβ1-42 may decline with age. The first
report of passive immunization came in 2000 from Elan pharmaceuticals, who
administered antibodies against Αβ via an intraperitoneal injection in PDAPP mice (Bard
et al, 2000). The antibodies were administered weekly for a period of six months. This
resulted in a significant reduction in plaque burden in both the cortex and hippocampus.
Importantly they showed by immunohistochemical methods that the injected antibody
does cross the blood-brain barrier and enter the brain. They also estimated the amount of
IgG entering the brain to be 0.1% as calculated by examining endogenous IgG levels in
brain parenchyma. The amount of IgG entering the CNS was confirmed by a study
specifically aimed at detection of peripherally injected anti-Αβ IgG in the CNS of
SAMP8 mice, which overexpress APP but do not deposit amyloid. The authors found
that 0.11% of injected IgG enters the brain within 1 hour, IgG was still detectable in the
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brain 72 hours following injection (Banks et al, 2002). In the Bard et al study (2000) the
authors demonstrated that although the antibodies they had used for this immunization
were capable of triggering microglial-mediated phagocytosis of amyloid in culture, F(ab’)2
fragments were unable to activate microglial removal despite retaining the full ability to
bind to Αβ. This result suggests that clearance of fibrillar amyloid is via Fc receptor
mediated phagocytosis. This proposed mechanism was further supported by a study
involving direct imaging of amyloid deposits in living mice using multiphoton
microscopy (Bacskai et al, 2001). Three days following direct application of antiΑβ antibodies to the brain of PDAPP mice there was significant removal of amyloid
deposits accompanied by activation of microglia surrounding the remaining deposits.
Human postmortem microglia have been shown to phagocytose opsonized Αβ, which is
inhibited in the presence of excess non-specific IgG, suggesting the phagocytosis is Fc
receptor mediated (Lue et al, 2002).
More recently, studies involving passive immunization have suggested that the
primary mechanism for Αβ clearance is peripheral and is not due to the antibodies
entering the CNS. It has been shown that following intraperitoneal injection of antiΑβ antibodies in the PDAPP mouse there is a rapid 1,000-fold increase in circulating
plasma Αβ, suggesting that circulating Αβ antibodies bind to plasma Αβ and thus cause a
disruption in the equilibrium between the brain and plasma removing Αβ from the brain.
This study importantly used antibodies that have been shown not to bind to plaques in the
brain, so their effect on brain amyloid burden is not due to binding fibrils (DeMattos et al,
2001). This same group also demonstrated that administration of this same antibody to
PDAPP mice is capable of reversing memory deficits in only one day without a reduction
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in amyloid burden in the brain (Dodart et al, 2002). The authors suggest that this rapid
reversal of cognitive deficits is due to removal of soluble Αβ from the CNS as opposed to
reducing brain amyloid plaque burden. Cognitive improvement following passive
immunization has also been shown in the Tg2576 mouse with an antibody recognizing
Aß1-12 which did not reduce brain Aß levels but did reverse memory deficits (Kotilinek
et al, 2002). Application of anti-Aß antibodies to the surface of the brain has been shown
to not only reduce the size and number of amyloid deposits but also to recover dystrophic
neuritis from a curvy, distorted appearance to a straighter, more normal appearance
(Lombardo et al, 2003).
It appears that an important issue of passive immunization is the antibody isotype.
It has been shown that IgG2a antibodies clear Aß from PDAPP brain sections in an ex
vivo assay much more effectively than either IgG1 or IgG2b antibodies despite all
antibodies having the same epitope (Bard et al, 2003). This data also supports the
hypothesis that microglia are responsible for the clearance of Aß by immunotherapy since
FcγRI and III bind with the greatest affinity to murine IgG2a antibodies (Radaev and Sun,
2001). The fact that IgG2a anti-Aß antibodies appear to be the most effective indicate
that Aß clearance may be mediated through microglial Fc receptors. However, conflicting
data suggests that effective clearance of Aß by anti-Aß antibodies can be obtained in the
absence of Fc receptors. Das et al (2003) showed that when they actively immunized
APP transgenic mice crossed with Fc receptor knockout mice they showed the same
amount of Aß reductions as immunized, age-matched APP transgenic mice.
A concerning effect of passive immunization is a report showing an increase in cerebral
microhemorrhage in very old APP23 mice following passive anti-Αβ immunotherapy
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(Pfeifer et al, 2002). This effect has not been shown in any other study, but will need to
be investigated if passive immunization is to enter human trials.
To summarize, there are three main proposed mechanisms of action of
immunotherapy for AD. The first is the binding of antibody to Αβ and resulting in Fc
receptor mediated phagocytosis. The second is that antibodies binding to Αβ cause a
disggregation of the plaque and result in a dissolution. The third is that the effects are
primarily peripheral, with circulating antbodies binding to Αβ in plasma and causing a
disruption in equilibrium between brain and plasma causing the Αβ to be “drawn out” of
the brain. It would be naïve to think that only one of these could occur, as the data for all
three is convincing. However, the main question is which mechanism is going to produce
the most beneficial effect with the least adverse effects and whether immunotherapy can
be manipulated to take advantage of this mechanism.
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Abstract
Active immunization against Αβ1-42 with vaccines or passive immunization with
systemic monoclonal anti-Aß antibodies reduces amyloid deposition and improves
cognition in APP transgenic mice . In this report, intracranial administration of anti-Αβ
antibodies into frontal cortex and hippocampus of Tg2576 transgenic APP mice is
described. The antibody injections initially results in a broad distribution of staining for
the antibody which diminishes over 7 days. While no loss of immunostaining for
deposited Aß is apparent at 4 hours, a dramatic reduction in the Αβ load is discernable at
24 hours and maintained at 3 and 7 days. A reduction in thioflavine-S positive compact
plaque load is delayed until 3 days, at which time microglial activation also becomes
apparent. At one week after the injection, the microglial activation returns to control
levels, while the Αβ and thioflavine-S staining remains reduced. The results from this
study suggest a two phase mechanism of anti-Αβ antibody action. The first phase occurs
between 4 and 24 hours, clears primarily diffuse Αβ deposits and is not associated with
observable microglial activation. The second phase occurs between 1 and 3 days, is
responsible for clearance of compact amyloid deposits and is associated with microglial
activation. The results are discussed in the context of other studies identifying coincident
microglial activation and amyloid removal in APP transgenic animals.

Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by
progressive cognitive deficits. There are several pathological characteristics to the disease
process, including congophilic amyloid plaques containing the beta-amyloid peptide
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(Αβ), and intracellular inclusions of neurofibrillary tangles consisting of
hyperphosphorylated tau protein. Another characteristic of AD is the initiation and
proliferation of a brain-specific inflammatory response consisting of activated microglia
and astrocytes. Amyloid deposition is thought to be the key step in the pathogenesis of
AD (Selkoe, 1991; Hardy and Selkoe, 2002); this is the reason why development of
potential therapies focuses on clearance of amyloid.
Vaccination using Αβ1-42 was first described by Schenk et al. (1999). This report
demonstrated that active immunization using Αβ1-42 in the PDAPP transgenic mouse
dramatically reduced levels of Αβ deposits. This immunization protected APP+PS1
transgenic mice (Morgan et al., 2000) and TgCRND8 transgenic mice (Janus et al., 2000)
from memory deficits. More recent studies showed that treatment with a passive
immunization regimen consisting of anti-Αβ antibodies resulted in a dramatic reduction
in Αβ (Bard et al., 2000;DeMattos et al., 2001) and reversal of memory deficits (Dodart
et al., 2002;Kotilinek et al., 2002) in the PDAPP mouse.
In this experiment, we show that intracranially administered anti-Αβ antibodies
have both an early, microglia independent, and a later, possibly microglia dependent
mechanism of action. Αβ levels are dramatically reduced 24 hours following
administration in the absence of microglial activation. However, 72 hours after antibody
administration thioflavine-S positive compact plaques are reduced concomitant with a
striking activation of microglia.
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Materials and Methods.
Transgenic Tg2576 APP mice (Hsiao et al., 1996) were obtained following
breeding of Tg2576 APP mice with line 5.1 PS1 mice (Duff et al., 1996) which yields
four different genotypes; nontransgenic, transgenic APP, transgenic PS1 and doubly
transgenic APP+PS1 mice. Animals were provided food and water ad libitum and were
kept on a 12-hour light/dark cycle; they were housed in groups where possible until prior
to the surgery when they were all singly housed until kill. We used 2 cohorts of mice in
this study, the first cohort of 19 mo old APP mice (n=16) and the second cohort of 16 mo
old APP mice (n=22).
Mice from the first cohort all received anti-Αβ antibodies (Biosource, Camarillo
CA, mouse anti-Αβ IgG1, recognizing AA 1-16). Mice from the second group were
assigned to groups receiving either anti-Αβ antibodies, control antibody (anti-HIV, ID6,
K. Ugen, Dept. Med. Micro. USF) (N=5), or vehicle (0.02% thimerosal in PBS, SigmaAldrich, St Louis, MO) (N=5). All mice were injected in both the frontal cortex and
hippocampus of the right hemisphere while the left hemisphere remained untreated as an
internal control. Those mice receiving anti-Αβ antibodies were assigned survival times of
4 (N=5), 24 (N=7), 72 (N=8) or 168 (N=6) hr. Mice receiving either control antibody or
vehicle were examined after a 72 hr survival time. A third group of unreated 17 mo old
APP mice (N=5) were killed uninjected and unmanipulated to assess differences between
the right and left sides of the brain.
On the day of surgery the mice were weighed, anesthetized with isoflurane and
placed in a stereotaxic apparatus (51603 dual manipulator lab standard, Stoelting, Wood
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Dale, IL). A midsagittal incision was made to expose the cranium and two burr holes
were drilled using a dental drill over the right frontal cortex and hippocampus to the
following coordinates: Cortex: AP +1.5mm, L –2.0mm, hippocampus: AP –2.7mm, L –
2.5mm, all taken from bregma. A 26 gauge needle attached to a 10µl Hamilton (Reno,
NV) syringe was lowered 3mm ventral to bregma and a 2µl injection was made over a 2
minute period. The incision was cleaned with saline and closed with surgical staples.
On the day of kill the mice were overdosed with 100mg/kg of pentobarbital
(Nembutal sodium solution, Abbott laboratories, North Chicago IL) and perfused
intracardially with 25ml of 0.9% sodium chloride and 50ml of freshly prepared 4%
paraformaldehyde (pH=7.4). The brains were collected and post fixed for 24 hours in 4%
paraformaldehyde. The brains were then incubated for 24 hours in 10, 20 and 30%
sucrose sequentially to cyroprotect them. Horizontal sections of 25µm thickness were
then collected using a sliding microtome and stored at 4oC in DPBS buffer with sodium
azide to prevent microbial growth. Six to eight sections approximately 100µm apart were
selected spanning the injection site and stained using free-floating immunohistochemistry
methods for total Αβ (rabbit antiserum primarily reacting with the N-terminal of the Αβ
peptide 1:10000), CD45 (Serotec, Raleigh NC, 1:3000) and major histocompatibility
complex class II (MHC-II, BD Pharmingen, Palo Alto CA, 1:3000) as previously
described (Gordon et al., 2002). For immunostaining, some sections were omitted from
the primary antibody to assess non-specific immunohistochemical reactions. Also,
immunohistochemical methods were used to stain for the injected antibody using antimouse IgG conjugated to horseradish peroxidase (Sigma-Aldrich, St Louis MO, 1:1000).
Adjacent sections were mounted on slides and stained using 4% thioflavine-S (Sigma- 25 -

Aldrich, St Louis MO) for 10 minutes. Selected sections stained for CD45 were
counterstained for Congo red (Sigma-Aldrich, St Louis MO) to detect amyloid deposits
on these sections.
The immunohistochemical reaction product on all stained sections was measured
using using a videometric V150 image analysis system (Oncor, San Diego, CA) in the
injected area of cortex and hippocampus and corresponding regions on the contralateral
side of the brain. Data are presented as the average ratio of injected side to non-injected
side for Αβ, thioflavine-S and CD45, while data for MHC-II are expressed as area
occupied by positive stain since many values on the contralateral side were close to zero.
To assess possible treatment-related differences, the measurement for either
cortex or hippocampus of each subject were analyzed by ANOVA using StatView
software version 5.0.1 (SAS Institute Inc., NC) followed by Fischer’s LSD means
comparisons.

Results
Immunohistochemistry against mouse IgG was performed to trace the diffusion of
anti-Aß antibodies after injection into the hilus of the dentate gyrus. The injected anti-Αβ
antibody showed diffuse distribution throughout the entire hippocampus at 4 hours with a
focal concentration in the outer molecular areas of the dentate and ammons' horn near the
hippocampal fissure (Fig. 1A). By 24 hours, the diffuse pattern remained broad, but the
focal concentration began shifting towards the granule cell layers of the dentate (Fig. 1B).
At 72 hours, staining for the injected antibody was lighter and became concentrated at the
granule cell layer of the dentate gyrus (Fig. 1C). Interestingly, by the one week time- 26 -

point the injected antibody staining has largely cleared with some residual staining in the
outer molecular layer of the ventral (ventricular) blade of the dentate gyrus and the glial
limitans. A similar time course of staining was seen in the frontal cortex (data not
shown).
Αβ immunohistochemistry in APP transgenic mice resembled that reported by
others and ourselves earlier (Hsiao et al., 1996; Gordon et al., 2002). In both cortex (Fig.
2A) and hippocampus (Fig. 2C) there were a few intensely stained deposits and a number
of smaller, less intensely stained deposits. In prior work, we found the intensely stained
Aß deposits were usually also stained with thioflavine-S or Congo red (Holcomb et al.,
1998; Gordon et al., 2001) indicating they were analogous to compact deposits containing
fibrillar amyloid, while the less intense deposits were analogous to diffuse, nonfibrillar
deposits commonly observed in AD tissue. While the deposits were fairly uniformly
distributed within the cortex, in the hippocampus they were concentrated in the outer
molecular layers of the dentate gyrus and ammon’s horn (Fig. 2C). The subiculum also
appeared more rich in deposits than other areas.
The injection of anti-Αβ antibody into brain did not result in a rapid loss of signal
in postmortem immunohistochemical reactions since we did not observe a change in Αβ
staining 4 hours post-injection in either cortex (Fig 3A) or hippocampus (Fig 3B).
However, Αβ staining was reduced at the injection sites in frontal cortex and
hippocampus 24 hours after administration of anti-Αβ antibody (Fig 2B and D
respectively) and remained reduced to roughly the same extent through the one week
time-point (Fig 3). The reduction in the frontal cortex was over 60% as compared to both
the 4 hour time-points and the two control groups of vehicle and anti-HIV antibody (Fig
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3A, P<0.001). The reduction in the hippocampus was over 50% as compared to the 4
hour time-points and the control groups (Fig 3B, P<0.005).
An interesting phenomena was that the ratio of Aß staining on the right to left
sides in untreated mice was greater than 1, indicating more Αβ deposition on the right
side than the left (Figure 3). It appears that this pattern of Αβ deposition is a consistent
property of the APP mice. The Aß distribution seen in the mice administered control
injections at 3 days and anti-Αβ antibody at the 4 hour time point is the typical
distribution found in APP transgenic mice of this age.
As expected, the number of deposits stained with thioflavine-S were considerably
fewer than those stained by Αβ immunohistochemistry. Nonetheless, the regional
distribution of these deposits roughly paralleled that of Αβ positive deposits in the cortex
and hippocampus (Fig. 4A and C). In contrast to the Αβ, thioflavine-S positive staining at
the injection site was not reduced until 72 hours after administration of anti-Αβ antibody
(Fig 4B and D) and remained reduced at the one week time point (Fig. 5). The reduction
in frontal cortex was over 80% compared to the 4 and 24 hour time points as well as the
control groups (Fig 5A, P<0.001). The reduction in hippocampus was over 60%
compared to both the 4 and 24 hour time points and the control groups (Fig 5B, P<0.005).
In untreated mice, activated microglia stained with CD45 or MHC-II antibodies
are found only in the immediate periphery of compacted plaques. In the injected control
groups, some microglial activation was detected at the 72 hour survival time by CD45
antibodies and this was restricted primarily to the injection site (arrows, Fig 6A, C;
quantified in Fig 7). It should be noted that very little staining for CD45 was detected on
the uninjected side of the brain, leading to inflated R/L ratios with relatively small
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increases in staining. MHC-II had a lower overall level of expression than that of CD45,
and was largely unaffected in mice administered control injections (Fig 8A and C;
quantified in Fig 9).
In contrast, 72 hours after the injection of anti-Aß antibodies, the microglial
activation detected with CD45 antibodies was more widespread, detected not only at the
injection site but also away from the injection site in the frontal cortex (Fig 6B) and
throughout the dentate gyrus, with a concentration within the granule cell layer at the 72
h time point (Fig 6D). MHC-II staining revealed a similar pattern, although not as
extensive as that found with CD45 staining (Fig 8B, C).
Quantification of these results indicated that the injection of anti-Αβ antibodies
significantly increased expression of the microglial marker CD45 only at the 72 hour
time point as compared to all other time points and control groups in both cortex (Fig 7A;
P < 0.005) and hippocampus (Fig 7B; P < 0.005). Also, the injection of anti-Αβ
antibodies increased the expression of the microglial marker MHC-II at the 72 hour timepoint as compared to all other time points and control groups in both cortex (Fig 9A; P <
0.01) and hippocampus (Fig 9B; P , 0.005). The expression of CD45 and MHC-II in the
frontal cortex at the anti-Αβ injection site increased more than 8-fold over that of all
other time points including one week and both of the control groups . The expression of
CD45 in the hippocampus at the anti-Αβ injection site increased more than 2-fold while
the increase in expression of MHC-II is over 8 fold. As in our prior work, there is
considerable variability among samples with both microglial markers, however, all antiΑβ injected animals were higher than the means for the control groups.
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There are few remaining amyloid deposits near the injection sites in the anti-Αβ
antibody injected mice at 72 hours (Fig 4 and 5). These residual deposits are relatively
faint when stained with Congo red and are can be found contacted by rounded, CD45
positive microglial cells (Fig 10A). In contrast, the more abundant amyloid deposits on
the contralateral side and in the control animals are contacted by microglia with long
processes which are stained for CD45 while the cell body only stains faintly for this
marker of microglial activation (Fig 10B).

Discussion
We report here that intracranial anti-Aß antibody injections substantially reduce
Αβ load in the vicinity of the injection in both anterior cortex and hippocampus over a 7
day time frame. By 4 hours after the injection there is a broad distribution of injected
antibody filling a volume of roughly 0.5 mm3 as estimated from anti-IgG
immunohistochemistry. In addition to the broad pattern of diffusion, the antibody is
concentrated in the outer molecular layers of Ammon's horn and the dentate gyrus, a zone
which largely overlaps with the distribution of Aß staining in transgenic mice of this age
(see fig 2C). Thus, it appears the injected antibody is binding to in situ Aß at this early
time point, but is also spread throughout the hippocampus. By 24 hours there is a
reduction in the Aß immunostaining in the vicinity of the antibody injection in both
cortex and hippocampus. This reduction in Αβ load is unlikely to be an artifact caused
by the injected antibody masking the epitope of the primary antibody used for
immunohistochemistry because the reduced load was not detected 4 hours after
administration, and by 24 hours the injected IgG appears to be concentrated closer to the
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granule cell region than the outer molecular layer in the hippocampus. Furthermore, the
stoichiometry of injected antibody (13 pmol) to Αβ in deposits (estimated at 250 pmol in
0.5 mg, Chapman et al., 1999) is likely too low to interfere substantially with the
histochemical reaction. This early reduction in Aß load occurs in the absence of the
expression of microglial activation markers CD45 and MHC-II. Although this does not
preclude some rapid response of the microglia, it does suggest that the role of microglia is
qualitatively different at this early post-survival time than when markers of activation are
being expressed.
Between 24 and 72 hours after injection of anti-Aß antibodies, there were parallel
reductions in fibrillar amyloid deposits detected by thioflavine-S and increases in
microglial activation, evaluated by CD45 and MHC-II staining. Although the control
injections of anti-HIV antibody and vehicle caused some elevation of the CD45 marker,
the activation was restricted to the immediate vicinity of the injection site and likely
caused by mechanical injury associated with the needle insertion and fluid compression
of the tissue. Occasionally, in the anti-Aß antibody injected mice, some remaining wisps
of amyloid could be found in the vicinity of the antibody injection at 72 hours and these
were in contact with rounded CD45 immunopositive cells suggestive of phagocytic
microglia/macrophages. Also at the 72 hour time point, there is a concentration of
staining for both the injected antibody and the microglia near the granule cell layer of the
dentate gyrus. The temporal association of fibrillar amyloid loss with microglial
activation suggests some causal role for microglial activation in this process. One
possibility is that between 1 and 3 days activated microglia near the deposits in the outer
molecular layer phagocytose opsonized amyloid via Fc receptor or complement mediated
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mechanisms and migrate towards the granule cell layer. CD45 positive microglia can be
readily detected in the outer molecular layer near the fissure at 3 days, although they are
most heavily concentrated near the granule cell layer at this time point (Fig 6D). A
second option is that after dissolution of the Aß deposits, the antibodies diffuse to the
granule cell region independent of the microglia. possibly, the fibrillar deposits simply
require more time to dissolve than the more diffuse material. More detailed time course
studies of the period between 1 and 3 days coupled with immunoelectron microscopy will
likely be required to resolve between these options. Remarkably, the microglial activation
is terminated rapidly, and returns to normal levels by the 1 week time point in parallel
with a significant reduction in staining for the injected IgG and Aß.
An accumulating body of evidence finds an association between microglial
activation and amyloid reductions in transgenic mouse models of amyloid deposition.
Schenk et al (1999) noted in the first study evaluating Aß vaccines that the clearance of
amyloid was associated with enhanced microglial activity around the remaining deposits.
Wilcock et al (2001) largely confirmed this observation in a different transgenic model.
Nakagawa et al (2000) unexpectedly found that fluid percussion injury activates
microglia and results in reduced amyloid deposition as mice grow older. Lim et al (2001)
noted that transgenic mice treated with curcumin had a reduced amyloid load, but an
increase in the activation state of microglia surrounding plaques. Similarly, Jantzen et al
(2002) found a reduced amyloid load in transgenic mice treated with a nitro-NSAID,
NCX-2216, which was also associated with increased microglial activation. Wyss-Coray
(2001) found that crossing APP transgenic mice with mice over-expressing TGF-ß led to
increased microglial activation and reduced amyloid loads. Conversely, these same
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authors (Wyss-Coray et al, 2002) found that blocking complement activation with
sCRRY overexpression diminished the microglial reaction in APP transgenic mice, and
led to elevated amyloid loads. DiCarlo et al (2001) attempted to directly activate
microglia by injecting LPS and found this was associated with clearance of Aß in the
vicinity of the injection. However, note that Qiao et al, (2001) injected LPS chronically
into young transgenic mice prior to normal amyloid deposition and found it could
stimulate Aß deposition. It is also the case that careful serial section electron microscopy
failed to detect internalized amyloid in microglia associated with amyloid deposits in
untreated APP23 transgenic mice (Stalder et al, 2001), although mice treated to provoke
microglial activation have yet to be examined. Nonetheless, there is a growing literature
associating the activation of microglia with a reduction in Aß deposition in the transgenic
mouse models.
A number of studies have demonstrated that cultured microglial cells are capable
of internalizing Αβ1-42 aggregates (Paresce et al., 1996;Webster et al., 2001). Aß can
also be cleared from unfixed brain sections by anti-Aß antibodies in a microglia
dependent manner (Bard et al., 2000). Direct imaging of amyloid deposits in vivo by
multiphoton microscopy has shown clearance of plaque following application of an antiΑβ antibody in association with an upregulation of activated microglia (Bacskai et al.,
2001). Suggested alternative mechanisms to microglial phagocytosis include a physical
interaction between antibody and Αβ resulting in disaggregation of deposits, which was
demonstrated in vitro using monoclonal anti-Aß antibodies (Solomon, 2001). Consistent
with this idea, Backsai et al (2002) recently demonstrated that F(ab’)2 fragments, prepared
from an anti-Aß antibody reduce amyloid deposits as effectively as the intact antibody
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when applied topically to the cortex of transgenic mice through a craniotomy. Although
there is no measurement of microglial activation in this study, it is plausible this occurred
in the absence of microglial involvement. This antibody mediated dissolution hypothesis
is consistent with the early phase of Aß reduction described here, and may still be found
responsible for the second phase of fibrillar deposit reduction..
A major unresolved question is how this antibody mediated clearance of Aß might
apply to the human condition. Alzheimer's disease has increasingly been argued to
involve inflammation as a component of its pathogenesis (McGeer and McGeer, 2001).
The early stages of the Aß vaccine trials resulted in a small fraction of patients
developing adverse reactions consistent with inflammation of the central nervous system,
presumably including microglial activation (Schenk et al, 2002; Hock et al., 2002).
Although adverse reactions to immunotherapy have been rare in the transgenic models
(Pfeifer et al, 2002), it remains the best experimental system in which to understand the
different components of the immune reactions to vaccines and to identify those
components causing adverse outcomes. Certainly identification of immunotherapies
which avoid the problem of deleterious CNS inflammation will be necessary if this
treatment approach is to ever find use in the clinic. Better understanding the mechanisms
of antibody-mediated clearance of Aß in the transgenic models of amyloid deposition
should benefit this effort.
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Figure 1: Time course of injected anti-Αβ antibody distribution in the hippocampus from
4 hours to seven days. Immunohistochemical staining for the injected antibody in the
hippocampus at 4 hours (A), 24 hours (B), 72 hours (C) and 168 hours (D). Orientation
and locations of hippocampal subregions as in figure 2 D. Magnification = 40X. Scale bar
= 120µm.
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Figure 2: Reduction in Αβ immunohistochemistry one day after anti-Αβ antibody
injections. Immunohistochemical staining is shown for Αβ in the frontal cortex (A and B)
and hippocampus (C and D). A and C are from an animal injected with control antibody
while B and D received the anti-Αβ antibody. Magnification = 40X. Scale bar = 120µm.
Panel B: FCX: frontal cortex, STR: striatum. Panel D: CA1: cornu ammonis 1, CA3:
cornu ammonis 3, DG: dentate gyrus
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Figure 3: Quantification of reduced Αβ load after anti-Αβ antibody injections. Data are
expressed as the ratio of Aß staining in the injected hemisphere: control hemisphere. The
three bars on the left indicate the Αβ load in the untreated group (none) and the vehicle
(VEH) and anti-HIV antibody (Cont-Ab) groups at 72 hr. The line shows the ratio of Αβ
immunohistochemical staining at 4, 24, 72 and 168 hr survival times. Reduced Αβ load
was observed in the frontal cortex (panel A) and hippocampus (panel B) at 24, 72 and
168 hours compared with 4 hours and both control groups (** indicates P<0.005).
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Figure 4: Reduction in thioflavine-S staining three days after anti-Αβ antibody injections.
Thioflavine-S staining is shown in frontal cortex (A and B) and hippocampus (C and D).
A and C received control antibody while B and D received anti-Αβ antibody.
Magnification = 40X. Scale bar = 120µm. Orientation and locations of major subregions
as in figure 2B and 2D.
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Figure 5: Anti-Αβ antibody injections results in a reduction of thioflavine-S positive
plaques. Data are expressed as ratio of thioflavine-S staining in the injected hemisphere:
control hemisphere. The three bars show the thioflavine-S positive staining in the
untreated group (none) and the vehicle (VEH) and anti-HIV antibody (Cont-Ab) groups
at 72hr. The line shows the ratio of thioflavine-S staining at 4, 24, 72 and 168 hour
survival times. Reduced thioflavine-S staining was observed in the frontal cortex (panel
A) and hippocampus (panel B) at 72 and 168 hours compared with 4 and 24 hours and
both control groups (** indicates P<0.005).
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Figure 6: CD45 immunohistochemistry is increased three days following antiΑβ antibody injections. CD45 immunohistochemistryis shown in frontal cortex (A and B)
and hippocampus (C and D). A and C received control antibody while B and D received
anti-Αβ antibody. Magnification = 40X. Scale bar = 120µm. Arrows indicate the site of
injection identified from the needle tract.
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Figure 7: Anti-Αβ antibody injections results in an increased CD45
immunohistochemistry three days following injection. Data are expressed as the ratio of
CD45 staining in the injected hemisphere: control hemisphere. The three bars indicate the
CD45 expression in the untreated group (none) and the vehicle (VEH) and anti-HIV
antibody (Cont-Ab) groups at 72hr. The line shows the ratio of CD45 staining at 4, 24, 72
and 168 hour survival times. Increased CD45 staining was observed in the frontal cortex
(panel A) and hippocampus (panel B) at 72 hours compared with 4, 24 and 168 hours and
both control groups (** indicates P<0.005).
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Figure 8: MHC-II immunhistochemistry is increased three days following anti-Αβ
antibody injections. MHC-II immunohistochemistry is shown in frontal cortex (A and B)
and hippocampus (C and D). A and C received control antibody, B and D received antiΑβ antibody. Magnification = 40X. Scale bar = 120µm.
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Figure 9: Anti-Αβ antibody injections results in an increase in MHC-II
immunohistochemistry three days following injection. Data are expressed as percent area
occupied by MHC-II positive staining in the injected hemisphere. The three bars indicate
the MHC-II expression in the untreated (none) group and the vehicle (VEH) and antiHIV antibody (Cont-Ab) groups at 72hr. The line shows the amount of MHC-II staining
at 4, 24, 72 and 168 hour survival times. Increased MHC-II staining was observed in the
frontal cortex (panel A) and hippocampus (panel B) at 72 hours compared with 4, 24 and
168 hours and both control groups (** indicates P<0.01).
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Figure 10: Anti-Αβ antibody injections results in rounded microglia in association with
remaining Congophilic amyloid deposits three days after injection. CD45
immunostaining counterstained with Congo red is shown in the hippocampus at the 72
hour time-point. Panel A shows a typical intensely stained Congophilic deposit
surrounded by CD45 immunostained microglial processes, with faintly stained somata
(arrow). Panel B shows a faintly stained Congophilic deposit in the anti-Αβ antibody
injected hippocampus. Note the two rounded intensely CD45 positive cells in contact
with the faintly stained deposit (arrow). Magnification = 600X. Scale bar = 8.33 µm
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Abstract
The mechanisms by which anti-Aβ antibodies clear amyloid plaques in Aβ
depositing transgenic mice are unclear. In the current study we demonstrate that
inhibition of anti-Aβ antibody-induced microglial activation with anti-inflammatory
drugs, such as dexamethasone, inhibits removal of fibrillar amyloid deposits. We also
show that anti-Aβ F(ab’)2 fragments fail to activate microglia and are less efficient in
removing fibrillar amyloid than the corresponding complete IgG. Diffuse Aβ deposits are
cleared by antibodies under all circumstances. These data suggest that microglial
activation is necessary for efficient removal of compact amyloid deposits with
immunotherapy. Inhibition of this activation may result in an impaired clinical response
to vaccination against Aβ.

Introduction
Alzheimer’s disease (AD) is characterized clinically by progressive cognitive
decline and characterized pathologically by amyloid plaques, neurofibrillary tangles and
neuron loss (Hardy and Selkoe, 2002). Another pathological event in AD is an
inflammatory response which involves the activation and proliferation of microglia and
astrocytes (Akiyama et al, 2000). The amyloid hypothesis has targeted the Aβ peptide as
the primary focus for therapeutic interventions in AD (Hardy and Selkoe, 2002).
Amyloid plaques consist of amyloid-β protein fibrils which are positively stained by
Congo red and thioflavine-S. In addition, diffuse amyloid deposits can be identified using
immunohistochemistry.
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Vaccination using Aβ1-42 was first described by Schenk et al (Schenk et al, 1999).
That report showed that immunization with Aβ1-42 in the PDAPP transgenic mouse
dramatically reduced Aβ deposit accumulation, both diffuse and compact. The
vaccination was later shown to prevent cognitive decline in APP+PS1 (Morgan et al,
2000) and TgCRND8 (Janus et al, 2000) transgenic mice. Passive immunization with
anti-Aβ antibodies was also demonstrated to have benefit pathologically (Bard et al,
2000) and cognitively (Dodart et al, 2002 and Kotilinek et al, 2002). The Aβ vaccine
advanced quickly to human clinical trials where, in Phase II, several patients developed
cerebral inflammation, leading to a halt in further inoculations (Schenk 2002).
The exact mechanism by which immunotherapy reduces Aβ deposition remains
unknown; suggested mechanisms include Fc receptor mediated phagocytosis via
microglia (Schenk et al, 1999, Wilcock et al, 2001 and Wilcock et al, 2003), dissolution
of amyloid fibrils (Solomon et al, 1997 and Frenkel et al, 1999) and sequestration of
circulating Aβ resulting in an increased net efflux of Aβ from brain and plasma
(DeMattos et al, 2001).
These competing hypotheses have led to disputes regarding the accessibility of
circulating antibodies to the CNS, the role of systemic Aβ content in this process and the
degree of requirement for specific Aβ epitopes to be targeted by the antibodies (Bard et
al, 2003 and Holtzman et al, 2002). Moreover, in AD patients the blood-brain barrier is
variably leaky (Hock et al, 2002). Bacskai et al (2001) were the first to demonstrate antiAβ antibody removal of amyloid deposits following direct application into the brain,
therefore bypassing the blood-brain barrier. To identify the potential role of microglia in
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antibody-mediated removal of Aβ deposits, we have opted to avoid some of the
complications regarding brain penetration and apply antibodies directly to the CNS by
intracranial injections.
We have recently reported that following intracranial anti-Aβ antibody
administration there is a biphasic clearance of Aβ deposits (Wilcock et al, 2003). The
first is a rapid removal of diffuse Aβ deposits occurring between 4 and 24 hours after
injection. The second is the removal of compact, thioflavine-S positive amyloid deposits
between 24 and 72 hours following injection. This removal of fibrillar deposits is
associated with a transient activation of microglia, detectable at 72 hours, but not 7 days
after the injection. Remarkably, by 7 days both diffuse and compacted Aβ deposits are
largely cleared, the microglial reaction has resolved, and the injected anti-Aβ antibody is
almost completely removed.
In the current study we further investigate the relationship between microglial
activation and fibrillar amyloid removal. First, we test the capacity of several antiinflammatory agents to impair the microglial response and monitor their effect on Aβ
clearance. We also investigate whether antibody fragments lacking the Fc domain can
clear the fibrillar deposits, and monitor the effects on microglial activation. The results
are consistent with the argument that microglial activation and Fc receptor mediated
phagocytosis are important steps in the rapid clearance of Aβ deposits by intracranially
administered anti-Aβ antibodies.
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Materials and Methods
Anti-inflammatory drug study
Singly transgenic APP Tg 2576 mice were obtained from our breeding program
at USF started in 1996 (Holcomb et al, 1998). In the first experiment, 39 APP transgenic
mice aged 16 months were assigned to one of 5 experimental groups. Four of these
groups received intracranial anti-Aβ antibody injections (44-352; Mouse monoclonal
anti-human Aβ1-16 IgG1; Biosource, Camarillo, CA) into the frontal cortex and
hippocampus at a concentration of 2µg/2µl in each region. The remaining group received
intracranial anti-HIV monoclonal antibody directed against gp120 (from Ken Ugen,
Univ. South Florida) into frontal cortex and hippocampus at a concentration of 2µg/2µl in
each region (N=7) as a control for potential nonspecific activity associated with injecting
IgG into the brain. Of the 4 groups receiving anti-Aβ antibody one group received no
further treatment (N=8), one group received twice daily intraperitoneal injections of
dexamethasone (Sigma-Aldrich, St Louis MS) at a dose of 5mg/kg (N=9), one group
received twice daily intraperitoneal injections of minocycline (Sigma-Aldrich, St Louis
MS) at a dose of 45mg/kg (N=7) and one group received once daily subcutaneous
injections of NCX-2216 (nitro-ferulo-flurbiprofen; NiCox, S.A., Sophia-Antipolis,
France) at a dose of 7.5mg/kg (N=8). All treatments following the intracranial injection
were commenced immediately following a 30 minute recovery from surgery. All mice
were killed 72 hours following surgery and treatments were continued through the
morning of kill.
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Antibody Fragment Study
Twenty Tg2576 APP transgenic mice aged 19.5 months were assigned to one of
four groups, all groups received intracranial injections into the frontal cortex and
hippocampus. The first group received anti-Aβ antibody (2286; Mouse monoclonal antihuman Aβ28-40 IgG1; Rinat Neurosciences, Palo Alto, CA) at a concentration of 2µg /2µl
in each region. The second group received anti-Aβ F(ab’)2 fragments prepared from the
anti-Aβ antibody at 2.2 µg /2µl in each region. The third group received IgG directed
against drosphila amnesiac protein (Rinat neurosciences, Palo Alto, CA) as a control for
nonspecific aspects of intact IgG injection. The final group received control F(ab’)2
fragments prepared from the IgG directed against drosophila amnesiac protein to control
for nonspecific effects of F(ab’)2 injection. All mice survived for 72 hours after surgery.
Preparation of F(ab’)2 fragments
The Immunopure IgG1 Fab and F(ab’)2 preparation kit (Pierce Biotechnology,
Rockford, IL) was used to prepare the F(ab’)2 fragments from the anti-Aβ IgG and the
control IgG against drosophila protein. The instructions provided with the kit were
followed (http://www.piercenet.com/files/0465jm5.pdf). Briefly, 0.5ml of 1mg/ml IgG
was added to 0.5ml mouse IgG1 mild elution buffer. This was applied to an equilibrated
immobilized ficin column, allowed to enter the column and digested at 37oC for 20 hours.
A 4ml elution was obtained and applied to an equilibrated immobilized protein A column
for separation of the F(ab’)2 from Fc fragments and undigested IgG. Four 1ml fractions of
product were obtained. As determined by running a gel electrophoresis only the 2nd and
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3rd elutions were found to contain F(ab’)2 fragments and appeared of similar intensities on
the gel. The two elutions containing F(ab’)2 fragments were pooled and concentrated
using centricon centrifugal filter devices (Millpore Corp. Bedford, MA) to a volume of
approximately 200 µl. Preliminary experiments found that injections of the F(ab’)2
fractions concentrated directly from the column caused seizures when injected into some
mice. Thus the initial concentrate was diluted in 4 ml of fresh PBS and reconcentrated to
dilute residual proprietary elution buffer components which may cause seizures. No
seizures or neurotoxicity were found in the mice included here. The concentrated product
was run on an SDS-PAGE. A Bradford assay was also performed to establish
concentrations of the F(ab’)2 fragments using Bradford protein assay reagent concentrate
(Bio-Rad, Hercules, CA).
Surgical procedure
On the day of surgery the mice were weighed, anesthetized with isoflurane and
placed in a stereotaxic apparatus (51603 dual manipulator lab standard, Stoelting, Wood
Dale, IL). A midsagittal incision was made to expose the cranium and two burr holes
were drilled using a dental drill over the right frontal cortex and hippocampus to the
following coordinates: Cortex: AP +1.5mm, L –2.0mm, hippocampus: AP –2.7mm, L –
2.5mm, all taken from bregma. A 26 gauge needle attached to a 10µl Hamilton (Reno,
NV) syringe was lowered 3mm ventral to bregma and a 2µl injection was made over a 2
minute period. The incision was cleaned with saline and closed with surgical staples.
Tissue Preparation
On the day of kill mice were weighed, overdosed with 100mg/kg pentobarbital
(Nembutal sodium solution, Abbott laboratories, North Chicago IL) and intracardially
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perfused with 25ml 0.9% sodium chloride followed by 50ml freshly prepared 4%
paraformaldehyde (pH=7.4). Brains were rapidly removed and immersion fixed for 24
hours in freshly prepared 4% paraformaldehyde. The brains were then incubated for 24
hours in 10, 20 and 30% sucrose sequentially to cyroprotect them. Horizontal sections of
25µm thickness were then collected using a sliding microtome and stored at 4oC in DPBS
buffer with sodium azide to prevent microbial growth.
Immunohistochemical methods
Six to eight sections approximately 100µm apart were selected spanning the
injection site and stained using free-floating immunohistochemistry methods for total Αβ
(rabbit antiserum primarily reacting with the N-terminal of the Αβ peptide 1:10000) and
CD45 (Serotec, Raleigh NC, 1:3000) as previously described (Gordon et al, 2002). For
immunostaining, some sections were omitted from the primary antibody to assess nonspecific immunohistochemical reactions. Adjacent sections were mounted on slides and
stained using 4% thioflavine-S (Sigma-Aldrich, St Louis MO) for 10 minutes. It should
be noted that there are a limited number of sections that include the injection volume.
We have opted to measure a few markers reliably rather than a larger number of markers
with fewer sections each.
Data analysis
The immunohistochemical reaction product on all stained sections was measured
using using a videometric V150 image analysis system (Oncor, San Diego, CA) in the
injected area of cortex and hippocampus and corresponding regions on the contralateral
side of the brain. Data are presented as the ratio of injected side to non-injected side for
Αβ, thioflavine-S and CD45. Normalizing each injection site to the corresponding
- 65 -

contralateral site diminishes the influence of inter-animal variability and permits reliable
measurements of drug effects with a smaller number of mice. Importantly, there is no
injected antibody detectable in the contralateral side. To assess possible treatment-related
differences, the ratio values for each treatment group were analyzed by ANOVA using
StatView software version 5.0.1 (SAS Institute Inc., NC) followed by Fischer’s LSD
means comparisons.

Results
Following intracranial injection of anti-Aβ antibody 44-352 into the hippocampus
and frontal cortex there was a significant activation of microglia detectable by CD45
immunohistochemistry. In the hippocampus, the most intense area of activation appeared
in the granule cell layer of the dentate gyrus close to the site of injection within the
hilus/CA4 region. However, there was a much more diffuse activation which filled the
remainder of the dentate gyrus (Fig. 1A). In the frontal cortex, the activation formed a
gradient surrounding the injection site without a clear laminar profile (not shown).
Following the intracranial injection of anti-Aβ antibody, treatment with the steroidal antiinflammatory agent dexamethasone completely inhibited the microglial activation with
only several small cells faintly stained for CD45 in hippocampus (Fig 1B; P < 0.05 Fig
2A) and in frontal cortex (Fig 2A, P < 0.001). The staining pattern and values observed in
this group matched that of the group administered a control IgG directed against an HIV
protein in both brain regions (Fig. 1E, Fig. 2A).
Minocycline, a drug previously shown to inhibit microglial activation in several
CNS inflammation models, appeared relatively ineffective at inhibiting the microglial
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activation observed as a result of intracranial anti-Aβ antibody administration. In the
hippocampus the intense area of activation in the granule cell layer was still present, as
was the more diffuse activation in the remainder of the dentate gyrus (Fig 1C). In the
frontal cortex, although there was a significant difference between the minocyclinetreated mice and the untreated mice (P < 0.01), the microglial activation in the
minocycline treated mice was still significantly greater than in the dexamethasone treated
mice (p<0.05; Fig 2A).
NCX-2216 combines a nitric oxide generating moiety with the typical NSAID
drug flurbiprofen. In the hippocampus, NCX-2216 treatment following the intracranial
injection of anti-Aβ antibody partially inhibited the activation of microglia (Fig 1D). This
drug did not inhibit the intense activation observed in the granule cell layer of the dentate
gyrus but did diminish the more diffuse activation. The quantification from the frontal
cortex found a significant inhibition of microglial activation (P < 0.01; Fig 2A). Thus,
with respect to inhibiting microglial activation following anti-Aß antibody injection,
dexamethasone was the most effective drug with NCX-2216 having a partial inhibition
followed by an even weaker inhibition caused by minocycline.
Total Aβ immunohistochemistry in mice administered the control antibody
directed against human immunodeficiency virus (HIV) protein gp120 was similar to that
described previously in the APP transgenic mouse (Hsiao et al, 1996 and Gordon et al,
2002). The ratio of Aβ in the right: left sides was also the same as that observed
previously in unmanipulated APP transgenic mice (Wilcock et al, 2003). The Aβ
immunohistochemistry showed a few large, intensely stained deposits, which are
normally also stained by Congo red or thioflavine-S, indicating fibrillar compact amyloid
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deposits. There were also a large number of smaller, less intensely stained deposits
analogous to diffuse amyloid deposits observed in human AD brain tissue. In the
hippocampus, Aβ deposition was localized primarily to the molecular layers of the
dentate gyrus and Ammon’s horn adjacent to the hippocampal fissure, as well as a large
concentration in the subiculum (Fig. 1J).
Anti-Aβ antibody administration into frontal cortex and hippocampus resulted in
a reduction of total Aβ immunohistochemistry 72 hours following injection (Fig 1F).
This reduction was approximately 80% in frontal cortex and 65% in hippocampus
compared to APP transgenic mice administered HIV antibody (Fig. 2B). The antiinflammatory agents dexamethasone, NCX-2216 and minocycline had no effect on the
removal of this largely diffuse Aβ staining (Fig. 1G, H and I and Fig 2B).
Thioflavine-S staining showed a different response to anti-inflammatory drug
treatment than Aβ immunostaining. Although fewer in number, the subregional
distribution of thioflavine-S positive plaques matched that observed with Aβ
immunohistochemistry in APP transgenic mice administered control IgG (Fig 1O). AntiAβ antibody injected into the frontal cortex and hippocampus resulted in a virtually
complete removal of thioflavine-S positive plaques 72 hours following injection,
reaching 90% in frontal cortex and 85% in the hippocampus (Fig 1K; Fig 2C).
Administration of dexamethasone resulted in complete arrest of anti-Aβ antibody
mediated clearance of thioflavine-S compact amyloid deposits in the hippocampus (Fig.
1L) or the frontal cortex, with values equivalent to those mice given anti-HIV control
antibody (Fig. 2C). In contrast, administration of minocycline had no detectable effects
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on anti-Aβ antibody mediated clearance of thioflavine-S deposits in either frontal cortex
(Fig. 2C) or hippocampus (Fig. 1M, Fig. 2C). NCX-2216 treatment had a partial effect on
thioflavine-S reduction following intracranial anti-Aβ antibodies. In the frontal cortex the
levels of thioflavine-S were almost equivalent to those seen following anti-HIV control
antibody administration, and were significantly different from the levels observed
following anti-Aβ antibody administration alone (Fig. 2C). The levels of thioflavine-S in
the hippocampus were not significantly different from mice administered anti-Aβ
antibody or mice administered anti-HIV control antibody, and their values were in
between these two groups (Fig. 2C), suggesting a partial impairment of antibody
mediated clearance by this drug.
A second series of studies investigated the potential role of the Fc domain of the
antibody in microglial activation and amyloid clearance. F(ab’)2 fragments prepared
from anti-Aβ monoclonal antibody 2286, and a control monoclonal antibody directed
against the drosophila protein amnesiac were analyzed via SDS-polyacrylamide-gel
electrophoresis (PAGE). The gel showed very pure product, with a single band at
approximately 105kDa, the molecular weight for F(ab’)2 fragments. The intact IgG
molecule produced one intense band at approximately 150kDa, the correct molecular
weight for IgG molecules and a less intense band at approximately 110 kDa. Following
confirmation of purity via SDS-PAGE we then performed a Bradford assay to assess the
recovery of F(ab’)2 in the purified fraction. Because we dissolved the anti-Aβ F(ab’)2
fragments in a smaller volume than was used for the starting material the concentration of
F(ab’)2 fragments injected intracranially was 1.2µg/µl, while the complete IgG
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concentration was 1 µg/µl, resulting in an excess of anti-Aß Fv domains in the F(ab’)2
solutions.
The only antibody which activated microglia 72 hours following intracranial
injection into frontal cortex and hippocampus was the intact anti-Aβ antibody. The
frontal cortex shows a greater degree of activation than the hippocampus, however, in
both regions the activation is significantly greater than that in the groups receiving
control anti-amnesiac protein IgG, F(ab’)2 , or anti-Aβ F(ab’)2 (Fig 3A, C and D, Fig.
4A; P < 0.01 or greater in all comparisons). The pattern of activation in the hippocampus
following the anti-Aβ antibody 2286 injection resembled that shown in Fig 1A when
using the anti-Aβ antibody 44-352. There is a very intense area of activation in the
granule cell layer of the dentate gyrus, with a much more diffuse activation filling the
remainder of the dentate gyrus (Fig. 3A). Interestingly, the anti-Aβ F(ab’)2 fragments
produced no microglial activation in either the frontal cortex and hippocampus (Fig. 3B,
Fig. 4A).
Aβ immunohistochemistry in the two anti-amnesiac protein control groups shows
the typical staining pattern observed in APP transgenic mice at 19.5 months (Fig. 3G and
H). This pattern was qualitatively the same as observed at 16 months (Fig 1J), although
quantitatively greater as the mice were 3.5 months older. Both the anti-Aβ antibody and
the anti-Aβ F(ab’)2 groups significantly reduced total Aβ immunohistochemistry to a
similar extent 72 hours following injection into frontal cortex and hippocampus. In the
frontal cortex there was a reduction of approximately 60% (Fig. 4B). In the hippocampus
the reduction was approximately 65% (Fig. 3E and F, Fig. 4B).
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Thioflavine-S staining detects only compact fibrillar amyloid deposits. The mice
receiving intracranial injections of either control anti-amnesiac protein IgG or control
F(ab’)2 resembled the typical staining observed in the APP transgenic mouse at this age.
In the hippocampus the majority of thioflavine-S positive plaques were located in the
outer molecular layer of Ammon’s horn and the dentate gyrus near the hippocampal
fissure (Fig. 3K and L). Anti-Aβ antibody IgG significantly reduced thioflavine-S
positive compact plaque by approximately 90% in the frontal cortex and hippocampus
(Fig. 4C). There were no, or very few, remaining thioflavine-S positive deposits in the
hippocampus (Fig. 3I). In contrast, the anti-Aβ F(ab’)2 fragments did not remove
compact amyloid plaques as effectively as the whole IgG molecule. In the frontal cortex
there was no significant reduction in thioflavine-S staining when compared to either
control antibody group (Fig. 4C). In the hippocampus there was a significant difference
between the anti-Aβ F(ab’)2 group and the control groups (P < 0.05), however, this
reduction was also significantly less than the reduction observed with the whole IgG
molecule (Fig. 3J, Fig. 4C; P < 0.02 or greater).

Discussion
The data presented here support the argument that activation of microglia in APP
transgenic mice facilitates the removal of compact amyloid plaques. The first experiment,
using several anti-inflammatory agents to regulate the microglial response, showed that
the extent of fibrillar amyloid removal roughly corresponds to the extent of microglial
activation 3 days after intracranially applied anti-Aβ antibody. The second study
identified that anti-Aβ F(ab’)2 fragments were less capable of activating microglia
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(presumably because they lacked the Fc domain) and were significantly less effective
than the corresponding whole IgG in removing fibrillar Aβ, despite the presence of
excess anti-Aβ Fv in the F(ab’)2 injections.
Our earlier work in this system demonstrated that intracranial administration of
anti-Aβ antibodies into APP Tg2576 mice resulted in diffusion of the antibody
throughout most of the hippocampus by 4 hours, however, no specific localization to
amyloid plaques was noted. This caused a rapid removal of diffuse Aβ deposits between
4 hours (when no reduction is detected) and 24 hours (when removal of diffuse deposits
appeared complete; Wilcock et al, 2003). This removal was not associated with any
apparent activation of microglia using markers such as MHC-II or CD45 at 24 hours, nor
was there any reduction of the fibrillar amyloid deposits measured with thioflavine-S
staining. However, by 72 hours following the injection there was a dramatic reduction of
thioflavine-S positive compact amyloid deposits associated with a florid microglial
activation as detected by CD45 immunohistochemistry. One week following the anti-Aβ
antibody injection, the injection site remained devoid of most forms of amyloid, the
microglial reaction had terminated and the injected antibody had been fully cleared from
the area.
An issue of concern with these studies is whether the Aβ epitope utilized for
immunohistochemistry is masked by the injected antibody. This issue was addressed in
our previous work where it was shown that although there is a broad distribution of the
injected antibody 4 hours following injection, no reduction in Aβ immunohistochemistry
is apparent (Wilcock et al, 2003). Also, if the reduction observed is simply an artifact of
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masking the Aβ epitope, a reduction in thioflavine-S staining would not be observed
since this is a conformation dependent stain and not epitope dependent. Further, the
stoichiometry of injected antibody (13 pmol) to Αβ in deposits (estimated at 250 pmol in
0.5 mg, Chapman et al., 1999) is likely too low to interfere substantially with the
histochemical reaction. Finally, 7 days after injection, the injected antibody is no longer
detectable, yet the Aβ immunostaining remains absent.
The present report further investigated the relationship between activation of
microglia and the clearance of the fibrillar amyloid plaques associated with anti-Aβ
antibody injections. We used several distinct pharmacological agents in an attempt to
inhibit the microglia activation observed 72 hours following intracranial injection of antiAβ antibodies. Dexamethasone is a glucocorticosteroid which inhibits the
cyclooxygenase and lipoxygenase inflammatory pathways as well as inducing a general
state of immunosuppression. It has been shown that microglia respond differently to
mineralocorticoid and glucocorticoid receptor stimulation. Mineralocorticoid receptor
activation stimulates the microglia while glucocorticoid receptor activation inhibits
microglia (Tanaka et al, 1997). All pharmacological glucocorticosteroids possess some
degree of mineralocorticoid action also. For the present study we selected dexamethasone
as it has the maximum glucocorticoid receptor activity with the minimum
mineralocorticoid receptor activity detectable among all available pharmacological
glucocorticosteroids (Schimmer and Parker, 2001). It was found that dexamethasone was
the most efficacious compound for the inhibition of microglial activation among those
used in this study. Dexamethasone administered immediately following intracranial antiAβ antibody administration completely inhibited the microglial activation caused by the
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injection. Associated with this profound arrest of microglial activation was a complete
inhibition of the antibody's ability to remove compact amyloid deposits detected with
thioflavine-S staining, strongly suggesting a role for microglial involvement in the
removal of compact amyloid deposits.
The novel non-steroidal anti-inflammatory (NSAID) NCX-2216, which is a
flurbiprofen molecule conjugated to an antioxidant and a nitric oxide releasing group,
was moderately effective at inhibiting microglial activation. Interestingly, this compound
has previously been shown to cause the activation of microglia and removal of amyloid
from the brains of otherwise untreated doubly transgenic APP+PS1 mice (Jantzen et al,
2002). NCX-2216 has also been shown to inhibit the microglial activation caused by
intracranial infusion of lipopolysaccharide (LPS), a proinflammatory agent in young rats,
but to increase microglial activation in old rats (Hauss-Wegrzyniak et al, 1999). In the
present study, NCX-2216 partially reduced the activation of microglia caused by
antibody injection. Associated with this partial inhibition of microglial activation is also
a partial impairment of the anti-Aβ antibody’s capacity to remove the compact amyloid
plaques. The discrepancy between the effects observed in the current study and the
effects previously observed by Jantzen et al (2002) may be explained by the fact that
NCX-2216 essentially is three drugs. In a situation where there is intense, local
microglial activation the anti-inflammatory properties of the drug appears to dominate. In
a situation where there is diffuse microglial activation it appears that maybe the nitric
oxide release dominates to enhance microglial activation and aid in the clearance of Aβ.
Although not quantified, the microglial reaction immediately adjacent to amyloid
deposits appeared more intense in NCX-2216 treated mice in regions distant from the
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injection (e.g. contralateral anterior cortex). A similar bidirectional effect of this drug was
found by Hauss-Wegrzyniak et al, 1999, who found reduced microglial activation in
young rats, but enhanced activation in old rats treated with the NCX-2216 relative,
nitroflurbiprofen.
Minocycline is a tetracycline derivative which has been shown to have a novel
action independent of its antibiotic property. This agent has been shown to inhibit
microglial activation following excitotoxicity (Tikka et al, 2001), ischemia (Yrjanheikki
et al, 1998) and 6-hydroxydopamine lesions (He et al, 2001). In the present study we
demonstrate that minocycline is capable of a modest inhibition of microglial activation
following antibody injection. Associated with this is no difference in compact plaque
removal in either the frontal cortex or hippocampus.
To further investigate whether the activation of microglia, which appears to be
specific to the anti-Aβ antibody, is due to Fc receptor activation we administered F(ab’)2
fragments intracranially into APP transgenic mice as well as the whole IgG, control IgG
and F(ab’)2 fragments from the control IgG. We found that of the four experimental
groups only the animals receiving anti-Aβ IgG showed significant activation of
microglia. The fact that anti-Aβ F(ab’)2 fragments were unable to activate microglia,
strongly suggests that Fc receptor activation is required for the significant activation of
microglia following intracranial administration of anti-Aβ antibodies.
Associated with this inability to activate microglia was a significantly impaired
capacity to remove fibrillar amyloid deposits. Still, at least in hippocampus, there was
some residual capacity for fibrillar amyloid removal using the F(ab’)2 fraction. However,
with respect to diffuse Aβ clearance, the F(ab’)2 are just as effective as the corresponding
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intact IgG. These results suggest that there may be an equilibrium between the fibrillar
deposits and the diffuse deposits, and the F(ab’)2 antibody fragments can whittle away at
the fibrillar plaques without requiring Fc receptor mediated phagocystosis. This is also
the likely explanation why Bacskai et al (2002) found topically applied F(ab’)2 fragments
equally effective to intact antibodies in the clearance of thioflavine-S labeled material. It
is plausible that had we injected a greater amount of F(ab’)2 fragments, or extended the
post-injection interval, we also might have found complete clearance of fibrillar amyloid
with the F(ab’)2 material. However, even though it may be capable of clearing fibrillar
amyloid, the results presented here demonstrate F(ab’)2 fragments were much less
efficient than the intact IgG molecule in mediating clearance associated with microglial
activation. It is plausible that this also explains the recent observations from Bard et al
(2003) that the ability of different monoclonal anti-Aβ antibodies to clear brain amyloid
when administered systemically was correlated better with their capacity to bind Fc
receptors than with their affinity for Aβ. The amounts of antibody entering the brain are
roughly 0.1% of the injected amount per hour (Banks et al, 2002). Thus, a 500 µg
injection of a monoclonal antibody should result in 0.5 µg entering the CNS within 60
minutes, somewhat less than the amounts injected directly in our system (2 µg).
Therefore, with systemically injected antibodies, the facilitation of amyloid removal by
Fc receptor mediated phagocytosis is likely to be even greater than that observed here
with intracranially administered antibodies.
Certainly, it will be useful to measure Αβ content by means other than
histochemistry. Increasingly complex methods of fractionating homogenates are being
used to identify Αβ pools linked most closely to neuropathology and cognitive disruption
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(Lue et al, 1999 and Golde et al, 2000) but consensus regarding the specific fractions
corresponding to the most toxic form of amyloid has not yet been achieved (Walsh et al,
2002 and Kayed et al, 2003). Additionally, the relatively small portions of the brain
affected by the intracranial injections and difficulty dissecting these regions consistently
limits the ability to use solution methods to evaluate Aβ loads in our studies. As
consensus emerges regarding the relationships between soluble, oligomeric and fibrillary
forms of Aβ in the solution domain and the histochemical domain, and larger portions of
the brain become involved with either intraventricular or systemic antibody injections, we
will investigate the effects of anti-Aβ antibodies on these different Aβ pools in both
domains.
It has been shown previously that vaccination using Aβ1-42 results in activation of
microglia, which is associated with a reduction in Aβ accumulation in PDAPP transgenic
mice (Schenk et al, 1999) and APP+PS1 transgenic mice (Wilcock et al, 2001). It has
also been shown that following direct application of anti-Aβ antibodies to the brains of
PDAPP mice there is an activation of microglia and a reduction in amyloid deposits
(Bacskai et al, 2001). In vitro studies using F(ab’)2 fragments demonstrated that they were
unable to activate microglia despite retaining full ability to bind to Aβ (Bard et al, 2000).
These fragments also failed to remove fibrillar Aβ in an ex vivo assay. Human
postmortem microglia have been shown to phagocytose opsonized Aβ, which is inhibited
by excess non-specific IgG, suggesting this phagocytosis is Fc receptor mediated (Lue et
al, 2002). All of these data suggest that one likely mechanism of antibody action in
removing amyloid deposits from transgenic mouse brains is via binding to microglial Fc
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receptors and triggering activation of the microglia, possibly including phagocytosis of
the opsonized amyloid. This by no means precludes other possible mechanisms, such as
catalytic dissolution of amyloid fibrils (Solomon et al, 1997), or sequestration of Aβ in
the periphery, effectively drawing Aβ out of the brain (DeMattos et al, 2001).
Recently, the first pathology report from a patient receiving the Aβ1-42 vaccination
(AN1792) was published (Nicoll et al, 2003). This report showed that the patient had
considerably fewer amyloid deposits than would have been predicted from other AD
cases. Interestingly, it is reported that in those regions devoid of amyloid plaques, the
remaining Aβ-immunoreactivity was associated with activated microglia. This patient did
develop meningoencephalitis and other symptoms of CNS inflammation, as did several
others in the trial. The treatment chosen for the CNS inflammation in this case was
dexamethasone.
Assuming that the mechanisms of Aβ vaccination in clearing amyloid is similar to
that demonstrated in the present work, it might be anticipated that dexamethasone would
counter the amyloid removing effects of the vaccine. Although the case described by
Nicoll et al above did show evidence of removal, the patient had received 5 inoculations
before developing adverse reactions and being administered dexamethasone. It was also
not indicated what the antibody titer was in the patient, nor how long the dexamethasone
treatment had continued. The data presented here suggest that administration of
glucocorticoids to vaccinated patients may counteract any benefit the vaccine has with
respect to amyloid clearance and possibly cognitive function. It is also conceivable that
removal of only the soluble and diffuse Aβ may provide cognitive improvement and
inhibition of microglial activation by anti-inflamnmatory drugs or administration of
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F(ab’)2 fragments may avoid some of the inflammatory adverse effects observed in the
human clinical trial (Orgogozo et al, 2003). The inhibition of microglial mediated
amyloid clearance may also have been a factor in the failure of the prednisone clinical
trial for AD (Aisen et al, 2000).
The adverse reactions in the human vaccine trial demonstrates a need to more
fully investigate the mechanisms involved in beneficial and detrimental effects of
immunotherapy. Encouraging data recently published by Hock et al (2003) showed that
the a subset of patients administered the Aβ vaccine remained cognitively stable for one
year after treatment while the control patients declined at a normal rate, some vaccinated
patients actually improved. While the immunotherapeutic approach may hold promise for
the treatment of AD, it would appear very important to better understand both the
mechanisms of vaccine action, and how the tools to effectively modulate the immune
reaction interact with these mechanisms. The data presented here make some headway
toward determining what effects modulation of the immunotherapeutic approach
mechanisms would have pathologically. Future studies will extend these investigations to
a more clinically relevant, systemically administered, passive immunization regimen to
determine the importance of the mechanisms discussed in the current study.
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Figure 1: Anti-inflammatory drugs impaired fibrillar amyloid removal to roughly the
same extent as they decreased microglial activation following anti-Aß antibody
injections. Panels A-E show CD45 immunohistochemistry in the hippocampus. Panels FJ show Aβ immunohistochemistry in the hippocampus. Panels K-O show thioflavine-S
staining in hippocampus. Mice were injected intracranially with anti-Aβ antibody
followed by no treatment (A, F, K), dexamethasone treatment (B, G and L), minocycline
treatment (C, H and M) or NCX-2216 treatment (D, I and N). Mice shown in panels E,
J, and O were injected with anti-HIV antibody as a control for nonspecific effects of IgG
injection. Magnification = 40X. Scale bar =120µm.
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Figure 2: Quantification of CD45, total Aβ and thioflavine-S following inhibition of
microglial activation by anti-inflammatory compounds. Panel A shows the ratio of right
to left sides for CD45 immunohistochemistry. Panel B shows the ratio of right to left
sides for total Aβ immunohistochemistry. Panel C shows the ratio of right to left sides for
thioflavine-S staining. The solid bars indicate values for frontal cortex, the open bars
indicate values for hippocampus. On the x-axis the type of antibody injected (anti-Aβ
antibody; Abeta, or control antibody; HIV) is shown. The post-injection treatment the
mice received is also shown; Dex: dexamethasone , Min: minocycline treatment, NCX:
NCX-2216 treatment. *** indicates P<0.001, ** indicates P < 0.01, * indicates P<0.05 as
compared to the anti-Aβ antibody alone.
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Figure 3: Anti-Aβ F(ab’)2 fragments do not activate microglia, nor do they remove
compact amyloid deposits as effectively as the complete anti-Aβ IgG. Panels A-D show
CD45 immunohistochemistry in the hippocampus. Panels E-H show total Aβ
immunohistochemistry in the hippocampus. Panels I-L show thioflavine-S staining in the
hippocampus. Mice were injected with intact anti-Aß IgG (A, E and I), anti-Aβ F( ab’)2
fragments (B, F and J), control (anti-amnesiac) IgG (C, G and K), or control (antiamensiac) F(ab’)2 fragments (D, H and L). Magnification = 40X. Scale bar=120µm.
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Figure 4: Quantification of CD45 and total Aβ immunohistochemistry and thioflavine-S
staining following intracranial injection of anti-Aβ antibodies and anti-Aβ F(ab’)2
fragments. Panel A shows the ratio of right to left sides for CD45 immunohistochemistry.
Panel B shows the ratio of right to left sides for total Aβ immunohistochemistry. Panel C
shows the ratio of right to left sides for thioflavine-S staining. The solid bars indicate
values for frontal cortex, the open bars indicate values for hippocampus. On the x-axis
IgG-Cont= control (anti-amnesiac) intact IgG,; F(ab’)2-Cont = Control (anti-amnesiac)
F(ab’)2 fragments; IgG-Abeta = anti-Aβ intact IgG; F(ab’)2-Abeta= anti-Aβ F(ab’)2
fragments.*** indicates P<0.001, * indicates P<0.05 as compared to both control
antibody groups. Lines over bars indicates P values for comparisons between the specific
pair of groups indicated.
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Abstract
The role of microglia in the removal of amyloid deposits following systemically
administered anti-Aβ antibodies remains unclear. In the current study we injected Tg2576
APP transgenic mice weekly with anti-Aβ antibody for a period of one, two or three
months such that all mice were 22 months at the end of the study. In mice immunized for
three months we found an improvement in alternation performance in the Y maze.
Histologically, we were able to detect mouse IgG bound to congophilic amyloid deposits
in those mice treated with anti-Aβ antibody but not in those treated with control antibody.
We found that Fcγ receptor expression on microglia was increased following one month
of treatment while CD45 was increased following two months of treatment. Associated
with these microglial changes was a reduction in both diffuse and compact amyloid
deposits following two months of treatment. Interestingly, the microglia markers were
reduced to control levels following three months of treatment while amyloid levels
remained reduced. Serum Aβ levels and anti Aβ antibody levels were elevated to similar
levels at all three survival times in mice given anti-Aβ injections rather than control
antibody injections. These data show that antibody is able to enter the brain and bind to
the amyloid deposits, likely opsonizing the Aβ and resulting in Fcγ receptor mediated
phagocytosis. Together with our earlier work, our data argue that all proposed
mechanisms of anti-Aβ antibody mediated amyloid removal can be simultaneously
active.
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Introduction
Reduction of brain amyloid following anti-Aβ immunotherapy was first
demonstrated by Schenk and colleagues (1999). Their report showed that vaccination
with Aβ1-42 in the PDAPP transgenic mouse model of Alzheimer’s disease dramatically
reduced levels of Aβ deposits in the brain. Later it was shown that using the same
vaccination protocol in APP+PS1 doubly transgenic mice (Morgan et al, 2000) and in
TgCRND8 transgenic mice (Janus et al, 2000) not only reduced Aβ levels in the brain but
also protected these mice from memory deficits. More recent studies have demonstrated
that passive immunization consisting of direct anti-Aβ antibody injections not only
results in dramatic reduction of Aβ levels (Bard et al, 2000; DeMattos et al, 2001) in the
brain but also reverses memory deficits in transgenic mouse models of AD (Dodart et al,
2002; Kotilinek et al, 2002).
The mechanism(s) by which immunotherapy acts remain unclear. Suggested
mechanisms include microglial mediated phagocytosis (Schenk et al, 1999, Wilcock et al,
2001, 2003, 2004), disaggregation of amyloid deposits (Solomon 1997, Wilcock et al,
2003, 2004), and removal of Aβ from the brain by binding of circulating Aβ in plasma
with the anti-Aβ antibodies, resulting in a concentration gradient from brain to plasma.
This latter mechanism is also known as the peripheral sink hypothesis (DeMattos et al,
2001, Dodart et al, 2002, Lemere et al, 2003, Das et al, 2003).
We have previously reported that following intracranial anti-Aβ antibody
injections into APP transgenic mice there is a rapid removal of diffuse amyloid deposits
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apparently independent of microglial activation and also a later removal of compact
amyloid deposits which appears to require microglial activation (Wilcock et al, 2003). In
fact, in a later study using the same model, administration of dexamethasone, which
suppresses microglial activation, anti-Aβ antibody administration inhibits the removal of
compact, thioflavine-S positive, amyloid deposits (Wilcock et al, 2004).
In this report we show that weekly systemic administration of anti-Aβ antibodies
for a period of one, two or three months results in a dramatic reduction of both diffuse
and compact amyloid deposits. Associated with this reduction is a behavioral
improvement using the Y-maze task. Following one month of treatment there is a large
induction of Fcγ receptor expression on microglia and following two months of
administration there is an increase in CD45 expression indicative of microglial activation.
We have detected antibody binding to congophilic plaque in APP transgenic mice treated
with anti-Aβ antibody. We also observe a dramatic increase in circulating Aβ levels
following one month of administration. Two months following administration we observe
a dramatic reduction in compact and diffuse deposits. After three months of
administration the microglia markers are down to control levels whilst the compact and
diffuse amyloid deposits remain reduced. These results demonstrate systemically
administered anti-Aβ antibodies are accessing the brain, binding to amyloid deposits and
activating microglia. The data also show an increase in circulating Aβ in plasma,
consistent with the peripheral sink hypothesis.
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Materials and Methods.
Experiment design:
Singly transgenic APP Tg 2576 mice were obtained from our breeding program
at USF started in 1996 (Holcomb et al, 1998). Twenty two APP transgenic mice aged 19
months were assigned to one of four experimental groups. The first three groups received
weekly intraperitoneal anti-Aβ antibody injections (antibody 2286; Mouse monoclonal
anti-human Aβ28-40 IgG1; Rinat Neurosciences, Palo Alto, CA) for 1 month (n=6), 2
months (n=9) or 3 months (n=4). The fourth group received weekly intraperitoneal antiAMN antibody injections (2906; Mouse monoclonal anti-drosophila amnesiac protein
IgG1; (Rinat Neurosciences, Palo Alto, CA) for 3 months (n=3). Twelve nontransgenic
mice were assigned to one of two experimental groups. The first group received
intraperitoneal anti-Aβ antibody injections for 3 months (n=4). The second group
received no treatment (n=3). Treatment of 1 month and 2 month groups was delayed to
insure the mice were killed at the same age (22mo). One week prior to kill and one day
following the 5th, 9th or 13th injection mice were tested behaviorally using the Y maze
task.
Behavioral testing:
The Y maze is a three arm maze with equal angles between all arms. Mice were
initially placed within one arm and the sequence and number of arm entries was recorded
for each mouse over an 8 minute period. The percentage of triads in which all three arms
were represented (ABC, CAB or BCA but not BAB) was recorded as an alternation to
estimate short-term memory of the last arms entered. The total number of possible
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alternations is the number of arm entries minus two. Additionally, the number of arm
entries serves as an indicator of activity.
Antibody Purification:
Antibody 2286 (mouse monoclonal anti-human Aβ28-40 IgG1) and the antibody
2906 (mouse monoclonal anti-drosophila amnesiac protein IgG1) was purified from
mouse ascites on AKTA instrumentation using protein A beads (MabSelect, Amersham
Biosciences). Briefly, ascites was filtered in pyrogen-free .22µm filter system (Corning)
and applied to a 20ml bed volume in a XK16/20 column (Amersham Biosciences) after
equilibrating the beads with 5 vol of binding buffer (0.6M NaCl, 0.3M glycine, pH 8.0).
The column was washed with 3 vol of binding buffer and the antibody was eluted in 4 vol
of elution buffer (0.1M Na Citrate pH 3.0), and held at low pH for 30 min for viral
inactivation. The resulting eluant was neutralized with 1/10th vol of 1.0M Tris, pH 9.5.
The antibody was dialyzed into sterile PBS, pH 7.4 and the concentration was determined
by reading absorbance at 280. All buffers were made in pyrogen-free water.
Tissue preparation:
On the day of kill mice were weighed, overdosed with 100mg/kg pentobarbital
(Nembutal sodium solution, Abbott laboratories, North Chicago IL). Blood was collected
and allowed to coagulate at 4oC for at least one hour before being centrifuged and the
serum removed and stored at -80oC until required. The mice were then intracardially
perfused with 25ml of 0.9% sodium chloride. Brains were rapidly removed and the right
half of the brain was dissected and frozen for biochemistry while the left half of the brain
was immersion fixed for 24 hours in freshly prepared 4% paraformaldehyde in 100mM
PO4 (pH 7.2) for histopathology. The latter hemibrains were then incubated for 24 hours
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in 10, 20 and 30% sucrose sequentially to cyroprotect them. Horizontal sections of 25µm
thickness were collected using a sliding microtome and stored at 4oC in Dulbecco’s
phosphate buffered saline with sodium azide (pH 7.2) to prevent microbial growth.
ELISA methods; Aβ and anti-Aβ antibody:
For the Aβ assay serum was diluted and incubated in 96-well microtiter plates
(NUNC MaxiSorp, Denmark), which were pre-coated with antibody 6E10 (Signet,
Dedham, MA) at 5µg/ml in PBS buffer, pH 7.4. The secondary antibody was biotinylated
4G8 (Signet, Dedham, MA) at 1:5000 dilution. Detection was done using streptavidin
horseradish peroxidase conjugate (Amersham Biosciences), followed by TMB substrate
(KPL, Maryland). Standard curves of Aβ-40 (Global Peptide, Ft. Collins, CO) scaling
from 400 - 6pm were used.
Anti-Aβ antibody was dissociated from endogenous Aβ in serum as described previously
(Li et al, 2004). Briefly, serum was diluted in dissociation buffer (0.2M glycine HCl,
1.5% BSA pH 2.5) and incubated at room temperature for 20 min. The sera were pipetted
into the sample reservoir of Microcon centrifugal device, YM-10 (10,000 MW cut-off,
Millipore) and centrifuged at 8,000 x g for 20 min. at RT. The sample reservoir was then
separated from the flow through, placed inverted into a second tube and centrifuged at
1000 x g for 3 min. The collected solution containing the antibody dissociated from the
Aß peptide was neutralized to pH 7.0 with 1M Tris buffer pH 9.5. The dissociated sera
were assayed by ELISA for antibody titer. Aβ1-40 (Global Peptide, Ft. Collins, CO) coated
96-well microtiter plates (NUNC MaxiSorp, Denmark) were incubated with dissociated
serum samples. A biotinylated goat-anti mouse IgG (H+L) (Vector, Burlingame, CA) at
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1:5000 dilution, followed by peroxidase -conjugated streptavidin (Amersham
Biosciences) was used to detect serum anti-Aβ binding activity.
Immunohistochemical methods:
A series of eight equally spaced tissue sections 2.4mm apart were randomly
selected spanning the entire brain and stained using free-floating immunohistochemistry
methods for total Αβ (rabbit polyclonal anti-pan Aβ Bisource, Camarillo, CA, 1:10000),
CD45 (rat anti-mouse CD45, Serotec, Raleigh NC, 1:3000), Fcγ receptors II /III (rat antimouse CD16/ CD32, BD Pharmingen, San Diego, CA, 1:3000) as previously described
(Gordon et al, 2002). Briefly, tissue was incubated in primary antibody overnight at room
temperature. Sections were then washed and incubated in the appropriate biotinylated
secondary antibody (for Aβ: goat anti-rabbit 1:3000; for CD45 and FcγR: goat anti-rat
1:1000. All Vector Laboratories, Berlingame, CA ) for two hours. Following multiple
washes tissue was incubated in ABC (Vector Laboratories, Berlingame, CA) for a period
of one hour. Color development was performed using 3,3’-Diaminobenzidine (DAB,
Sigma-Aldrich, St Louis, MO) enhanced with nickelous ammonium sulfate (J.T. Baker
Chemical Co., Phillipsburg, NJ) for CD45 and FcγR, or without enhancement for Aβ. For
immunostaining, some sections were omitted from the primary antibody to assess nonspecific immunohistochemical reactions.
Additional sections were also stained for mouse IgG using imunohistochemical
methods similar to that described above. Briefly, sections were incubated overnight in a
1:3000 concentration of anti-mouse IgG conjugated to horseradish peroxidase (SigmaAldrich, St Louis, MO). The sections were then washed and incubated for 5 minutes in
100ml TBS (tris-buffered saline) containing 50mg DAB (3,3’-diaminobenzidine, Sigma- 100 -

Aldrich, St Louis, MO), 500mg nickelous ammonium sulfate (J.T. Baker Chemical Co.
Phillipsburg, NJ) and 100µl 30% hydrogen peroxide to produce a purple/ black color
reaction product. The sections were then mounted on slides and counterstained with a
0.2% Congo red solution in 80% ethanol to assess the localization of positive mouse IgG
stain with compact amyloid deposits.
A set of sections also mounted and stained using 0.2% Congo red solution in
NaCl saturated 80% ethanol. Another set of sections was also mounted and stained using
4% thioflavine-S (Sigma-Aldrich, St Louis MO) for 10 minutes.
The immunohistochemical reaction product on all sections was measured using
the Image-Pro Plus version 4.5 software (Media Cybernetics, Silver Spring, MD). One
region of the frontal cortex for all sections from each animal was analyzed and the
average of 6-7 sections was taken to give a value for each animal. Three regions of the
hippocampus were analyzed on approximately 4-5 sections where hippocampus was
present; the CA1, CA3 and dentate gyrus. These regions were analyzed both individually
to yield an average per region and also combined to give an overall value for
hippocampus for each animal. This ensured that there was no regional bias in the
hippocampal values. These same analysis methods were used to evaluate the Congo red
stain also. To assess possible treatment-related differences, the values for each treatment
group were analyzed by one-way ANOVA followed by Fischer’s LSD means
comparisons. Nontransgenic mice showed no treatment related differences in any
histological analyses and so these groups were pooled.
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Data analysis:
Percent alternation and arm entry numbers from the Y-maze behavior task were
analyzed using a one-way analysis of variance (ANOVA) followed by Fischer’s LSD
means comparisons using StatView software version 5.0.1 (SAS Institute Inc., NC).
Nontransgenic mice showed no treatment related differences in any behavioral analyses
and so these groups were pooled. ELISA values for serum Aβ levels and circulating
antibody levels were analyzed using a one- ANOVA followed by Fischer’s LSD means.

Results.
Transgenic APP mice given control antibody injections showed significantly
reduced Y-maze alternation when compared to the nontransgenic mice (Fig. 1A). This
reduced alternation was reversed in the APP transgenic mice receiving weekly anti-Aβ
antibody injections for three months. This group of mice was indistinguishable from the
nontransgenic animals and showed significantly increased alternation compared to the
APP transgenic mice receiving control antibody (Fig. 1A). The APP transgenic mice
given weekly anti-Aβ antibody injections for either one or two months were intermediate
between nontransgenic and transgenic mice given control antibodies and not significantly
different from either group. Nontransgenic mice also made significantly fewer arm
entries than the APP transgenic mice receiving control antibody injections indicating
hyperactivity in the APP transgenic mice. The APP transgenic mice receiving anti-Aβ
antibody injections for two and three months did not exhibit this hyperactivity and were
not significantly different from any other treatment groups (Fig 1B).
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One day following anti-Aβ antibody administration anti-Aβ antibodies were
detected in serum at high levels (400nM) following one month of administration. This
level of antibody in the serum was the same after two or three months of administration
with no apparent accumulation of antibody (Fig 2A). Associated with high anti-Aβ
antibody levels in serum at one month was a dramatic increase in circulating Aβ levels in
serum. APP transgenic mice receiving control antibody had only 1.5nM circulating Aβ in
plasma compared to APP transgenic mice receiving Aβ antibody for one month which
had 130nM circulating Aβ in plasma; an almost 100-fold increase (Fig 2B). Despite
similar levels of anti-Aβ antibody at one, two or three months of administration,
circulating Aβ levels declined between one and two month. They also showed a slight
decline between two and three months of administration although with both two and three
months of administration circulating Aβ levels were still significantly elevated compared
to APP transgenic mice receiving control antibody (Fig 2B).
Following systemic administration of anti-Aβ antibodies weekly for one month
staining for mouse IgG could be detected on plaques throughout the brains of APP
transgenic mice (Fig 3B). The staining was the most intense where plaque load is
greatest; the hippocampus and frontal cortex. This staining was not observed in APP
transgenic mice receiving control antibody (Fig 3A). It should be noted that staining with
higher concentrations of anti-mouse IgG-HRP did show staining of plaques in both
control treated and anti-Aβ treated APP transgenic mice. Staining for mouse IgG was
still present, and slightly more intense, around the plaques that remain following two
(Fig. 3C) and three (Fig. 3D) months of treatment.
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Total Aβ immunohistochemistry in the APP transgenic mice receiving control
antibody (Fig. 4A) showed a few intensely stained deposits suggesting compacted
amyloid deposits along with more numerous diffuse deposits. There was a concentration
of deposits around the hilus of the hippocampus as well as the molecular layers of
Ammon’s horn. This was a typical amount and distribution of Aβ for APP transgenic
mice of this age, as previously described (Hsiao et al, 1996 and Gordon et al, 2002).
Following one month of weekly anti-Aβ antibody injections there appeared to be a slight
reduction in Aβ immunohistochemistry in the hippocampus (Fig 4B) although this was
not statistically significant (Fig 4E). The reduction appeared to be primarily diffuse
deposits, with most of the compact amyloid deposits remaining (Fig 4B). After two
months of weekly anti-Aβ antibody injections we observed a dramatic reduction in Aβ
immunohistochemistry which appeared to be both compact and diffuse amyloid deposits
from the hilus and dentate gyrus regions of the hippocampus as well as the pyramidal cell
regions, with only a few deposits remaining, often in the vicinity of the hippocampal
fissure and outer molecular layers (Fig 4C). This reduction in Aβ load at two months was
approximately 60% in the hippocampus and approximately 55% in the frontal cortex (Fig
4E, hippocampus P<0.001, frontal cortex P<0.005). Total Aβ levels remained reduced
after three months of treatment but did not appear to decrease any further (Fig 4D and E).
Congo red staining detects only compact amyloid deposits in the beta pleated
sheet structure. There were far fewer Congo red positive amyloid deposits than Aβ
deposits detected by total Aβ immunohistochemistry. Congo red positive deposits were
located primarily along the fissure of the hippocampus as well as the CA1/ subiculum
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region in APP transgenic mice receiving control antibody (Fig 5A). There was no
reduction in Congophilic deposits 1 month following treatment in either the hippocampus
(Fig. 5B and E) or the frontal cortex (Fig 5E). Following two months of treatment there
was a significant reduction in both number and size of congophilic deposits in both the
hippocampus (Fig. 5C and E) and frontal cortex (Fig. 5E). This reduction was
approximately 60% in the frontal cortex and approximately 50% in the hippocampus
(Fig. 5E, P<0.005 frontal cortex P<0.01 hippocampus,). There was a small further
reduction between two months and three months which is approximately 30% in
hippocampus and frontal cortex (Fig. 5E). Thioflavine-S staining was also measured and
confirmed the Congo red data showing the same reductions in stained area as did Congo
red (data not shown).
Immunohistochemical staining for Fcγ receptors II and III in APP transgenic mice
receiving control antibody treatment for three months showed only very faint staining of
microglia in close association with amyloid deposits (Fig 6A). Following one month of
anti-Aβ antibody administration there was a dramatic induction of Fcγ receptors II and III
on microglia. The microglia expressing the Fcγ receptors after 1 month of treatment were
not only associated with amyloid deposits but are also diffusely distributed (Fig 6B). This
induction averaged 100-fold in the hippocampus (Fig. 6B and E, P<0.05) and frontal
cortex (Fig. 6E, P<0.05). Fcγ receptor expression levels fell only slightly between one
month and two months of treatment although this expression was once again concentrated
on microglia around remaining amyloid deposits (Fig. 6D). Induction remained
approximately 100-fold in hippocampus (Fig. 6E, P<0.05) and frontal cortex (Fig. 6E,
P<0.05). Following three months of treatment Fcγ receptor expression was reduced to
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levels observed in APP transgenic mice receiving control antibody (Fig. 6E) although it
appeared to be increased in microglia around the few remaining amyloid deposits (Fig.
6D).
CD45, a protein tyrosine phophatase, is normally moderately expressed on
microglia around amyloid deposits in aged APP transgenic mice and is a commonly used
marker for microglial activation. This moderate expression was observed in the APP
transgenic mice receiving control antibody treatment for three months (Fig 7A and E).
Following one month of treatment we observed an increase in CD45 expression on
microglia surrounding amyloid deposits in both the hippocampus (Fig. 7B, F and I) and
frontal cortex (Fig. 7I). While the expression in hippocampus was approximately 2.5
times that observed in control treated APP transgenic mice in the hippocampus (Fig. 7I,
not significant) and twice the values found in the frontal cortex of control animals, the
elevation was not statistically significant (Fig. 7I, not significant). Following two months
of anti-Aβ antibody treatment there was a further increase in CD45 expression on
microglia not only surrounding the amyloid deposits but also diffusely distributed
throughout the amyloid containing brain regions (Fig. 7C and G). It is possible that this
more widespread activation is in association with diffuse amyloid deposits although we
cannot confirm this. The increased expression was approximately 3.5 times that observed
in control treated mice in the hippocampus (Fig. 7I, P<0.05) and 3 times in the frontal
cortex (Fig. 7I, P<0.01). After three months of anti-Aβ antibody treatment CD45
expression remained at the same levels as that observed after one month of treatment (Fig
7I),however, the microglia were still diffusely distributed with fewer microglia around
deposits compared to one or two months of treatment (Fig 7D and H).
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Discussion.
The data presented here suggest that peripherally administered anti-Aβ antibodies
entered the brain, bound to congophilic amyloid plaques, and led to removal of deposited
amyloid. In support of the argument that anti-Aβ antibodies entered the brain, we found
mouse IgG decorating the remaining congophilic amyloid plaques of APP transgenic
mice administered anti-Aβ antibody, but no IgG in APP transgenic mice administered
control antibody. This difference was best discerned when low titers of the anti-mouse
IgG-HRP were used. Lemere et al (2004) also reported immunohistochemical labeling of
amyloid deposits for mouse IgG after passive immunization, but detected signals in both
immunized and non-immunized mice. It is unclear whether lower anti-mouse IgG
concentrations might have revealed selective staining in anti-Aβ treated animals. These
data confirm in parafomaldehyde fixed tissue the observations of Bard et al (2000), who
used unfixed cryostat sections.
Associated with the presence of antibody in the brain after one month of treatment
was a dramatic activation of Fcγ receptor expression on microglia, further arguing that
anti-Aβ antibodies entered the brain and opsonized the amyloid deposits. Later, following
two months of treatment, we observed an increase in CD45 expression on microglia,
indicating activation of these cells beyond the level normally associated with amyloid
deposits. It has previously been shown that following active immunization with Aβ1-42 in
humans that anti-Aβ antibodies are present in cerebrospinal fluid, in some instance equal
to serum concentration, suggesting some penetration into the brain from the periphery
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(Hock et al, 2002). It has also been shown that 0.1% of an intravenous injection of
radiolabeled anti-Aβ antibody crosses the blood-brain barrier of SAMP8 mice (Banks et
al, 2002). Thus, accumulating data indicates that circulating antibodies can access the
brain parenchyma, which has important implications not only for the use of
immunotherapy in Alzheimer’s disease but also for other diseases in which
immunotherapy is being pursued such as Creutzfeldt-Jakob disease (Manuelidis, 1998;
Sigurdsson et al, 2003) and neural infections associated with human immunodeficiency
virus (McMichael and Hanke, 2003).
Associated with the changes in microglial markers was a significant reduction in
both compact and diffuse amyloid deposits following two months of treatment, these
remained reduced following three months of treatment. Removal of Aβ deposits from the
brain appeared to be a gradual process. We did not observe significant reductions in
either diffuse or compact amyloid deposits following one month of weekly anti-Aβ
antibody treatment. Following two months of treatment there was a dramatic reduction in
total Aβ immunohistochemistry, Congo red staining and thioflavine-S staining,
suggesting removal of both diffuse and compact amyloid deposits. There appeared to be
no accumulation of the injected antibody, since serum anti-Aβ antibody levels were the
same regardless of duration of treatment. This would suggest that this time-dependent
removal of amyloid deposits was not occurring because of increasing antibody levels,
rather, it appears that some mobilization of removal mechanisms must be present for
some time before significant removal is apparent.
An early feature we observed was the increase in Fcγ receptors II and III (CD16 /
CD32) expression on microglia, which was apparent following one and two months of
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treatment. The murine Fcγ receptors II and III share a high affinity for IgG1 antibodies
(the isotype used in the current study) as well as IgG2a (Gessner et al, 1998). Following
this increased Fcγ receptor expression was an increase in CD45 expression on microglia
following two months of treatment. CD45 is a protein tyrosine phosphatase which is
elevated with microglial activation. In this study, it appears that the increase in CD45
expression represents a further activation step from that seen after one month of treatment
where we observe the increased Fcγ receptor expression. Following three months of
treatment, both Fcγ receptor and CD45 expression on microglia were reduced to control
levels, possibly due to the substantial reduction in amyloid deposits. It is important to
note that if we had looked at only the three month time-point we would not have detected
the activation of the microglia by CD45 or, likely by other markers such as Mac-1 (Das et
al, 2003).
We have previously observed a similar loss of microglia activation following
intracranial antibody administration (Wilcock et al, 2003) and active immunization
(Wilcock et al, 2001). Three days following a single injection of anti-Aβ antibody in the
frontal cortex and hippocampus we observed an increase in CD45 expression, however,
seven days following injection the CD45 expression was reduced to control levels, in
parallel with clearance of the Aβ deposits (Wilcock et al, 2003). This suggests that the
reduced microglial activation could possibly be due to the clearance of most amyloid
plaques. It is also conceivable that the microglia could be undergoing apoptosis due to the
robust activation as has been described previously by Liu et al (2001) when microglia are
overactivated by LPS. An alternative explanation could be tolerance of the microglia to
antibody opsonized Aβ. We have previously shown a reduction in microglial reaction in
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an active immunization model using doubly transgenic APP +PS1 mice. Following five
monthly inoculations we observed a significant increase in CD45 expression, however,
following nine monthly inoculations, CD45 levels were comparable to control animals
despite continued high antibody titer levels (Wilcock et al, 2001).
Due to the inflammatory adverse effects seen in the human clinical trial of the
active immunization by Elan pharmaceuticals it could be suggested that the microglial
activation observed in this study was due to an immune response unrelated to
opsonization of Aβ by the antibody. To evaluate whether this was the case we examined
the thalamus and cerebellum, which do not contain any amyloid deposits, for any
increase in CD45 or Fcγ receptor expression and did not observe any such increase. Thus
it appears that the microglial activation is specific to amyloid containing brain regions
and is likely a specific response to opsonized Aβ as opposed to a general non-specific
inflammatory reaction.
The data presented here extend our earlier observations of the benefits of active
anti-Aβ immunization on learning and memory (Morgan et al, 2000). We show that
passive immunization with anti-Aβ antibodies for a period of three months reduced
amyloid deposits and improved behavioral performance as indicated by a significant
increase in alternation in the y-maze as well as a decrease in the number of arm entries.
The arm entry data suggests that there is not a complete reversal of the increased activity.
There is a trend towards some improvement in alternation at the 1 month time point
(although not significant) despite no reduction in total Aβ immunohistochemistry. Such
improvements may reflect rapid reductions of an Aβ pool (oligomeric?) closely linked to
memory impairments yet not easily detected by immunohistochemistry. This phenomena
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was previously described by Dodart et al (2002) and Kotilinek et al (2002) who showed
rapid reversal of memory deficits in transgenic mice following passive immunization
without significant reduction in brain Aβ.
The results described above indicating entry of anti-Aβ antibody into brain and
activation of microglia suggests that some opsonization of Aβ is likely stimulating
microglial involvement in the clearance of Aβ deposits. This is consistent with the
phagocytosis mechanisms of amyloid removal put forward by the Elan group (Schenk et
al, 1999; Bard et al, 2000; Bard et al, 2003). Our earlier work with direct injection of
anti-Aβ antibody into brain suggests two mechanisms; one not requiring an Fc
component nor activation of microglia which can clear diffuse Aβ, and a second that
requires the Fc domain and activation of microglia (Wilcock et al, 2003; Wilcock et al,
2004). It is conceivable that the first non-Fc requiring mechanism is analogous to the
catalytic dissolution mechanism described by Solomon et al (1996). The diffuse material,
whatever its state of oligomerization may be more accessible to this action of anti-Aβ
antibodies. Finally, at all durations of antibody exposure we observe a dramatic increase
in circulating Aβ levels in plasma. This is consistent with a role for the peripheral sink
mechanism (DeMattos et al, 2001, Dodart et al, 2002; Lemere 2003) in the reduction of
CNS Aβ after passive immunization.
We conclude that our studies using antibody 2286, in aggregate, provide
support for all three major proposed mechanisms of anti-Aβ antibody action in lowering
brain amyloid. It is essential to recognize that these mechanisms are not mutually
exclusive, and are likely to be synergistic if multiple mechanisms are elicted by a single
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antibody/serum. It is also important to recognize that not all monoclonal antibodies need
work via all three mechanisms. Both isotype and epitope selectivity could regulate which
anti-Aβ action is dominant for a specific antibody. These studies also do not speak
towards other immune system related actions that might underlie the benefits (or adverse
effects) of active immunization. Nonetheless, given the preliminary data that anti-Aβ
immunotherapy may stabilize cognitive function in Alzheimer patients (Hock et al, 2003)
and the consistent reversal of the phenotype found in APP transgenic mice by such
approaches, these results support further development of the optimal strategies for using
anti-Aβ immunotherapy as a treatment for Alzheimer's dementia.
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Figure 1: Y-maze behavioral improvement after systemic anti-Aβ antibody
administration. Panel A shows percent alternation for nontransgenic (NTg) mice
receiving no treatment (ø), APP transgenic mice (APP) receiving control antibody (Cont)
for three months and APP transgenic mice (APP) receiving anti-Aβ (Aβ) antibody for 1,
2 or 3 months. * indicates P<0.05 when compared to nontransgenic untreated mice and
APP transgenic mice receiving anti-Aβ antibody for 3 months. Panel B shows number of
arm entries for nontransgenic (NTg) mice receiving no treatment (ø), APP transgenic
mice (APP) receiving control antibody (Cont) for three months and APP transgenic mice
(APP) receiving anti-Aβ (Aβ) antibody for 1, 2 or 3 months. * indicates P<0.05 when
compared to nontransgenic untreated mice.
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Figure 2: Increased serum levels of anti-Aβ antibody and Aβ after anti-Aβ antibody
administration. Panel A shows amounts of circulating anti-Aβ antibodies in APP
transgenic mice (APP) receiving either control antibody (Cont) for 3 months or anti-Aβ
antibody (Aβ) for 1, 2 or 3 months, nontransgenic (NTg) mice receiving either control
antibody (Cont) or anti-Aβ antibody (Aβ) for 3 months and nontransgenic mice receiving
no treatment. ** indicates P<0.001 compared to APP mice given control antibody
injections. Panel B shows amounts of circulating Aβ in sera in APP transgenic mice
(APP) receiving either control antibody (Cont) for 3 months or anti-Aβ antibody (Aβ) for
1, 2 or 3 months, nontransgenic (NTg) mice receiving either control antibody (Cont) or
anti-Aβ antibody (Aβ) for 3 months and nontransgenic mice receiving no treatment. **
indicates P<0.01, * indicates P<0.05.
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Figure 3: Mouse IgG immunohistochemistry shows antibody binding to congophilic
plaques in anti-Aβ antibody treated mice but not control antibody treated mice. Panels AD show anti-mouse IgG-HRP immunohistochemistry counterstained with Congo red to
detect compact amyloid deposits. Panel A shows a representative amyloid deposit and
associated anti-mouse IgG immunostaining (black) in the hippocampus of a mouse
injected with control antibody for three months. Panels B-D shows a representative
amyloid deposit (red) associated with anti-mouse IgG immunostaining (black) in the
hippocampus of a mouse injected with anti-Aβ antibody for one month (B), two months
(C) or three months (D). Magnification = 200X, scale bar = 25µm.
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Figure 4: Total Aβ immunohistochemistry is reduced following two months of systemic
anti-Aβ antibody administration. Panels A-D show total Aβ immunohistochemistry in the
hippocampus of APP transgenic mice receiving control antibody for three months (Panel
A. Percent area for this section was 9.12%), anti-Aβ antibody for one month (Panel B.
Percent area for this section was 6.84%), anti-Aβ antibody for two months (Panel C.
Percent area for this section was 3.23%) or anti-Aβ antibody for three months (Panel D.
Percent area for this section was 2.49%). Magnification = 40X, scale bar = 120µm. In
panel D, CA1 indicates cornu ammonis 1, CA3 indicates cornu ammonis 3, F indicates
the hippocampal fissure and DG indicates the dentate gyrus. Panel E shows quantification
of the percent area occupied by Aβ positive stain in the frontal cortex and hippocampus.
The single bar shows the value for APP transgenic mice receiving control antibody for
three months. The line shows the values for APP transgenic mice receiving anti-Aβ
antibody for a period of one, two and three months. ** indicates P<0.01.
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Figure 5: Congophilic compact amyloid plaques are reduced following two months of
anti-Aβ antibody administration. Panels A-D show Congo red staining in the
hippocampus of APP transgenic mice receiving control antibody for three months (Panel
A), anti-Aβ antibody for one month (Panel B), anti-Aβ antibody for two months (Panel
C) or anti-Aβ antibody for three months (Panel D). Magnification = 40X, scale bar =
120µm. In panel D, CA1 indicates cornu ammonis 1, CA3 indicates cornu ammonis 3, F
indicates the hippocampal fissure and DG indicates the dentate gyrus. Panel E shows
quantification of the percent area occupied by Congo red positive stain in the frontal
cortex and hippocampus. The single bar shows the value for APP transgenic mice
receiving control antibody for three months. The line shows the values for APP
transgenic mice receiving anti-Aβ antibody for a period of one, two and three months. **
indicates P<0.01.
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Figure 6: Fcγ receptor expression on microglia is increased following one month of antiAβ antibody treatment and remains increased following two months of treatment. Panels
A-D show Fcγ receptor immunohistochemistry in the hippocampus of APP transgenic
mice receiving control antibody for three months (Panel A), anti-Aβ antibody for one
month (Panel B), anti-Aβ antibody for two months (Panel C) or anti-Aβ antibody for
three months (Panel D). In panel A, F indicates the hippocampal fissure, DG indicates the
dentate gyrus. Magnification = 100X, scale bar = 50µm. Panel E shows quantification of
the percent area occupied by Fcγ receptor positive stain in the frontal cortex and
hippocampus. The single bar shows the value for APP transgenic mice receiving control
antibody for three months. The line shows the values for APP transgenic mice receiving
anti-Aβ antibody for a period of one, two and three months. * indicates P<0.05.
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Figure 7: CD45 expression on microglia is increased following two months of anti-Aβ
antibody treatment. Panels A-D show CD45 immunohistochemistry in the hippocampus
of APP transgenic mice receiving control antibody for three months (Panel A), anti-Aβ
antibody for one month (Panel B), anti-Aβ antibody for two months (Panel C) or anti-Aβ
antibody for three months (Panel D). In panel A, F indicates the hippocampal fissure, DG
indicates the dentate gyrus. Magnification = 100X, scale bar = 50µm. Panels E-H are
magnified images of non-amyloid containing areas from panels A-D. Panels E-H show
CD45 immunohistochemistry in the hippocampus of APP transgenic mice receiving
control antibody for three months (Panel E), anti-Aβ antibody for one month (Panel F),
anti-Aβ antibody for two months (Panel G) or anti-Aβ antibody for three months (Panel
H). Panel I shows quantification of the percent area occupied by CD45 positive stain in
the frontal cortex and hippocampus. The single bar shows the value for APP transgenic
mice receiving control antibody for three months. The line shows the values for APP
transgenic mice receiving anti-Aβ antibody for a period of one, two and three months. *
indicates P<0.05.
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Abstract
Background:
Anti-Aß immunotherapy in transgenic mice reduces both diffuse and compact
amyloid deposits, improves memory function and clears early-stage phospho-tau
aggregates. As most AD cases occur well past midlife, the current study examined
adoptive transfer of anti-Aβ antibodies to 19 and 23 month old APP transgenic mice.
Results:
After three months of weekly injections, this passive immunization protocol
completely reversed learning and memory deficits in these mice, a benefit which was
undiminished after 5 months of treatment. Dramatic reductions of diffuse Aß
immunostaining and parenchymal Congophilic amyloid deposits were observed after 5
months, indicating even well established amyloid deposits are susceptible to
immunotherapy. However, cerebral amyloid angiopathy increased substantially with
immunotherapy and some deposits were associated with microhemorrhage. Reanalysis of
results collected from an earlier time course study demonstrated that these increases in
vascular deposits were dependent on the duration of immunotherapy.
Conclusions:
The cognitive benefits of passive immunotherapy persist in spite of the presence
of vascular amyloid and small hemorrhages. These data suggest that clinical trials
evaluating such treatments will require precautions to minimize potential adverse events
associated with microhemorrhage.
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Introduction
Alzheimer’s disease (AD) is characterized not only by the presence of
parenchymal amyloid deposits and intracellular tangles but also by the presence of
amyloid deposits in the vasculature, a condition referred to as cerebral amyloid
angiopathy (CAA). The CAA observed in both Alzheimer’s disease patients (Iwatsubo et
al, 1994) and some of the transgenic mouse models (Gordon et al, 2002) is primarily
composed of the shorter form of amyloid beta (Aβ), Aβ 1-40, while the majority of
amyloid deposits in the parenchyma are composed of Aβ1-42, although the compact
amyloid deposits also contain Aβ1-40.
Anti-Aβ immunotherapy has been considered as a potential treatment for
AD for some time (Solomon et al, 1996; Schenk et al, 1999). Active immunization with a
vaccine including Aβ1-42 fibrils progressed to human clinical trials where its
administration was suspended due to meningoencephalitits in a subset of patients
(Orgogozo et al, 2003). To date there have been pathology reports on two patients who
participated in the trial and subsequently died (Nicoll et al, 2003, Ferrer et al, 2004). Both
reports note that while the numbers of parenchymal amyloid deposits appeared lower
than expected in these cases, the CAA in these patients did not appear outside the normal
range In addition, one report mentioned multiple cortical hemorrhages and the presence
of hemosiderin around the CAA vessels (Ferrer et al, 2004).
Given the adverse reactions to the active immunization, the irreversibility of such
procedures and the variable antibody response to vaccines in older individuals (Weksler
et al, 1997), passive immunization against the Aß peptide emerged as an alternative
immunotherapeutic strategy. Studies in young and middle aged APP transgenic mice
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have reported significant amyloid reductions with passive immunization (DeMattos et al,
2001, Bard et al, 2000, Wilcock et al, 2003). Such treatments also demonstrate rapid
improvements of memory function in APP mice, sometimes without detectable
reductions in amyloid (Dodart et al, 2002, Kotilinek et al, 2002, Wilcock et al, 2004b).
Most recently, intracranial administration of anti-Aβ antibodies has been shown to not
only remove Aβ but also clear early-stage hyperphosphorylated tau aggregates (Oddo et
al, 2004). Importantly, in the only prior study evaluating adoptive antibody transfer in
older APP mice, Pfeifer et al (2002) reported a doubling of cerebral microhemorrhages
associated with significant reductions in amyloid burden after administration of an Nterminal specific anti-Aß antibody.
Materials and Methods:
Experiment design:
Mice derived from APP Tg2576 mice were obtained from our breeding program
at USF started in 1996 (Holcomb et al, 1998). For the five month treatment study thirteen
APP transgenic mice aged 23 months were assigned to one of two groups. The first group
received weekly intraperitoneal anti-Aβ antibody injections (antibody 2286; Mouse
monoclonal anti-human Aβ28-40 IgG1; Rinat Neurosciences, Palo Alto, CA) for a period
of five months (n=6). The second group received weekly intraperitoneal anti-AMN
antibody (2906; Mouse monoclonal anti-drosophila amnesiac protein IgG1; (Rinat
Neurosciences, Palo Alto, CA) injections for a period of five months (n=7). Seven
nontransgenic mice were also assigned to one of two groups. The first group received
weekly intraperitoneal anti-Aβ antibody injections for a period of five months (n=4). The
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second group received weekly intraperitoneal anti-AMN antibody injections for a period
of five months (n=3).
For the time course study of 1, 2 or 3 mo treatment, twenty two APP transgenic
mice aged 19 months were assigned to one of four experimental groups, as described
previously (Wilcock et al, 2004b). The first three groups received weekly intraperitoneal
anti-Aβ antibody injections for 3 months, 2 months or 1 month, ending when all mice
were 22 mo of age. The fourth group received weekly intraperitoneal anti-AMN antibody
injections for 3 months.

Behavioral analysis:
Following three and five months of treatment the mice from the 5 month study
were subjected to a two day radial-arm water maze paradigm. The apparatus was a 6 arm
maze as described previously (Morgan et al, 2000). On day 1, 15 trials were run in 3
blocks of five. A cohort of 4 mice were run sequentially for each block (i.e. each of 4
mice get trial one, then the same mice get trial two, etc). After each 5 trial block, a second
cohort of mice were run permitting an extended rest period before mice were exposed to
the second block of 5 trials. The goal arm was different for each mouse in a cohort to
minimize odor cues. The start arm was varied for each trial, with the goal arm remaining
constant for both days. For the first 11 trials, the platform was alternately visible then
hidden (hidden for the last 4 trials). On day two, the mice were run in exactly the same
manner as day 1 except that the platform was hidden for all trials. The number of errors
(incorrect arm entries) were measured in a one minute time frame. As in prior studies,
mice failing to make an arm choice in 20 seconds were assigned 1 error (no mice in this
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study had to be assigned an error in this manner). The same individual administered the
antibody treatments and placed mice in the radial arm water maze. Due to the numbers of
mice in the study the researcher was unaware of treatment group identity of each mouse.
Also, the dependent measures in the radial-arm water maze task are quantitative, not
evaluative, so the potential for tester bias is reduced. In order to minimize the influence
of individual trial variability, each mouse's errors for three consecutive trials were
averaged producing 5 data points for each day which were analyzed statistically by
ANOVA using StatView (SAS Institute Inc., NC).
Tissue preparation and histology:
On the day of kill mice were weighed, overdosed with 100mg/kg Nembutal
sodium solution (Abbott laboratories, North Chicago IL). The mice were then
intracardially perfused with 25ml of 0.9% sodium chloride. Brains were rapidly removed
and the left half of the brain was immersion fixed for 24 hours in freshly prepared 4%
paraformaldehyde in 100mM KPO4 (pH 7.2) for histopathology. The hemibrains were
then incubated for 24 hours in 10, 20 and 30% sucrose sequentially to cyroprotect them.
Horizontal sections of 25µm thickness were collected using a sliding microtome and
stored at 4oC in Dulbecco’s phosphate-buffered saline with sodium azide (pH 7.2) to
prevent microbial growth. A series of eight equally spaced tissue sections 0600µm apart
were randomly selected spanning the entire brain and stained using free-floating
immunohistochemistry for total Αβ (rabbit polyclonal anti-pan Aβ Bisource, Camarillo,
CA, 1:10000) as previously described (Gordon et al, 2002, Wilcock et al, 2004b). A
second series of tissue sections 0.6mm apart were stained using 0.2% Congo red solution
in NaCl saturated 80% ethanol. Another set of sections were also mounted and stained for
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hemosiderin using 2% potassium ferrocyanide in 2% hydrochloric acid for 15 minutes
followed by a counterstain in a 1% neutral red solution for 10 minutes. Quantification of
Congo red staining and Aβ immunohistochemistry was performed using the Image-Pro
Plus (Media Cybernetics, Silver Spring, MD) to analyze the percent area occupied by
positive stain. One region of the frontal cortex and three regions of the hippocampus were
analyzed (to ensure that there was no regional bias in the hippocampal values). The initial
analysis of Congo red was performed to give a total value. A second analysis was
performed after manually editing out all of the parenchymal amyloid deposits to yield a
percent area restriced to vascular Congo red staining. To estimate the parenchymal area
of Congo red we subtracted the vascular amyloid values from the total percentage. For
the hemosiderin stain the number of Prussian blue positive sites were counted on all
sections and the average number of sites per section calculated. Looking at the sections at
a low magnification we were able to observe a qualitative difference between animals,
however, the percent area was so low that many fields contained no positive stain. Eight
equally spaced sections were examined and number of positive profiles were counted and
averaged to a per section value. To assess possible treatment-related differences, the
values for each treatment group were analyzed by one-way ANOVA followed by
Fischer’s LSD means comparisons.
Results
Reversal of cognitive deficits by passive amyloid immunotherapy:
The radial-arm water maze task detects spatial learning and memory deficits in
transgenic mouse models (Morgan et al, 2000; Gordon et al, 2001). We treated 23 mo old
mice for 5 mo with anti-Aß antibody 2286 or control antibody 2906 (against a
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drospohila-specific protein) and tested them for spatial navigation learning in a 2 day
version of the radial arm water maze after 3 mo of treatment and, using a new platform
location, again after 5 mo of treatment. At both testing times we found that APP mice
treated with the control antibody failed to learn platform location over two days of testing
and were significantly impaired compared to the nontransgenic mice treated with either
antibody (Fig 1). However, APP mice administered the anti-Aß antibodies demonstrated
a complete reversal of the impairment observed in the control APP transgenic mice,
ending day 2 with performance near 0.5 errors per trial (Fig. 1). Although learning at the
later time point, when the mice were 28 mo of age, may have been slightly slower for all
groups, there was no impairment of the anti-Aß antibody treated APP.
Passive amyloid immunotherapy clears parenchymal Aß deposits, but increases vascular
amyloid:
In a prior experiment examining the effects of passive anti-Aß immunotherapy for
1, 2 or 3 mo in APP mice killed at 21 mo of age (Wilcock et al, 2004b), we found a time
dependent reduction of both Aß immunostaining of diffuse and fibrillar deposits and
Congo red staining of fibrillar amyloid deposits. In the current study we found a similar
reduction in both Aß immunostaining (Table 1) and total Congo red staining (Fig 2A, left
panel; P<0.001 frontal cortex and P<0.01 hippocampus) after 5 months of
immunotherapy. We noted that the bulk of what remained was vascular amyloid. We then
separately analyzed vascular and parenchymal deposits which revealed a near 90%
reduction in parenchymal deposits (P<0.001), but a 3-4 fold elevation of vascular Congo
red staining (P<0.0001; Fig 2A, center and right panels resepectively). We also separately
analyzed vascular and parenchymal Congo red staining on mice from our earlier study
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(14) treated passively for 1, 2 or 3 months with anti-Aß or control antibody, and found a
similar result. There was a graded reduction in overall Congo red staining nearing 75% as
duration of antibody exposure increased (as reported previously; Fig 2B). However, when
separated into vascular Congo red deposits and parenchymal deposits, there was an
antibody exposure time dependent increase in vascular deposition in both hippocampus
and frontal cortex (Fig 2C; P<0.05 frontal cortex and hippocampus) and a corresponding
near 90% decrease in parenchymal deposits (Fig 2D; P<0.001 in frontal cortex and
hippocampus).
These differences were readily observed examining micrographs of sections from
these mice. Mice treated with control antibodies revealed occasional cortical vascular
amyloid deposits (22 mo Fig 3A, 28 mo Fig 3C), while mice administered anti-Aß
antibodies had increased amounts of vascular amyloid staining (3 mo treatment Fig 3B; 5
mo treatment Fig 3D). Those vessels containing amyloid following treatment with antiAβ antibody also exhibited apparent increases in microglial activation as measured by
CD45 expression (Fig 3F) compared to mice treated with control antibody (Fig 3E).
Unfortunately, the shifting numbers and sizes of vascular and parenchymal deposits
caused by the antibody therapy greatly complicated measurement of microglial activation
per vascular deposit area. This apparent increase in staining intensity could not be
quantified accurately.
Passive amyloid immunotherapy causes increased microhemorrhage:
We used the Prussian blue histological stain to label hemosiderin, a ferric oxide
material produced in the breakdown of hemoglobin. Extravenous blood in the brain leads
to microglial phagocytosis of the erythrocytes and breakdown of hemoglobin within
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them. These ferric oxide containing microglia are thus markers of past hemorrhage. In
untreated, aged APP transgenic mice we observed very few profiles positive for Prussian
blue staining in the frontal cortex (section counterstained with neutral red; Fig. 4A).
However, following anti-Aβ antibody treatment for five months we observed an increase
in the number of Prussian blue profiles in the frontal cortex which were readily detectable
at a low power in the microscope (Fig 4B). In the absence of anti-Aß treatment, or even
when treated with antbody for 1 month, most vessels did not stain with Prussian blue, and
could be identified only using the red counterstain (Fig 4C). However, even with 3
months of anti-Aß antibody treatment we observed frequent vessels with associated
Prussian blue staining (Fig 4D) Using adjacent sections stained for Congo red, we
confirmed that all vessels showing microhemorrhage contained amyloid (Fig 4E and 4F;
we were unable to double-label Prussian blue with either Congo red or thioflavine-S).
However, only a minority of vessels containing amyloid demonstrated hemorrhage.
When we counted the number of Prussian blue positive profiles in those animals
receiving control antibody there was an average of one profile per every 2 sections (Fig
5) and this number remained the same in both control groups (aged 22 or 28 mo).
Following treatment with anti-Aβ antibody for a period of two months we observed a
striking increase in Prussian blue staining, approximately five times that observed in
either the control group or the mice immunized for one month (Fig 5, P<0.001).
Following this initial increase in Prussian blue staining we observed a linear increase in
staining associated with increasing duration of anti-Aß antibody treatment (Fig 5). Five
months of anti-Aβ antibody treatment demonstrated a 6-fold increase in Prussian blue
staining when compared the control groups (Fig 5).
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Discussion
Earlier studies with vaccines against the Aß peptide demonstrated protection from
the learning and memory deficits associated with amyloid accumulation in APP
transgenic mice (Morgan et al, 2000, Janus et al, 2000). Passive immunization protocols
with anti-Aß antibodies also produced cognitive benefits, in some cases even in the
absence of significant reduction in amyloid burden (Dodart et al, 2002, Kotilinek et al,
2002). Our recent work found that 3 months of anti-Aß treatment of 18 mo old APP mice
improved spontaneous alternation performance on the Y-maze (Wilcock et al, 2004b). In
the present work we confirmed that passive anti-amyloid immunotherapy can reverse
spatial learning deficits in APP transgenic mice and that this benefit of immunotherapy is
retained even in aged mice (26 and 28 mo at testing) with long established amyloid
pathology.
Additionally, we describe a more rapid means of testing spatial reference memory
to reveal learning and memory deficits in APP transgenic mice. This 2 day version of the
radial arm water maze included greater spacing of individual trials (mice spent time in
their home cage after every trial), combined with less spacing of aggregate trials (15 trials
per day rather than 4 or 5) to facilitate learning of platform location in the nontransgenic
mice with a clear absence of learning in the age-matched transgenic mice.
A substantial reduction in total Congophilic amyloid deposits was observed in old
APP mice treated with anti-Aß antibodies for 2 or more months. This measurement of
total Congo red staining included both parenchymal and vascular amyloid staining. When
we analyzed the sections for only CAA we found that this measure was significantly
increased following two, three and five months of anti-Aβ antibody treatment. The
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remaining parenchymal amyloid load was almost completely eliminated with this
antibody approach. Clearly, since total amyloid load is significantly reduced not all
amyloid was shifted into the vessels but it appears that at least some of the Congophilic
material was redistributed to the vasculature. At the present time the mechanism for this
redistribution is unclear. However, one possibility is that the microglia associated with
the antibody-opsonized amyloid, either by phagocytosis or surface binding, and
transported the material to the vasculature, possibly in an attempt to expel it. We and
others have shown evidence for microglial involvement in the removal of amyloid using
both intracranial anti-Aβ antibody injections (Wilcock et al, 2003, 2004a) and
systemically administered anti-Aβ antibody treatment (Wilcock et al, 2004b) as well as
ex vivo studies (Bard et al, 2000, 2003). Here we also report our impression that
microglia surrounding CAA vessels in immunized mice expressed more CD45 than
control transgenic mice. This increased expression could be due to either increased
expression in the same number of microglial cells or an increased number of microglial
cells in these animals. It is feasible that this microglial activation was simply in reaction
to the presence of increased amyloid in the blood vessels. However, it is equally likely
that microglia activated by the opsonized material migrated to the vessels for disposal of
the amyloid.
CAA is defined as the deposition of congophilic material in meningeal and
cerebral arteries and arterioles (capillaries and veins can also show CAA but less
frequently) and it occurs to some extent in nearly all Alzheimer’s disease patients
(Jellinger, 2002). Severe CAA affecting about 15% of cases, can be associated with both
infarction and hemorrhagic injury (Olichney et al, 1997, Maurino et al, 2001). It has also
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been shown that the severity of CAA can be directly linked to the severity of dementia in
Alzheimer’s disease patients (Thal et al, 2003).
In the current study we show a significantly increased number of
microhemorrhages in the brain as detected by Prussian blue staining associated with the
increase in CAA following passive immunization. Another transgenic mouse model of
amyloid deposition, the APP23 mice, have been shown to deposit amyloid in both brain
parenchyma and blood vessels and show a CAA associated increase in spontaneous
cerebral hemorrhages (Winkler et al, 2001). Moreover, Pfeifer et al (2002) showed that
these spontaneous hemorrhages were significantly increased following 5 months of
passive immunization of 21 mo old APP23 mice using an anti-Aβ antibody with an Nterminal epitope, similar to those typically developed against active immunization with
vaccines (Schenk et al, 1999, Dickey et al, 2001, McLaurin et al, 2002) When young
mice (6 mo) were immunized following the same protocol no hemorrhages were
observed. More recently DeMattos et al (9th International Conference on Alzheimer’s
disease and related disorders, 2004) showed that passive immunization with an Nterminal antibody (3D6: directed against aa 1-5 of Aβ) of PDAPP transgenic mice also
resulted in significantly increased microhemorrhage. They were unable to detect
increased microhemorrhage with a mid-domain antibody (266: directed against aa 13-28
of Aβ). Notably, antibody 266 fails to bind Aß deposited in CAA vessels or amyloid
plaques (9th International Conference on Alzheimer’s disease and related disorders,
2004). Importantly, Ferrer et al (2004) noted the presence of CAA and microhemorrhage
in the brain of one patient that participated in the Aß vaccine trial, even though the
parenchymal amyloid appeared lower than expected. Also, Nicoll et al [6] noted that
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CAA appeared unaffected in the brain of another patient that participated in the Aß
vaccine trial.
It remains to be determined whether these observations regarding increased CAA
and microhemorrhage in transgenic mice are relevant to trials of passive immunotherapy
in humans. It should be noted that in spite of extending the period of immunotherapy to 5
months, there was no discernable loss of the cognitive benefits of immunotherapy in the
transgenic mice, all of whom showed increased microhemorrhage. While the observation
that antibody 266 does not result in vascular leakage encourages testing of this idiotype,
data from the Zurich cohort of the Aß vaccine trial argue that brain reactive antibodies
may be important for cognitive benefits (Hock et al, 2003). Our opinion is that these
results suggest that passive immunotherapy against Aß should proceed with appropriate
precautions taken to minimize the risk of hemorrhage (e.g. by excluding patients taking
anticoagulants), and instituting measures to detect such hemorrhages if they do occur
irrespective of the antibody specificity or proclivity for microhemorrhage in aged APP
transgenic mice.
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Figure 1: Spatial learning deficits in APP transgenic mice were reversed following three
and five months of immunization. Mice were tested in a 2 day version of the radial arm
water maze. Solid lines represent APP transgenic mice while dashed lines represent
nontransgenic mice. Open symbols indicate anti-AMN control antibody treatment ({:
APP control antibody, U: Nontransgenic control antibody) while closed symbols indicate
anti-Aβ antibody treatment (z: APP Aβ antibody, S: Nontransgenic Aβ antibody).
Panel A shows mean number of errors made over the two day trial period following three
months of immunization. Each datapoint is the average of three trials. Panel B shows the
mean number of errors made over the two day trial period following five months of
immunization. For both graphs * indicates P<0.05, ** indicates P<0.001 when the APP
mice receiving control antibody are compared with the remaining groups.
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Figure 2: Passive immunization with anti-Aß antibodies decreases total and parenchymal
amyloid loads while increasing vascular amyloid in frontal cortex and hippocampus of
APP transgenic mice. Panel A shows total amyloid load measured with Congo red,
vascular amyloid load and parenchymal amyloid load from APP transgenic mice
administered control IgG (C) or anti-Aβ IgG (Aβ) for a period of five months. Panels BD show total amyloid load (Panel B), vascular amyloid load (Panel C) and parenchymal
amyloid load (Panel D) from APP transgenic mice administered control IgG for 3 months
(Cont IgG) or anti-Aβ IgG for a period of one, two or three months (Anti-Aβ IgG). For
all panels, the solid bar and solid line represent values from the frontal cortex while the
open bar and dashed line represent values from the hippocampus. ** P<0.01.
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Figure 3: Increased Congo red staining of blood vessels following anti-Aβ antibody
administration is associated with activated microglia. Panels A and B are from the frontal
cortex of 22 month old APP transgenic mice immunized for 3 months with either control
antibody (3A) or anti-Aβ antibody (3B). Panels C and D are from the frontal cortex of 28
month old APP transgenic mice immunized for five months with either control antibody
(3C) or anti-Aβ antibody (3D). Panels E and F show a high magnification image of CD45
immunohistochemistry (black) counterstained with Congo red (red) from 28 month old
APP transgenic mice immunized for five months with either control antibody (Panel E)
or anti-Aβ antibody (Panel F). Panels A-D magnification = 100X. Scale bar in Panel B =
50µm for panels A-D. Panels E-F magnification = 200X. Scale bar in Panel E = 25µm for
panels E-F.
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Figure 4: Microhemorrhage associated with CAA following systemic administration of
anti-Aβ antibodies. Panels A and B are low magnification images of the frontal cortex of
APP transgenic mice receiving either control antibodies (Panel A) or anti-Aβ antibodies
(Panel B) for a period of five months. Panels C and D show representative images of
amyloid containing vessels stained for Prussian blue (blue) counterstained with neutral
red (red) from APP transgenic mice receiving either control antibodies (Panel C) or antiAβ antibodies (Panel D) for a period of three months. Panel E shows a blood vessel in the
frontal cortex stained for Prussian blue (blue) counterstained with neutral red from an
APP transgenic mouse administered anti-Aβ antibodies for five months. Panel F shows
the same blood vessel on an adjacent section stained for Congo red indicating that the
blood vessel does in fact contain amyloid. Scale bar panel A = 120µm for panels A-B.
Scale bar panel C = 25µm for panels C-D. Scale bar in panel F = 25µm for panels E-F.
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Figure 5: Number of Prussian blue positive profiles increases with duration of anti-Aβ
antibody exposure. The graph shows quantification of the average number of Prussian
blue positive profiles per section from mice administered control IgG for 3 or 5 months
(Control) or anti-Aβ IgG for 1, 2, 3 or 5 months (anti-Aβ). ** P<0.01.
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Table 1. Aß Loads after 5 months of Immunotherapy
Region

% area control
antibody treated

% area anti-Aβ
antibody treated

Frontal Cortex
Hippocampus

34.855±2.265
23.994±0.985

9.681±0.754
8.212±0.596
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% reduction
following anti-Aβ
antibody treatment
72
66
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CONCLUSIONS
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that slowly
robs sufferers of their ability to remember, reason, make judgements and carry out daily
activities; it is the most common cause of dementia with a duration of anywhere from 3 to
20 years. It is estimated that in 2004 there are currently 4.5 million Americans have the
disease, with a projected number of 11.6 to 16 million sufferers by the year 2050 (Hebert
et al, 2003). Several genes have been found to cause AD in humans; these are the
amyloid precursor protein (APP) and presenilin 1 and 2 (PS1 and PS2). Mutations in
these genes result in a rare, aggressive form of the disease known as familial early onset
Alzheimer’s disease (FAD) with the disease commonly occurring by age 60 and
sometimes in the 30s and 40s. The discovery of these mutations led to the development of
transgenic mouse models, the first of which carried normal beta-APP751 with no
mutations and demonstrated some extracellular Aß deposits (Quon D et al, 1991).
The first mouse overexpressing mutated human APP which developed extensive
amyloid pathology but no tau pathology or neuron loss was the PDAPP transgenic mouse
(Games et al, 1995). The Tg2576 APP transgenic mouse was the first transgenic model to
show learning and memory deficits associated with the amyloid pathology (Hsiao et al,
1996). Mice overexpressing human PS1 mutations were less successful models on their
own, not developing any amyloid deposits (Duff et al, 1996). However, it was shown that
crossing an APP transgenic mouse with a PS1 transgenic mouse (APP+PS1) results in an
accelerated model of amyloid deposition (Borchelt et al, 1997; Citron et al, 1998;
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Holcomb et al, 1998). It was also later shown that an APP+PS1 transgenic mouse model
developed reliable cognitive dysfunction which correlated with the extent of amyloid
pathology (Gordon et al, 2001). These transgenic mouse models of amyloid pathology
also develop another pathological characteristic of AD which is activation of
inflammatory cells in the brain; namely microglia and astrocytes, which has been shown
to be associated with the extent of amyloid deposition (Gordon et al, 2002).
The amyloid hypothesis for AD is currently the most favored hypothesis for the
cause of the disease which states that the precipitating event in the development of AD is
the over-production and deposition of Aß in the form of diffuse and compact amyloid
deposits which in turn results in hyperphosphorylation of tau and neuronal death (Hardy
et al, 1992). This hypothesis has been the focus of therapeutic intervention in AD
including the development of immunotherapy as a potential treatment for AD.
Immunotherapy was first shown in 1999 by Schenk et al (1999) of Elan pharmaceuticals.
In this report the authors showed that immunization of young PDAPP transgenic mice
with Aß1-42 fibrils in Freund’s adjuvant over a period of 11 months prevented amyloid
deposition while immunization of older PDAPP mice for 4 and 7 months resulted in
significant reductions in amyloid burden. Following this initial report it was later shown
that immunization not only ameliorated amyloid pathology but also in resulted in
improved cognition in both APP+PS1 transgenic mice (Morgan et al, 2000) and
TgCRND8 APP transgenic mice (Janus et al, 2000). We later reported that over a series
of several immunization studies in APP+PS1 mice that the degree of microglial
activation strongly correlated with the reduction in compact, Congophilic amyloid
deposits (Appendix A) suggesting a critical role of microglia in the removal of amyloid
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by this active immunization approach. Since the original report in 1999 there has been a
plethora of data published regarding the use of both active and passive immunization for
the treatment of AD. Following the failure of active immunization in phase II clinical
trials we decided that discovery of the mechanism(s) by which immunotherapy acts to
reduce amyloid pathology would be critical if immunotherapy was to be successful in
humans.
Here we show evidence for three mechanisms for Aß removal by immunotherapy
as well as some potentially unwanted effects of passive immunization which will likely
need to be overcome if immunotherapy is to be successful in humans. By 2001 there had
been three suggested mechanisms of action. The first was microglial phagocytosis via the
Fcγ receptor which was first suggested by Schenk et al (1999) in their active
immunization report and later by Bard et al (2000) in a report showing the benefits of
passive immunization in the PDAPP mouse. We also show evidence for this mechanism
in Appendix A where we observed a correlation between microglial activation and
amyloid reduction. Another mechanism was shown before immunotherapy for AD was
suggested; this showed that anti-Aß antibodies are capable of inhibiting amyloid fibril
formation (Solomon et al, 1996). The same group also showed that anti-Aß antibodies
could disaggregate already formed amyloid fibrils (Solomon et al, 1997). A third
suggested mechanism stated that anti-Aß antibodies need not enter the CNS but act
peripherally by binding to circulating Aß in the plasma and therefore resulting in a shift
in the concentration gradient between CNS and plasma causing Aß to exit the brain and
enter the serum where it would be bound by antibodies and removed. This was evidenced
by a rapid and dramatic increase in circulating Aß levels hours following anti-Aß
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antibody administration. Importantly, this study used an anti-Aß antibody shown not to
bind to amyloid deposits in the brain (DeMattos et al, 2001).
To approach the question of which mechanism was important for Aß removal by
immunotherapy we decided to bypass the issue of blood-brain barrier penetration and
work on finding out what happens when antibody is in the brain. To answer this question
we injected anti-Aß antibodies (anti-Aß1-16) into the right frontal cortex and hippocampus
of aged Tg2576 APP transgenic mice with significant amyloid burdens, leaving the left
side of the brain untreated as an internal control for each mouse. We then examined what
effects the antibody had after 4, 24, 72 and 168 hours. We found that diffuse amyloid
deposits, stained immunohistochemically for Aß but not stained by thioflavine-S, were
significantly reduced following 24 hours of treatment (Paper 1; Figures 2 and 3) but there
was no associated microglial reaction or any reduction in compact, thioflavine-S positive,
amyloid deposits. These compact deposits were found to be significantly reduced 72
hours following injection of anti-Aß antibodies (Paper 1; Figures 4 and 5) and this was
associated with a significant activation of microglia as detected by CD45 (Paper 1;
Figures 6 and 7) and MHC-II (Paper 1; Figures 8 and 9) immunohistochemistry. 168
hours following injection we found that both diffuse and compact amyloid deposits
remained reduced with no further reduction and microglial activation had returned to
control levels. These data suggest two phases of removal of Aß by anti-Aß antibodies
which may be occurring through two different mechanisms. The first phase is the
removal of diffuse amyloid deposits by a mechanism independent of microglial activation,
possibly via a direct dissolution of the deposits. The second phase is the removal of
compact amyloid deposits associated with activation of microglia.
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Since the time-course data was performed using an anti-Aß antibody recognizing
the 1-16 portion of the Aß peptide we decided to examine the differences in anti-Aß
epitopes on removal of Aß from the brains of APP transgenic mice seven days following
intrahippocampal and intracortical injections. We injected antibodies recognizing 1-16,
12-28 and 28-40 portions of the Aß peptide as well as a control antibody directed against
drosophila amnesiac protein. We found that both total Aß and compact amyloid deposits
were removed equally as effectively by all three antibodies directed against Aß
(Appendix B; Figures 1 and 2). We also found that anti-Aß28-40 was slightly more
efficacious in microglial activation than either anti-Aß1-16 or anti-Aß 12-28 (Appendix B;
Figure 3) although no microglial activation would have been expected given that the mice
were killed seven days following injection and the time-course data indicated that
microglial activation peaks at three days and is over by seven days.
Additional evidence for for microglial involvement in removal of compact
amyloid deposits was found when we injected anti-Aß1-16 antibodies into the frontal
cortex and hippocampus of aged Tg2576 APP transgenic mice again but this time some
mice were treated with anti-inflammatory drugs for the three days post-injection while
others remained untreated. We treated mice with NCX-2216, minocycline or
dexamethasone immediately following surgery and continued treatment until the morning
of killing. NCX-2216 is the non-steroidal anti-inflammatory drug (NSAID) flurbiprofen
with a nitric oxide donor group and a ferulic acid group attached. In APP+PS1 transgenic
mice this drug has been shown to cause an activation of microglia and reduction of
amyloid burden (Jantzen et al, 2002) but has also been shown to inhibit microglial
activation following lipopolysaccharide (LPS) injection (Hauss-Wegrzyniak et al, 1999).
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Minocycline, a tetracycline derivative, was chosen as it had been shown to suppress
microglial activation following global brain ischemia (Tikka et al, 2001), 6hydroxydopamine administration (He et al, 2001) and excitotoxicity (Yrjanheikki et al,
1998). Dexamethasone was used as it is a potent glucocorticosteroid which is known to
inhibit the cyclooxygenase and lipoxygenase inflammatory pathways as well as induce a
general state of immunosuppression (Schimmer and Parker, 2001).
Dexamethasone was found to be the most efficacious anti-inflammatory for
inhibition of microglial activation due to anti-Aß antibodies; NCX-2216 had a moderate
effect while minocycline appeared to have very little effect on the activation of microglia
(Paper 2; Figure 1 and Figure 2A). Interestingly, inhibition of microglial activation had
no effect on removal of diffuse amyloid deposits, in all cases where anti-Aß antibodies
were injected diffuse deposits were reduced to the same extent (Paper 2; Figure 1 and
Figure 2B). In dexamethasone treated mice, however, there was no apparent reduction in
compact, thioflaine-S positive, amyloid deposits demonstrating that the inhibition of
microglial activation had also inhibited the removal of compact amyloid deposits. Mice
treated with NCX-2216, which had a moderate effect on microglial activation showed
modest reductions in compact amyloid deposits while those mice treated with
minocycline which failed to affect microglial activation showed reductions in compact
amyloid deposits comparable to those observed in mice receiving no anti-inflammatory
treatment (Paper 2; Figure 1 and Figure 2C). These data strongly suggest that microglial
activation is necessary for the removal of compact amyloid deposits by anti-Aß
antibodies but is not necessary for removal of diffuse amyloid deposits.
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To determine whether the microglial activation by anti-Aß antibodies occurred via
the Fcγ receptor and to also determine whether it was this receptor responsible for
removal of compact amyloid deposits we made F(ab’)2 fragemnts from an anti-Aß28-40
IgG. These F(ab’)2 fragments lack the Fc portion of IgG, therefore rendering them unable
to interact with Fcγ receptors on effector cells like microglia yet fully capabale of binding
to Aß in the same way as the complete IgG. We injected these anti-Aß F(ab’)2 fragments
into the frontal cortex and hippocampus of aged Tg2576 APP transgenic mice and killed
them 72 hours following injection. We found that the F(ab’)2 fragments were unable to
activate microglia as effectively as the complete IgG is and the activation levels were
comparable to that observed in the mice receiving either control IgG or control F(ab’)2
fragments (Paper 2; Figure 3 and Figure 4A). We also found that anti-Aß F(ab’)2
fragments were capable of reducing diffuse amyloid deposits as effectively as the
complete IgG (Paper 2; Figure 3 and Figure 4B). However, anti-Aß F(ab’)2 fragments
were significantly worse in removing compact amyloid deposits than the complete IgG
although there was small reductions observed in the hippocampus (Paper 2; Figure 3 and
Figure 4C). These data suggest that although some removal of compact amyloid deposits
may be possible with anti-Aß F(ab’)2 fragments, removal is much more efficient when
the Fc portion of IgG is present. This further demonstrates that not only is microglial
activation necessary for compact amyloid reeduction by anti-Aß antibody treatment but
also it appears that the Fc receptor is the component of microglia mediating this effect.
Knowing that once anti-Aß antibodies enter the brain parenchyma they remove
Aß by mechanisms independent of microglial activation and also dependent upon
microglial activation via the Fc receptor we systemically injected anti-Aß antibodies as a
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form of passive immunization since this is more clinically relevant. We injected antiAß28-40 antibodies weekly for 1, 2 or 3 months such that all the mice were 22 months of
age at killing. Mice received Y-maze testing during the week prior to killing to test for
any cognitive benefit. We found significant improvement in Y-maze performance
following three months of treatment by both an increase in alternations and a decrease in
the number of arm entries (Paper 3; Figure 1) suggesting that the antibody treatment had
improved cognitive function. We had previously demonstrated cognitive improvement
following active immunization (Morgan et al, 2000) but this is the first time we had
shown improvement following passive immunization. We also found evidence for
peripheral action of anti-Aß antibodies. Following intraperitoneal anti-Aß antibody
injection we found that circulating Aß levels in the serum were increased 100-fold
following 1 month of treatment and remained significantly elevated following 2 and 3
months of treatment despite a slight decline compared to 1 month (Paper 3; Figure 2B).
Importantly, we showed that when we stained brain tissue for mouse IgG and
counterstained with Congo red to detect amyloid deposits we found that plaques were
decorated with mouse IgG following anti-Aß antibody treatment but no staining was
observed in those mice receiving control IgG (Paper 3; Figure 3). This suggests that antiAß antibodies administered systemically are able to cross the blood-brain barrier and bind
to Aß in amyloid plaques in the brain parenchyma. We also found that Aß was
significantly reduced following two months of anti-Aß antibody treatment with a further
slight reduction following three months of treatment (Paper 3; Figure 4) as were compact
amyloid deposits as detected by Congo red staining (Paper 3; Figure 5).
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It was apparent in this passive immunization study that there is an associated
complex microglial response. The first microglial marker to be increased was the Fcg
receptors II and III, which were dramatically increased following one month of anti-Aß
antibody treatment by approximately 100-fold. The expression of these receptors fell only
slightly between one and two months but were reduced to control levels following three
months of treatment (Paper 3; Figure 6). CD45 expression was not significantly increased
until two months of anti-Aß antibody treatment and was reduced to control levels
following three months of treatment (Paper 3; Figure 7). We later examined expression of
phospho-p38 MAPK and phospho-p44/42 MAPK (also known as ERK1/2), which have
been shown to be increased in microglia during activation. Phospho-p38 MAPK was high
in APP transgenic mice receiving control antibody for three months indicating activation
of microglia due to the presence of amyloid plaques. However, following treatment with
anti-Aß antibodies for two and three months we observed a decrease in expression in
microglia despite observing increases in other microglial activation markers at these
time-points (Appendix C Figures 3 and 4). The phospho-p44/42 MAPK showed an
opposite effect from the phospho-p38 MAPK which was that it was low in APP
transgenic mice receiving control antibody for 3 months but was increased significantly
following two and three months of anti-Aß antibody treatment, in fact it was the only
microglial marker which was still significantly increased following three months of antiAß antibody treatment (Appendix C; Figures 1 and 2).
This complex microglial reaction observed following systemic administration of
anti-Aß antibodies suggests that activation of microglia may not be a simple on-off
phenomena but rather there may exist multiple states of activation dependent upon the
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stimulus and these states may result in different functional consequences. One potential
hypothesis for different activation states is that microglia may exist in two states; antigen
presenting and phagocytic, as exists in peripheral macrophages. In peripheral
macrophages it has been shown that phosphorylation of p38 MAPK results in production
of IL-1β (Baldassare et al, 1999), IL-6 (Vanden Berghe et al, 1998) and IL-8 (Hobbie et
al, 1999) and cuases upregulation of other proinflammatory molecules such as COX-2,
iNOS and TNF-α by upregulating NF-κB driven gene expression (Carter et al, 1999;
Kostinaho and Kostinaho, 2002). All of these processes associated with phospho-p38
MAPK are proinflammatory in nature and are associated with an antigen-presentation
phenotype. Phagocytosis of apoptotic cells by peripheral macrophages results in an antiinflammatory phenotype with down regulation of pro-inflammatory chemokines, possibly
via phosphorylation of p44/42-MAPK which has been shown to inhibit phosphorylation
of p38-MAPK and therefore contribute to the anti-inflammatory characteristics of this
state (Xiao et al, 2002). Using human polymorphonuclear neutrophils it has been shown
that phagocytosis of microbes is inhibited when phosphorylation of p44/42 MAPK is
inhibited (Zhong et al, 2003). Since microglia are known to be derived from peripheral
macrophages it is feasible that this same scenario is occurring in microglial cells. Little is
currently known about the function of p38 and p44/42 MAPKs in microglia. In human
AD postmortem tissue it has been shown that phopsho-p38 MAPK is highly expressed in
microglia aound amyloid plaques (Hensley et al, 1999). This upregulation of phopshop38 MAPK has also been shown in the transgenic mouse model of amyloid deposition
APP751 (Koistinaho et al, 2002). In microglia it has been shown that Fcγ receptor
mediated phagocytosis is inhibited by PP2, a Src inhibitor and piceatannol, a Syk
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inhibitor which both ultimately inhibit phosphorylation of p44/42, further suggesting that
phosphorylation of p44/42 is necessary for phagocytosis (Song et al, 2004).
The inflammation hypothesis of AD proposed that inflammation via activation of
microglia and astrocytes in response to amyloid deposits in the brain actually contributes
to the disease process. Activated microglia are capable of producing numerous cytokines,
chemokines, complement components and other inflammatory mediators. Activated
astrocytes are also capable of producing similar molecules. All of these inflammatory
molecules are capable of eliciting numerous effects in the brain such as neuronal
dysfunction and death as well as casuing further inflammation via activation of additional
microglia and astrocytes. Despite all of the detrimental effects of inflammation in AD it
has been shown that microglia are capable of eliciting beneficial effects in the AD brain
as well. In APP transgenic mice crossed with TGF-β1 overexpressing mice there was
significant activation of microglia and also a reduced amyloid burden when compared to
the APP transgenic mice alone, however, vascular amyloid levels were increased (WyssCoray et al, 2001). The same group also showed that mice expressing soluble
complement receptor-related protein y (sCrry), a complement inhibitor, crossed with APP
transgenic mice showed reduced microglial activation, increased amyloid plaque load and
neurodegeneration (Wyss-Coray et al, 2002). Lipopolysaccharide (LPS) injection into the
hippocampus of aged APP transgenic mice has been shown to result in significant
microglial activation and dramatic reductions in Aß (DiCarlo et al, 2001; Herber et al,
2004). Finally there is the evidence from papers 1-3 here that microglia are necessary for
effective removal of compact amyloid deposits by microglia and also are activated in
response to systemic anti-Aß injection.
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Following the three month time-course study in which we observed an
improvement in Y-maze performance following three months of anti-Aß antibody
treatment we took an older cohort of APP transgenic mice and treated them weekly for a
period of five months and examined their cognitive function using the much more robust
method of the radial-arm water maze. Following three months of treatment mice were
tested in a rapid two-day radial-arm water maze task and number of errors was measured.
A significant impairment was observed in the APP transgenic mice receiving control
antibody while the APP transgenic mice receiving anti-Aß antibody performed as well as
the nontransgenic mice and were significantly better than the control antibody treated
group (Paper 4; Figure 1A). Mice were tested two months later having received a total of
five months of treatment and the benefit of the anti-Aß antibody treatment was still
present to the same degree (Paper 4; Figure 1B). This data suggests that complete
reversal of cognitive deficits in APP transgenic mice is possible following systemic antiAß antibody treatment.
Histopathological analysis of Congo red and Aß showed the same result as had
been observed in the previous time course study; dramatic reductions in both compact
and diffuse deposits were observed following anti-Aß antibody treatment (Paper 4;
Figure 2A and Table 1). During image analysis of the Congo red and Aß it was observed
that some of the animals appeared to have high levels of amyloid in the vasculature. To
quantify this we took the images used for quantification of total Congo red and ran the
analysis again manually deselecting the parenchymal amyloid deposits and therefore
quantifying only the amyloid in the vasculature. There was a dramatic increase in
vascular amyloid load following five months of anti-Aß antibody treatment. When these
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values were subtracted from the total amyloid load the result was parenchymal amyloid
load which now showed an even more dramatic decrease due to anti-Aß antibody
treatment (Paper 4; Figure 2A). Once we obtained this data we decided to perform the
same analyses on the three month time-course tissue. The same observation was made;
vascular amyloid load increased in concert with the decreases in parenchymal amyloid.
Following two months of anti-Aß antibody treatment vascular amyloid burden showed a
significant increase with a slight further increase following three months of treatment.
Parenchymal amyloid burden showed a significant decrease following two months of
treatment with a further slight decrease following three months of treatment (Paper 4;
Figure 2 B, C and D). Despite this increase in cerebral amyloid angiopathy (CAA) due to
anti-Aß antibody treatment the mice showed tremendous cognitive benefit and so at this
point the CAA is not compromising their cognitive ability, however, if the increase in
CAA were to continue it may be predicted that at some point this would cause a decline
in cognition as it does in the human condition. It is important to note that not all amyloid
is redistributed to the vessel, as there is still a significant decrease in total Congo red
staining, although some of the amyloid is clearly redistributed into the vasculature.
Due to the increase in CAA in our passive immunization studies and the
observation by Pfeifer and colleagues (Pfeifer et al, 2002) that anti-Aß antibody treatment
in hemorrhage prone APP transgenic mice resulted in a significant increase in the number
of microhemorrhages present we decided that we should stain the tissue for hemosiderin
using a Prussian blue stain to examine for microhemorrhages. We found that there was a
significant increase in the number of Prussian blue positive profiles following two, three
and five months of anti-Aß antibody treatment. There was a dramatic increase between
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one and two months of anti-Aß antibody treatment after which the number of profiles
increased linearly with increasing duration of antibody treatment (Paper 4; Figures 4 and
5). Importantly, all vessels showing microhemorrhage were also positive for CAA,
although not all CAA positive vessels showed microhemorrhage.
The mechanism by which anti-Aß antibody therapy results in increased CAA
remains unclear. One hypothesis is that the microglia are capable of phagocytosing the
amyloid plaques but are unable to degrade it so transport the amyloid to the vessels where
they dispose of it into the vessel wall. Support for this hypothesis comes from CD45
immunohistochemistry which showed that despite overall microglial activation being
reduced to control levels following three months of anti-Aß antibody treatment there
appeared to be high levels of microglial activation around those vessels containing
amyloid (Paper 4; Figure 3E and F). We were unable to quantify this observation due to
the diffuse nature of the microglial staining; we could not manually deselect all nonvessel associated staining. It is also plausible that anti-Aß immunotherapy is removing
more Aß1-42, since this is the more prevelant species in both human AD and APP
transgenic mice, and therefore shifting the ratio towards more Aß1-40, thus resulting in
amyloid deposition in the vasculature. It has previously been shown that APPDutch
transgenic mice and human hereditary cerebral hemorrhage with amyloidosis-Dutch type
(HCHWA-D) have a significantly higher ratio of Aß40 to Aß42 than that observed in
APP transgenic mice or human AD brain. Aß1-40 predominates in vascular amyloid in AD
and APP transgenic mice and thus both the APPDutch transgenic mice and the human
HCHWA-D have high levels of CAA, microhemorrhage and a perivascular microglial
reaction. When APPDutch transgenic mice were crossed with PS1 transgenic mice
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known to increase Aß1-42 production it was observed that now the mice developed
parenchymal amyloid deposits with much less prominent CAA (Herzig et al, 2004).
These data suggest that a shift in the ratio of Aß40:Aß42 may influence the location of
deposition.
Table 1 summarizes the evidence we found for each mechanism of ß-amyloid
removal by anti-Aß antibody therapy. We have demonstrated here by intracranial
injection that anti-Aß antibodies in the brains of aged APP transgenic mice removes Aß
by two distinct mechanisms. Diffuse amyloid deposits are removed rapidly, within 24
hours, and this removal is independent of microglial activation. Compact amyloid
deposits are removed between 24 and 72 hours, this removal is dependent upon
microglial activation and Fcγ receptor activation. When anti-Aß antibodies were
administered systemically as a passive immunization the antibodies crossed the blood
brain barrier and bound to amyloid plaques in the parenchyma. Aß removal was
associated with microglial activation, Fcγ receptor upregulation and increased Aß in the
serum. Also, systemically administered anti-Aß antibodies provided complete reversal of
cognitive deficits following just three months of treatment. It was also observed that there
were increased levels of vascular amyloid and multiple microhemorrhages in the brains
of APP transgenic mice administered anti-Aß antibodies for two or more months. Overall,
we have shown evidence for three distinct mechanisms of Aß removal by immunotherapy
which appear to occur in concert to produce robust pathological effects. These
mechanisms are direct dissolution of amyloid fibrils, microglial phagocytosis via the Fcγ
receptor and a peripheral sink mechanism which results from a shift in the concentration
gradient of Aß between brain and plasma.
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There are many more questions to be answered if anti-Aß antibody therapy is to
be successful in the clinic given the pathological effects observed in the current studies.
The main issue that needs to be overcome is the increased vascular amyloid and
associated microhemorrhage. The first question is whether dose of antibody and
frequency of dosing would alter the pathological consequences of anti-Aß antibody
therapy. It is plausible that a lower dose may not produce such a robust microglial
response and as such, if indeed the microglia are responsible for the increase in vascular
amyloid, the increased microhemorrhage and CAA may be avoided. The first way to
approach this would be to establish a detailed dose response with doses ranging from 1
to10 mg/kg for a period of three months with radial-arm water maze testing at the end.
An optimal dose would provide cognitive benefit as well as reductions in parenchymal
amyloid loads without an increase in CAA or microhemorrhage. In the current studies
mice were injected weekly with 10mg/kg anti-Aß antibody. It is conceivable that dosing
as little as once every four weeks may be sufficient for amyloid reductions and cognitive
benefit if the study were to be extended to six and nine months as opposed to three
months. A study to address this would use a 10mg/kg dose and inject at intervals ranging
from two to four weeks with radial-arm water maze testing at six and nine months.
Ideally, there would be an interval which produces significant cognitive benefit and
amyloid reductions with minimal increases in CAA and microhemorrhage.
What contribution each of the three mechanisms make to the improved cognition,
amyloid reductions and increases in CAA and microhemorrhage is currently unknown.
Conjugating a large, polar molecule to anti-Aß antibodies would prevent blood-brain
barrier passage but would still permit binding of Aß in the plasma and therefore only the
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peripheral sink mechanism would be functioning. Treating the mice in exactly the same
way as with the standard antibody would permit comparisons of efficacy to be made. If
the peripheral sink mechanism alone is sufficient to provide cognitive benefit and
amyloid reductions it is likely that this would be a safe alternative if microglial
phagocytosis is responsible for the increased CAA and microhemorrhage.
If the peripheral sink mechanism alone is found not to be sufficient to obtain
optimal effects another approach would be to modify antibodies so that they still cross the
blood-brain barrier, can still act peripherally but are unable to effectively activate
microglia. One such antibody is a deglycosylated anti-Aß antibody. IgG molecules have
carbohydrates attached and these are critical to the recognition of IgGs by the Fcγ
receptor (Radaev and Sun, 2001). If these carbohydrates are removed the IgG molecule
would maintain its pharmacokinetics as the carbohydrates contribute very little to the
overall molecular weight and would also not interact with the Fcγ receptor. Another
option would be to systemically administer anti-Aß F(ab’)2 fragments similar to those
used in paper 2. These, again would not interact with the Fcγ receptor however, due to
their reduced molecular weight, their half-life in serum would be much lower as they now
would be filtered out by the kidney. This means that they would need to be administered
more frequently. It has been shown that attachment of polyethylene-glycol groups to
F(ab’)2 fragments, a process called PEGylation, results in comparable half-lives to the
whole IgG molecule (Weir et al, 2002). It has been shown that PEGylation of an antiinterleukin-8 F(ab’)2 results in longer serum half-life and retention of comparable
bioactivity (Koumenis et al, 2000). It is unclear whether pegylated F(ab’)2 fragments will
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cross the blood-brain barrier however, if they do not, this would be an alternative way to
test the peripheral sink mechanism.
It is possible that microglial phagocytosis via the Fcγ receptor is necessary for
effective amyloid removal and cognitive improvement and that only targeting the
peripheral sink and the direct dissolution mechanisms is insufficient for clinically
relevant benefits. If this is the case, attenuating the microglial resonse using antiinflammatory drugs may minimize redistribution of amyloid to the vasculature and
therefore reduce the incidence of microhemorrhage. We showed in paper 2 that an
NSAID such as NCX-2216 partially inhibits microglial activation and yet significant
reductions in compact amyloid deposits were observed. Co-administration of an NSAID
with the anti-Aß antibody therapy may attenuate the microglial response sufficiently to
prevent increases in CAA and microhemorrhage while providing sufficient removal of
compact amyloid deposits to demonstrate cognitive benefit. Since the addition of a nitricoxide donor group to flurbiprofen in the NCX-2216 compound provides gastrointestinal
protection this drug would be safe for long-term daily administration to elderly AD
patients receiving the immunotherapy. NCX-2216 has also been shown to inhibit
microglial reaction to intracranial infusion of lipopolysaccharide (Hauss-Wegrzniak et al,
1999). Administration of glucocorticosteroids such as dexamethasone would likely not be
effective for this approach as we showed in paper 2 that these completely inhibit
microglial reaction and also completely inhibit the ability of anti-Aß antibodies to remove
compact amyloid deposits.
The isotype of the antibody may be critical in determining clinical efficacy and
prevelance of increased CAA and microhemorrhage. In papers 3 and 4 we used an IgG1
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antibody with an epitope recognizing amino acids 28-40 of the Aß molecule. Microglia
express three different classes of Fcγ receptors; FcγRI is a high affinity receptor while
FcγRII and FcγRIII are low affinity receptors (Ravetch and Kinet, 1991). It is known that
in mice IgG2a binds FcgRI and III with the highest affinity while IgG1 and IgG2b bind
with a lower affinity (Radaev and Sun, 2001). In fact, in a study using both in vivo and ex
vivo methods, it was shown that IgG2a anti-Aß antibodies are more effective in removing
amyloid than are IgG1 or IgG2b antibodies of the same epitope (Bard et al, 2003). In the
ex vivo study the authors examined the effects of isotype on plaque removal from
PDAPP brain sections by primary cultured microglial cells. In this study IgG2a
antibodies were much more effective than IgG1 or IgG2b antibodies of the same epitope.
If microglial phagocytosis via the Fcγ receptor is responsible for not only removal of
parenchymal amyloid but is also responsible for the increased CAA and
microhemorrhage then it is possible that an IgG2a isotype antibody may in fact cause
more CAA and microhemorrhage as this has a much higher affinity for the Fcγ receptors
than the IgG1 antibody used in paper 4.
The epitope may be another important issue to be addressed in determining
efficacy. In a study using in vivo and ex vivo methods it was shown that antibodies
directed against the N-terminal of Aß are most effective in Aß removal (Bard et al, 2003).
However, we show in papers 3 and 4 that C-terminal antibodies are highly effective in the
removal of Aß. Also, a mid-domain antibody has been shown to significantly reduce
brain amyloid (DeMattos et al, 2001) and reverse cognitive deficits (Dodart et al, 2002).
Since mid-domain antibodies are able to bind soluble Aß but are unable to bind Aß in
amyloid plaques these antibodies are highly effective for the peripheral sink mechanism
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but would be unable to trigger effective microglial phagocytosis. It was recently shown
that mid-domain antibodies do not cause microhemorrhage while N-terminal antibodies
do (DeMattos et al, 2004).
Overall, we have shown evidence that three different mechanisms are acting in
concert to reduce amyloid burden in transgenic mice following anti-Aß antibody therapy.
We have also shown that one undesirable consequence of anti-Aß antibody therapy is
increased CAA and microhemorrhage. This will need to be overcome if anti-Aß
immunotherapy is to be successful clinically.
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Table 1: Summary of the evidence found for the different mechanisms of ß-amyloid
removal.
Mechanism
Microglial
phagocytosis
via Fcγ
receptors

Paper 1
Microglial
activation peaks at
the same timepoint as reductions
in compact
amyloid deposits
are observed.

Paper 2
Inhibition of microglial
activation inhibits
removal of compact
amyloid deposits.
F(ab’)2 fragments are
unable to produce
effective reductions in
compact amyloid
deposits.

Direct
dissolution

Diffuse amyloid
deposits are
reduced early with
no associated
microglial
activation.

Diffuse amyloid
deposits are removed
regardless of microglial
inhibition or F(ab’)2
fragments.

Peripheral
sink
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Paper 3
Microglial
expression of Fcγ
receptors and
CD45 is increased
following systemic
antibody
administration.
Phospho-p44/42
expression is also
increased.

Paper 4
Microglia are
activated around
vascular amyloid
deposits.

100-fold increase
in circulating Aß
levels following
systemic anti-Aß
antibody
administration.

Increased vascular
amyloid could
potentially be a
result of the
peripheral sink
mechanism.

REFERENCES
Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom
P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WST, Hampel H, Hull M,
Landreth G, Lue LF, Mrak M, Mackenzie IR, McGeer PL, O’Banion K, Pachter J,
Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R,
Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B,
Wenk G, Wyss-Coray T. 2000. Inflammation and Alzheimer’s disease. Neurobiol. Aging
21: 383-421.
Aloisi F. 2001. Immune function of microglia. Glia 36: 165-179.
Andorfer CA, Acker CM, Kress Y, Duff K, Davies P. 2004. Neuronal deatch
acoompanied by re-expression of cell cycle regulatory proteins in a mouse model of
neurofibrillary tangle formation. Program No. 602.3. Society for Neuroscience 34th
Annual Meeting, San Diego, CA.
Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde YA, Duff K, Davies P.
2003. Hyperphosphorylation and aggregation of tau in mice expressing normal human tau
isoforms. J Neurochem 86: 582-590.
Arendash GW, King DL, Gordon MN, Morgan D, Hatcher JM, Hope CE, Diamond DM.
2001. Progressive, age-related behavioral impairments in transgenic mice carrying both
mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:42-53.
Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT.
2002. Non-Fc-mediated mechanisms are involved in clearance of amyloid-β in vivo by
immunotherapy. J Neurosci 22: 7873-7878
Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman
BT. 2001. Imaging of amyloid-β deposits in brains of living mice permits direct
observation of clearance of plaques with immunotherapy. Nat Med 7: 369-372.
Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE. 2002. Passage of
amyloid β protein antibody across the blood-brain barrier in a mouse model of
Alzheimer’s disease. Peptides 23: 2223-2226.

- 183 -

Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K,
Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A,
Schenk D, Tang P, Vasquez N, Seubert P, Yednock T. 2003. Epitope and isotype
specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's
disease-like neuropathology. Proc Natl Acad Sci USA 100:2023-2028.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J,
Johnson-Wood K, Khan K, Kholofenko D, Lee M, Lieberburg I, Motter R, Nguyen M,
Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. 2000.
Peripherally administered antibodies against amyloid β-peptide enter the central nervous
system and reduce pathology in a mouse model of Alzheimer’s disease. Nat Med 6: 916919.
Borchelt DR, Ratovitski T, van Lare J, Lee MK, Gonzales V, Jenkins NA, Copeland NG,
Price DL, Sisodia SS. 1997. Accelerated amyloid deposition in the brains of transgenic
mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19: 939945.
Bowers WJ, Federoff HJ. 2002. Amyloid
inflammation. Neurobiol Aging 23: 675-676.

immunotherapy-engendered

CNS

Cadavid D, Mena H, Koeller K, Frommelt RA. 2000. Cerebral beta amyloid angiopathy
is a risk factor for cerebral ischemic infarction. A case control study in human brain
biopsies. J Neuropathol Exp Neurol 59: 768-773.
Castellani RJ, Smith MA, Perry G, Friedland RP. 2004. Cerebral amyloid angiopathy:
major contributor or decorative response to Alzheimer's disease pathogenesis. Neurobiol
Aging 25:599-602.
Chang JY, Liu LZ. 2000. Inhibition of microglial nitric oxide production by
hydrocortisone and glucocorticoid precursors. Neurochem Res 25(7): 903-908.
Citron M, Eckman CB, Diehl TS, Corcoran C, Ostaszewski BL, Xia W, Levesque G, St
George Hyslop P, Younkin SG, Selkoe DJ. 1998. Additive effects of PS1 and APP
mutations on secretion of the 42-residue amyloid beta-protein. Neurobiol Dis 5: 107-116.
Das P, Howard V, Loosbrock N, Dickson D, Murphy MP, Golde TE. 2003. Amyloid-beta
immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J
Neurosci 23:8532-5838.
Das P, Murphy MP, Younkin LH, Younkin SG, Golde TE. 2001. Reduced effectiveness
of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition.
Neurobiol Aging 22:721-727.

- 184 -

DeMattos RB, Boone LI, Hepburn DL, Parsadanian M, Bryan MT, Ness DK, Piroozi KS,
Holzman DM, Bales KR, Gitter BD, Paul SM, Racke M. 2004. In vitro and in vivo
characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy
(CAA) and the selective exacerbation of CAA-associated microhemorrhage. Neurobiol
Aging 25: S577.
DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. 2001.
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ
burden in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. USA 98: 88508855.
DeWitt DA, Perry G, Cohen M, Doller C, Silver J. 1998. Astrocytes regulate microglial
phagocytosis of senile plaque cores of Alzheimer’s disease. Expt Neurol 149: 329-340.
Diamond DM, Park CR, Heman KL, Rose GM. 1999. Exposing rats to a predator impairs
spatial working memory in the radial arm water maze. Hippocampus 9: 542-552.
DiCarlo G, Wilcock D, Henderson D, Gordon M, and Morgan D. 2001. Intrahippocampal
LPS injections reduce Aß load in APP+PS1 transgenic mice. Neurobiology of Aging 22,
1007-1012.
Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu
S, Wu X, Holtzman DM, Paul SM. 2002. Immunization reverses memory deficits without
reducing brain Αβ burden in Alzheimer’s disease model. Nat Neuro 5(5): 452-457.
Duff K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Malester B, Hutton M,
Adamson J, Goedert M, Burki K, Davies P. 2000. Characterization of pathology in
transgenic mice over-expressing human genomic and cDNA tau transgenes. Neurobiol
Dis 7:87-98.
Duff K, Eckman C, Zehr C, Yu X, Prada CM, Perez-tur J, Hutton M, Buee L, Harigaya
Y, Yager D, Morgan D, Gordon MN, Holcomb L, Refolo L, Zenk B, Hardy J, Younkin
S. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.
Nature 383: 710-713.
Ferrer I, Boada Rovira M, Sanchez Guerra ML, Rey MJ, Costa-Jussa F. 2004.
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization
in Alzheimer's disease. Brain Pathol 14:11-20.
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T,
Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K,
Mike Lee, Paul Leibowitz, Ivan Lieberburg, Sheila Little, Eliezer Masliah,
Lisa McConlogue, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M,
Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin
- 185 -

B, Zhao J. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing
V717F beta-amyloid precursor protein. Nature 373: 523-527.
Gerlai R. 2001. Behavioral tests of hippocampal function: simple paradigms complex
problems. Behav Brain Res. 125:269-277.
Gordon, M.N. King D.L., Diamond D.M., Jantzen P.T., Boyett K.V., Hope C.E., Hatcher
J.M., DiCarlo G., Gottschall W.P., Morgan D., Arendash G.W. 2001. Correlation
between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol.
Aging 22:377-385.
Gordon, M.N. Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.W.,
Connor K., Melachrino J., O’Callaghan J.P., Morgan D. 2002. Time course of the
development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.
Exp. Neurol. 173: 183-195.
Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM. 2001. Novel amyloid
precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid
angiopathy. Ann Neurol 49:697-705.
Hardy J. 1997. Amyloid, the presenilins and Alzheimer’s disease. TiNS 4: 154-159.
Hardy JA, Higgins GA. 1992. Alzheimer’s disease: the amyloid cascade hypothesis.
Science 256: 184-185.
Hauss-Wegrzyniak B., Willard L.B., Del Soldato P., Pepeu G., Wenk G.L. 1999.
Peripheral administration of novel anti-inflammatories can attenuate the effects of
chronic inflammation within the CNS. Brain Res. 815: 36-43.
He Y., Appel S., Le W. 2001. Minocycline inhibits microglial activation and protects
nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 909: 187193.
Hebert, LE; Scherr, PA; Bienias, JL; Bennett, DA; Evans, DA. 2003. Alzheimer Disease
in the U.S. Population: Prevalence Estimates Using the 2000 Census. Archives of
Neurology 60: 1119 – 1122.
Hensley K, Floyd RA, Zheng NY, Nael R, Robinson KA, Nguyen X, Pye QN, Stewart
CA, Geddes J, Markesbery WR, Patel E, Johnson GV, Bing G. 1999. p38 kinase is
activated in the Alzheimer’s disease brain. J Neurochem 72: 2053-2058.
Herber DL, Roth LM, Wilson D, Mason JE, Morgan D, Gordon MN. 2004. Timedependent reduction in Aß levels after intracranial LPS administration in APP transgenic
mice. Exp Neurol 190: 245-253.

- 186 -

Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E, Schmidt SD, Danner S,
Abramowski D, Sturchler-Pierrat C, Burki K, van Duinen SG, Maat-Schieman ML,
Staufenbiel M, Mathews PM, Jucker M. 2004. Abeta is targeted to the vasculature in a
mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci 7: 954960.
Hobbie S, Chen LM, Davis RJ, Galan JE. 1997. Involvement of mitogen-activated
protein kinase pathways in the nuclear responses and cytokine production induced by
Salmonella typhimurium in cultured intestinal epithelial cells. J Immunol 159: 55505559.
Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Muller-Tillmanns B, Lemke U,
Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, de Quervain DJ, Hofmann M,
Maddalena A, Papassotiropoulos A, Nitsch RM. 2003. Antibodies against beta-amyloid
slow cognitive decline in Alzheimer's disease. Neuron 38: 547-554.
Hock C, Konietzko U, Papassotiropoulos A, Wollmer A, Streffer J, von Rotz RC, Davey
G, Moritz E, Nitsch RM. 2002. Generation of antibodies specific for beta-amyloid by
vaccination of patients with Alzheimer disease. Nat Med. 8:1270-1275.
Holcomb L, Gordon MN, McGowan E, Yu X, Benkovic S, Jantzen P, Wright K, Saad I,
Mueller R, Morgan D, Sanders S, Zehr C, O’Campo K, Hardy J, Prada CM, Eckman C,
Younkin S, Hsiao K, Duff K. 1998. Accelerated Alzheimer-type phenotype in transgenic
mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat
Med 4(1): 97-100.
Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G.
1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic
mice. Science 274: 99-102.
Jantzen P.T., Connor K.E., DiCarlo G., Wenk G.L., Wallace J.L., Rojiani A.M., Coppola
D., Morgan D., Gordon M.N. 2002. Microglial activation and beta –amyloid deposit
reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in
amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. 22: 2246-2254.
Janus, C. Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A.,
Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C.,
Fraser P.E., George-Hyslop P., Westaway D. 2000. A beta peptide immunization reduces
behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 408: 979982.
Jellinger KA. 2002. Alzheimer disease and cerebrovascular pathology: an update. J
Neural Transm. 109: 813-836.
Justement LB. 1997. The role of CD45 in signal transduction. Adv Immunol 66: 1-65.
- 187 -

Kalaria RN, Ballard C. 1999. Overlap between pathology of Alzheimer disease and
vascular dementia. Alzheimer Dis Assoc Disord. 13: S115-S123.
Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Hsiao-Ashe K, Younkin SG. 2001.
Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576
transgenic mouse model of Alzheimer’s disease. J Neurosci 21(2): 372-381.
Klein WL, Krafft GA, Finch CE. 2001. Targeting small Αβ oligomers: the solution to an
Alzheimer’s disease conundrum. TiNS 24(4): 219-224.
Koistinaho M, Kettunen MI, Goldsteins G, Keinanen R, Salminen A, Ort M, Bures J, Liu
D, Kauppinen RA, Higgins LS, Koistinaho J. 2002. Beta-amyloid precursor protein
transgenic mice that harbor diffuse A beta deposits but do not form plaques show
increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A 99:
1610-1615.
Koistinaho M and Koistinaho J. 2002. Role of p38 and p44/42 Mitogen-Activated Protein
Kinases in microglia. Glia 40: 175-183.
Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT,
Younkin S, Ashe KH. 2002. Reversible memory loss in a mouse transgenic model of
Alzheimer's disease. J Neurosci 22:6331-6335.
Koumenis IL, Shahrokh Z, Leong S, Hsei V, Deforge L, Zapata G. 2000. Modulating
pharmacokinetics of an anti-interleukin-8 F(ab’)2 by amine-specific PEGylation with
preserved bioactivity. Int J Pharm 198: 83-95.
Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G, Yen SH, Sahara N,
Skipper L, Yager D, Eckman C, Hardy J, Hutton M, McGowan E. 2001. Enhanced
neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science
293: 1487-1491.
Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van Slegtenhorst M,
Gwinn-Hardy K, Paul Murphy M, Baker M, Yu X, Duff K, Hardy J, Corral A, Lin WL,
Yen SH, Dickson DW, Davies P, Hutton M. 2000. Neurofibrillary tangles, amyotrophy
and progressive motor disturbances in mice expressing mutant (P301L) tau protein. Nat
Genet 25(4): 402-405.
Liu B, Hong JS. 2003. Role of microglia in inflammation-mediated neurodegenerative
diseases: Mechanisms and strategies for therapeutic intervention. J Pharm Expt Ther 304:
1-7.

- 188 -

Lombardo JA, Stern EA, McLellan ME, Kajdasz ST, Hickey GA, Bacskai BJ, Hyman
BT. 2003. Amyloid-beta antibody treatment leads to rapid normalization of plaqueinduced neuritic alterations. J Neurosci 23:10879-10883.
Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE,
Rogers J. 1999. Soluble amyloid β peptide concentration as a predictor of synaptic
change in Alzheimer’s disease. Am J Pathol 155(3): 853-862.
Quon D, Wang Y, Catalano R, Scardina JM, Murakami K, Cordell B. 1991. Formation of
beta-amyloid protein deposits in brains of transgenic mice. Nature. 352: 239-41.
McCarron MO, Nicoll JA. 2004. Cerebral amyloid angiopathy and thrombolysis-related
intracerebral haemorrhage. Lancet Neurol 3:484-492.
McGeer PL, McGeer EG. 2001. Inflammation, autotoxicity and Alzheimer disease.
Neurobiol Aging 22: 799-809.
Morgan, D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K.,
Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M.,
Arendash G.W. 2000. A beta peptide vaccination prevents memory loss in an animal
model of Alzheimer’s disease. Nature 408: 982-985.
Morris RG, Garrud P, Rawlins JN, O'Keefe J. 1982. Place navigation impaired in rats
with hippocampal lesions. Nature 297: 681-683.
Munch G, Robinson SR. 2002. Potential neurotoxic inflammatory responses to Αβ
vaccination in humans. J Neural Transm 109: 1081-1087.
Natte R, Maat-Schieman ML, Haan J, Bornebroek M, Roos RA, van Duinen SG. 2001.
Dementia in hereditary cerebral hemorrhage with amyloidosis-Dutch type is associated
with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary
tangles. Ann Neurol.50:765-772.
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. 2003.
Neuropathology of human Alzheimer disease after immunization with amyloid-beta
peptide: a case report. Nat Med 9:448-452.
Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R,
Mattson MP, Akbari Y, LaFerla FM. 2003. Triple-transgenic model of Alzheimer's
disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron
39: 409-421.
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois
B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C. 2003. Subacute
- 189 -

meningoencephalitis in a subset of patients with AD after Abeta42 immunization.
Neurology 61: 46-54.
Paresce DM, Ghosh RN, Maxfield FR. 1996. Microglial cells internalize aggregates of
the Alzheimer’s disease amyloid β-protein via a scavenger receptor. Neuron 17: 553-565.
Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. 1999.
Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.
Nature 402: 615-622.
Pfeifer M, Boncristiano L, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM,
Jucker M. 2002. Cerebral hemorrhage after passive anti-Aß immunotherapy. Science
298: 1379.
Radaev S and Sun P. 2001. Recognition of immunoglobulins by Fcγ receptors. Mol
Immunol 38: 1073-1083.
Ravetch JV and Kinet JP. 1991. Fc Receptors. Annu Rev Immunol 9: 457-492.
Rensink AA, de Waal RM, Kremer B, Verbeek MM. 2003. Pathogenesis of cerebral
amyloid angiopathy. Brain Res Rev: 43:207-223.
Rogers J, Strohmeyer R, Kovelowski CJ, Li R. 2002. Microglia and inflammatory
mechanisms in the clearance of amyloid β peptide Glia 40: 260-269.
Schenk, D. Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J.,
Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R.,
Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M.,
Yednock T., Games D., Seubert P. 1999. Immunization with amyloid-beta attenuates
Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
Schimmer B.P., Parker K.L. 2001. Adrenocorticotrophic hormone; adrenocortical
steroids and their synthetic analogs; inhibitors of the synthesis and actions of
adrenocortical hormones. In: Goodman & Gilman’s The Pharmaocological Basis of
Therapeutics. (Hardman J.G., Limbird L.E., Gilman A.G. ed.). pp1649-1677. McGraw
Hill Medical Publishing Division.
Selkoe DJ. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81: 741766.
Soininen HS, Riekkinen PJ Sr. 1996. Apolipoprotein E, memory and Alzheimer's disease.
TiNS 19:224-228

- 190 -

Solomon B., Koppel R., Hanan E., Katzav T. 1996. Monoclonal antibodies inhibit in
vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci
USA.93: 452-455.
Solomon B, Koppel R, Frenkel D, Hanan-Aharon E. 1997. Disaggregation of Alzheimer
beta-amyloid by site-directed monoclonal antibodies. Proc. Natl. Acad. Sci. USA 94:
4109-4112.
Song X, Tanaka S, Cox D, Lee SC. 2004. Fcgamma receptor signaling in primary human
microglia: differential roles of PI-3K and Ras/ERK MAPK pathways in phagocytosis and
chemokine induction. J Leukoc Biol 75: 1147-1155.
Stalder M, Deller T, Staufenbiel M, Jucker M. 2001. 3D-reconstruction of microglia and
amyloid in APP23 transgenic mice: no evidence of intracellular amyloid. Neurobiol
Aging 22: 427-434.
Streit WJ. 2002. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia
40: 133-139.
Streit WJ, Walter SA, Pennell NA. 1999. Reactive microgliosis. Prog Neurobiol 57: 653681.
Strittmatter WJ, Roses AD.1996. Apolipoprotein E and Alzheimer's disease. Annu Rev
Neurosci. 19: 53-77.
Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang
DY, Pericak-Vance M, Schmechel D, Roses AD. 1994. Isoform-specific interactions of
apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer
disease. Proc Natl Acad Sci USA 91: 11183-11186.
Tanaka J, Fujita H, Matsuda S, Toku K, Sakanaka M, Maeda N. 1997. Glucocorticoidand mineralocorticoid receptors in microglial cells: The two receptors mediate
differential effects of corticosteroids. Glia 20: 23-37.
Tikka T., Fiebich B.L., Goldsteins G., Keinanen R., Koistinaho J. 2001. Minocycline, a
tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation
and proliferation of microglia. J. Neurosci. 21: 2580-2588.
Tucker KL, Meyer M, Barde YA. 2001. Neurotrophins are required for nerve growth
during development. Nat Neurosci 4:29-37.
Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W,
Haegeman G. 1998. p38 and extracellular signal-regulated kinase mitogen-activated
protein kinase pathways are required for nuclear factor-kappaB p65 transactivation
mediated by tumor necrosis factor. J Biol Chem 273: 3285-3290.
- 191 -

Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pletrzik CU, Findlay KA, Smith TE,
Murphy MP, Butler T, Kang DE, Marquez-Sterling N, Golde TE, Koo EH. 2001. A
subset of NSAIDs lower amyloidogenic Αβ42 independently of cyclooxygenase activity .
Nature 414: 212-216.
Weir ANC, Nesbitt A, Chapman AP, Popplewell AG, Antoniw P, Lawson ADG. 2002.
Formatting antibody fragments to mediate specific therapeutic functions. Biochem Soc
Trans 30: 512-516.
Wilcock DM, Gordon MN, Ugen KE, Gottschall PE, DiCarlo G, Dickey C, Boyett KW,
Jantzen PT, Connor KE, Melachrino J, Hardy J, Morgan D. 2001. Number of Abeta
inoculations in APP+PS1 transgenic mice influences antibody titers, microglial
activation, and congophilic plaque levels. DNA Cell Biol 20: 731-736.
Wilson CJ, Finch CE, Cohen HJ. 2002. Cytokines and cognition – The case for a head-totoe inflammatory paradigm. JAGS 50: 2041-2056.
Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E. 2002.
Prominent neurodegeneration and increased plaque formation in complement-inhibited
Alzheimer’s mice. Proc Natl Acad Sci USA 99(16): 10837-10842.
Wyss-Coray T, Lin C, Yan F, Yu GQ, Rohde M, McConlogue L, Masliah E, Mucke L.
2001. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden
in transgenic mice. Nat Med 7(5): 612-618.
Xioa YQ, Malcolm K, Worthen GS, Gardai S, Schiemann WP, Fadok VA, Bratton DL,
Henson PM. 2002. Cross-talk between ERK and p38 MAPK mediates selective
suppression of pro-inflammatory cytokines by transforming growth factor β. J Biol Chem
277: 14884-14893.
Yamada M, Sodeyama N, Itoh Y, Otomo E, Matsushita M, Mizusawa H. 2002. No
association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy.
Stroke 33:896-900.
Yrjanheikki J., Keinanen R., Pelikka M., Hokfelt T., Koistinaho J. 1998. Tetracyclines
inhibit microglial activation and are neuroprotective in global brain ischemia. Proc. Natl.
Acad. Sci. USA. 99: 10837-10842.
Yu P, Oberto G. 2000. Alzheimer’s disease: Transgenic mouse models and drug
assessment. Pharm Res 42(2):107-114.
Zhong B, Jiang K, Gilvary DL, Epling-Burnette PK, Ritchey C, Liu J, Jackson RJ, HongGeller E, Wei S. 2003. Human neutrophils utilize a Rac/Cdc42-dependent MAPK
- 192 -

pathway to direct intracellular granule mobilization toward ingested microbial pathogens.
Blood 101: 3240-3248.

- 193 -

APPENDICES

- 194 -

APPENDIX A:
NUMBER OF Aß INOCULATIONS IN APP+PS1 TRANSGENIC
MICEINFLUENCES ANTIBODY TITERS, MICROGLIAL ACTIVATION AND
CONGOPHILIC PLAQUE LEVELS.

Donna M. Wilcock1, Marcia N. Gordon1, Kenneth E. Ugen2, Paul E. Gottschall1,
Giovanni DiCarlo1, Chad Dickey1, Kristal W. Boyett1, Paul T. Jantzen1 Karen E.
Connor1, Jason Melachrino1, John Hardy3, David Morgan1*.
1

Alzheimer’s Research Laboratory, Department of Pharmacology, University of South

Florida, Tampa, Florida 33612, USA.
2

Department of Medical Microbiology and Immunology, University of South Florida,

Tampa, Florida 33612, USA.
3

Mayo Clinic Jacksonville, Jacksonville, Florida.

This work was published in DNA and Cell Biology 2001 20(11): 731-736.

Acknowledgements:
This work was supported by AG 15490 (MNG) and AG 18478 (DM). We thank Karen
Hsiao for providing the APP mice and Karen Duff for providing the PS1 mice.

- 195 -
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Abstract
There have been several reports on the use of beta-amyloid (Aβ) vaccination in
different mouse models of Alzheimer’s disease (AD) and its effects on pathology and
cognitive function. In this report histopathology of the APP+PS1 doubly transgenic mice
is compared after 3, 5 or 9 Aβ inoculations. The number of inoculations influenced the
effects of vaccination on Congo red levels, microglia activation and anti-Aβ antibody
titers. After 3 inoculations, the antibody titer of transgenic mice was substantially lower
than that found in nontransgenic animals. However, after 9 inoculations, the levels were
considerably higher in both genotypes, and no longer discriminable statistically. The
number of inoculations influenced CD45 expression, an indicator of microglial
activation. There was an initial up-regulation, which was significant after 5 inoculations,
but by 9 inoculations, microglial activation was equivalent to mice given control
vaccinations. Along with this increased CD45 expression there was a correlative
reduction in Congo red staining, which stains compact plaques. When mice from all
groups were combined, there was a significant correlation between activation of
microglia and Congo red levels, suggesting that microglia play a role in clearance of
compact plaque.
Introduction
Alzheimer’s disease (AD) is a progressive, neurodegenerative disorder
characterized by accumulation of senile plaques consisting of beta-amyloid (Aβ) protein
of which there are 2 forms, Aβ1-40 and Aβ1-42. This is thought to be the key step in the
pathogenesis of Alzheimer’s disease (Selkoe, 1991). The disorder is also characterized by
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the formation of neurofibrillary tangles consisting of tau protein, and by the initiation and
proliferation of a brain-specific inflammatory response (Akiyama et al, 2000). Transgenic
mouse models of Alzheimer’s disease have been an invaluable source of information
regarding the pathological progression of AD and a vehicle in which to test possible
therapeutic interventions. Here we use a transgenic mouse model of AD carrying two
transgenes; amyloid precursor protein (APP) and presenilin-1 (PS1) previously described
(Duff et al, 1996, Hsiao et al, 1996, Holcomb et al, 1998, 1999, Gordon et al, 2001a,
Gordon et al, 2001b).
Schenk et al initially described the effects of Aβ1-42 immunization in the PDAPP
mouse. In a report published in 1999 they demonstrated the ability of their vaccination
regimen to reduce Aβ deposits in the brain. More recently, Aβ vaccination has also been
shown to prevent the cognitive decline in some transgenic mice (including the APP+PS1)
in addition to reducing Aβ load (Morgan et al, 2000, Janus et al, 2000). The data
presented in this report examines the effect of increasing numbers of Aβ1-42
immunizations on the pathology of the APP+PS1 mouse, specifically, anti-Aβ antibody
titers, the reduction in congophilic plaque load and the activation of microglia.
Of particular note in this study was the observed activation of microglial cells,
which are central to the inflammatory process in AD, along with a concomitant reduction
in congophilic plaque.
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Materials and Methods
Vaccination Protocol.
Tg2576 APP mice (Hsiao et al, 1996) were bred with PS1 line 5.1 mice (Duff et
al 1996) to obtain the double transgenic mice. These mice were then randomly assigned
to groups receiving vaccination with either human Aβ1-42 peptide (Bachem) or with
keyhole limpet hemocyanin (KLH) as described previously (Morgan et al, 2000). Briefly,
100µg of Aβ1-42 or KLH were dissolved in water at 2.2 mg/ml, mixed with PBS and
incubated overnight. One day later this suspension was mixed with Freund’s adjuvant
(complete for the primary inoculation, incomplete for the next 4 inoculations, and mineral
oil for the remaining inoculations). Three vaccination groups were used. The first group
was administered 3 inoculations starting at an average age of 13 months. These mice
were killed at an average of 16 months of age, 13 days after the final inoculation. A
second group of mice were given 5 inoculations starting at an average age 14.5 months.
These mice were killed at an average of 19.75 months of age, 10 days after the last
inoculation. A third group given 9 inoculations started at an average age of 7.5 months.
They were killed at an average of 16.25 months of age, 6 weeks after the last inoculation.
In addition, nontransgenic mice were vaccinated with Aβ peptide in the 3 and 9
inoculation groups. Antibody titers were measured by ELISA as described previously
(Morgan et al, 2000, Dickey et al, 2001). The KLH immunized mice are herein referred
to as control mice for these experiments.
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Histopathology.
Mice were overdosed with pentobarbital, perfused with 0.9% saline and the brain
removed. The right side of the brain was rapidly dissected over ice and the left side fixed
for 24 hours in freshly prepared, buffered 4% paraformaldehyde. Following
cryoprotection through increasing concentrations of sucrose solutions at 24-hour
intervals, frozen sections were taken on a sliding microtome at a 25µm thickness and
stored in DPBS (Dulbecco’s phosphate buffered saline) with sodium azide to prevent
microbial growth. Sections were stained using floating immunohistochemistry for total
Aβ (rabbit antiserum primarily reacting with the N terminal of the Aβ peptide, 1:10000)
and CD45 (Serotec, 1:10,000) as described previously (Holcomb et al, 1999, Gordon et
al, 1997). Sections were also mounted on slides and stained for Congo red (SigmaAldrich) (Gordon et al, 2001a). The area of hippocampus and frontal cortex occupied by
positive stain was measured with a Videometric V150 image analysis system (Oncor) on
a Nikon Microphot FX microscope as described in detail previously (Gordon et al,
2001a). Percentage area was measured and analyzed. Data were collected from 8-16
equally spaced horizontal sections. The values for all sections from one mouse were
averaged to represent a single sample for statistical analysis.
Statistical Analysis.
Data were first analyzed by comparing Aβ vaccinated and control mice within
each group by one-way ANOVA using the Statview software program (SAS). Because of
differences in the age of kill, the results from each Aβ vaccinated mouse were normalized
to the mean value of their respective control vaccinated group (percent of control) to
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correct for differences in age at kill and overall staining intensity for each inoculation
group. These were then analyzed by performing a simple regression analysis on the
Statview program.

Results
Antibody titers increase with increasing numbers of inoculations in both
transgenic and nontransgenic mice (Fig 1). Initially, doubly transgenic mice have lower
anti-Aβ titers than similarly treated nontransgenic mice. However, after the ninth
vaccination the transgenic mice produced antibody titers that were similar to nontransgenic mice.
In general, the Congo red staining in hippocampus was reduced as a result of Aβ
vaccination (Fig 2A,B). In the group receiving five inoculations this reduction was almost
50% and was significantly reduced in relation to control mice (p < 0.002; Figure 3). In
the groups receiving three or nine inoculations, the reduction in Congo red was not
statistically significant. The results from frontal cortex also follow these trends although
no significance is found at any time-points (Table 1).
CD45 expression in hippocampus was increased almost 2 fold in the hippocampus
of mice given 5 inoculations (Figure 2C,D; Figure 4; p < 0.001). There was a similar
trend for CD45 up-regulation in the group receiving three inoculations although not
statistically significant. However, the vaccinated mice were equivalent to the control
mice in the group receiving nine inoculations. The same trend was seen in frontal cortex
although not to the same degree (Table 1).
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When data from all three groups are combined, there is a correlation between CD45
expression and Congo red staining in the hippocampus as illustrated in Figure 5. This
relationship shows that mice with elevated CD45 expression had less Congo red staining
(r=0.691, p=0.002). This result did not occur because of a biased positioning of one of the
inoculation groups. By plotting the data from each group with a different symbol one can
see that in each inoculation group there are mice with high CD45 staining and other mice
with little, which was less than the control average. This bimodal distribution of CD45
staining has been observed in most groups of mice we have examined including the
control mice in the present study.
Discussion
CD45 expression is indicative of microglial activation. Here, we have shown that
CD45 expression in transgenic mice administered Aβ vaccination is up-regulated, after 5
inoculations. However, on average, the expression was no longer elevated after a 9th
inoculation. This suggests that the microglial activation resulting from Aβ vaccination is
transient. This likely represents a desensitization to the circulating antibodies because;
even though the interval between the last inoculation and kill after 9 inoculations was 6
weeks the antibody titers were still high at necropsy. Perhaps the most interesting data is
the high correlation between Congo red staining levels in hippocampi of transgenic mice
and activation of microglia. These data add to a growing body of literature suggesting
that in transgenic mice activation of microglia leads to clearance of Aβ deposits. Ongoing
work from our group shows reduction in amyloid deposits in association with microglial
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activation in several circumstances using the transgenic mouse model of amyloid
deposition. Administration of a flurbiprofen derivative which slowly releases nitric oxide
(NCX-2216) causes dramatic activation of microglia and substantial reduction in Congo
red staining (Jantzen et al, 2001). In another study, intrahippocampal injections of
lipopolysaccharide, a pro-inflammatory agent, simultaneously reduced Aβ load and
activated microglia (Di Carlo et al, 2001). Even in the normal time course of amyloid
accumulation there is a stabilization of the congophilic deposits in doubly transgenic
mice between 12 and 15 months, the age at which microglial activation becomes most
pronounced (Gordon et al, 2001b).
It has been well demonstrated that microglia in culture are readily capable of
internalizing Aβ1-42 aggregates (Paresce et al, 1996; Webster et al, 2001). The data
reported here are consistent with several other reports regarding Aβ vaccination and
microglial activation. In the original Aβ vaccination report, the vaccine was found to
result in activated microglia around the few deposits that did remain (Schenk et al, 1999).
Bard et al, 2000, also demonstrated that microglia can be activated to clear tissue amyloid
deposits by Fc receptor mediated phagocytosis in vitro. In a very direct experiment,
Bacskai et al, (2001), demonstrated that injection of anti-Aβ antibodies into transgenic
mouse brain induced a rapid disappearance of Aβ associated with a florid microglial
reaction. These results together with those from our research group indicate that
activation of microglia can have benefit in clearing Aβ deposits from the brains of
transgenic mice. It is unclear whether excessive activation of microglia can ultimately
cause autotoxic inflammatory reactions in this model or whether the mouse brain is
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somehow resistant to the development of such a reaction. It is intriguing that the
microglial activation in mice with 9 inoculations had largely subsided. This suggests that
under these circumstances the microglia can develop tolerance to the activating stimuli.
If so, vaccination may be one mechanism to, perhaps paradoxically, reduce an autotoxic
reaction in the AD brain.
The observation that the doubly transgenic mice are slower to mount an immune
response after Aβ vaccination than their non-transgenic counterparts is a significant one.
There are several plausible explanations for this impaired antibody response. One
explanation is that Aβ is a “self-antigen” in the transgenic mice (expressing human APP),
and thus, they do not mount as significant a humoral response to the injected human Aβ142. The

murine Aβ sequence is slightly different than the human sequence, thus

nontransgenic mice would not identify the human Aβ peptide as an autoantigen. Another
possibility that the transgenic mice are by some means “immune compromised” as is seen
in older humans; thus, they are slower to mount a significant immune response. A third
explanation is absorption of the serum antibodies by circulating Aβ, which interferes with
antibody binding to the ELISA plate. This might be most evident when the antibody titers
are low and antibody concentrations are stoichiometrically similar to that of Aβ. In any
event, repeated vaccinations ultimately overcome this restriction of antibody generation
in the transgenic mice. This may have significance for treatment of human populations,
with multiple vaccinations required to activate a vigorous antibody response.
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In conclusion, the data here are consistent with the argument that the Aβ
vaccination results in plaque clearance primarily through activation of microglial cells.
Still, we continue to entertain the possibility of antibodies dissolving plaques directly
(Solomon, this volume), or antibodies binding circulating Aβ, reducing the effective
plasma Aβ concentration, and increasing the concentration gradient between brain and
blood leading to more rapid Aβ removal from the CNS. Finally, we believe that multiple
inoculations are likely to be required if Aβ vaccination demonstrates efficacy in the
treatment or prevention of AD.
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Figure 1: Antibody titer averages as a function of number of inoculations in transgenic
and non-transgenic mice. Figure legends: z: Non-transgenic, S: Transgenic. There is a
highly significant difference between transgenic and non-transgenic (p=0.0002) after 3
inoculations, indicated by **, but not by 9 inoculations.
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Figure 2: A, B: Congo red staining in the hippocampus of the mice receiving 5 Aβ
inoculations (40X magnification). C, D: CD45 staining, counterstained with Congo red in
the hippocampus of the mice receiving 5 Aβ inoculations (200X magnification). A and C:
Control immunized mice. B and D: Aβ immunized mice. A and B; scale bar: 250µm. C
and D; scale bar: 50µm.
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Figure 3: Congo red levels in hippocampus relative to number of inoculations for
vaccinated and control mice. All mice for each group were averaged and are shown here
and are all APP+PS1 transgenic mice. ** Indicates high significance (p<0.002).
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Figure 4: CD45 expression in hippocampus relative to number of inoculations for
vaccinated and control mice. All mice for each group were averaged and are shown here
and are all double transgenic. ** Indicates high significance (p<0.001).
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Figure 5: Correlation of Congo red levels and CD45 expression both shown as percent
control in hippocampus. R=0.69 and p=0.002. Figure legends: ¬: 3 inoculations, S: 5
inoculations, z: 9 inoculations.
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Table 1: Effect of number of inoculations on Congo red and CD45 staining in the frontal
cortex. Data are percent of area occupied by reaction product, shown as mean ± SEM.

Congo red

CD45

Number of
inoculations

Aβ
vaccinated

Control

3

2.56+/- 0.22

2.3+/- 0.18

5

2.44+/- 0.28 2.99+/- 0.20

9

1.32+/- 0.08 1.66+/- 0.12 4.63+/- 0.67 4.96+/- 0.74
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Aβ
vaccinated

Control

1.94+/- 0.33 1.84+/- 0.45

7.0+/- 0.81

5.56+/- 0.96
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Figure 1: Total Aß is significantly reduced by anti-Aß antibodies regardless of their
epitope. The graph shows the ratio of right injected side: left uninjected side. Mice were
injected with one of anti-drosophila amnesiac antibodies (AMN), anti-Aß1-16 antibodies
(Aß1-16), anti-Aß12-28 antibodies (Aß12-28) or anti-Aß28-40 antibodies (Aß28-40). Solid
bars indicate values for the frontal cortex while open bars indicate values for the
hippocampus. *indicates P<0.05, **indicates P<0.01 when compared to both uninjected
and AMN groups.
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Figure 2:Thioflavine-S staining is significantly reduced by anti-Aß antibodies regardless
of their epitope. The graph shows the ratio of right injected side: left uninjected side.
Mice were injected with one of anti-drosophila amnesiac antibodies (AMN), anti-Aß1-16
antibodies (Aß1-16), anti-Aß12-28 antibodies (Aß12-28) or anti-Aß28-40 antibodies (Aß2840). Solid bars indicate values for the frontal cortex while open bars indicate values for
the hippocampus. *indicates P<0.05, **indicates P<0.01 when compared to both
uninjected and AMN groups.
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Figure 3: CD45 immunohistochemistry is increased by anti-Aß28-40 antibodies. The graph
shows the ratio of right injected side: left uninjected side. Mice were injected with one of
anti-drosophila amnesiac antibodies (AMN), anti-Aß1-16 antibodies (Aß1-16), anti-Aß12-28
antibodies (Aß12-28) or anti-Aß28-40 antibodies (Aß28-40). Solid bars indicate values for
the frontal cortex while open bars indicate values for the hippocampus. **indicates
P<0.01 when compared to both uninjected and AMN groups.
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Figure 1: Phospho-p38 MAPK exression is decreased in microglia with increasing
duration of anti-Aß antibody treatment. The upper graph shows data for frontal cortex
while the lower graph shows data for the hippocampus. All data are shown as percent
area occupied by positive stain. The bar indicates values for APP transgenic mice treated
with control antibody anti-AMN for three months. The line indicates values for APP
transgenic mice receiving anti-Aß28-40 antibodies for 1, 2 and 3 months. *indicates
P<0.05.
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Figure 2: Phospho-p38 MAPK immunohistochemistry shows microglial expression
around amyloid plaques which is decreased with increasing duration of anti-Aß antibody
treatment. Panels A-D show phospho-p38 MAPK immunohsitochemical staining around
the hippocampal fissure (F in panel D) and in the dentate gyrus (DG in panel D). APP
transgenic mice were treated for 3 months with control IgG (A) or with anti-Aß28-40 IgG
for one (B), two (C) or three (D) months. Magnification = 100X. Scale bar panel D =
50µm.
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Figure 3: Phospho-p44/42 MAPK exression is increased in microglia with increasing
duration of anti-Aß antibody treatment. The upper graph shows data for frontal cortex
while the lower graph shows data for the hippocampus. All data are shown as percent
area occupied by positive stain. The bar indicates values for APP transgenic mice treated
with control antibody anti-AMN for three months. The line indicates values for APP
transgenic mice receiving anti-Aß28-40 antibodies for 1, 2 and 3 months. *indicates P<0.05
when compared to control IgG treated animals.
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Figure 4: Phospho-p44/42 MAPK immunohistochemistry shows microglial expression
around amyloid plaques which is increased with increasing duration of anti-Aß antibody
treatment. Panels A-D show phospho-p44/42 MAPK immunohsitochemical staining
around the hippocampal fissure (F in panel A) and in the dentate gyrus (DG in panel A).
APP transgenic mice were treated for 3 months with control IgG (A) or with anti-Aß28-40
IgG for one (B), two (C) or three (D) months. Magnification = 100X. Scale bar panel A =
50µm.
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